Board Decisions

<ol><li> The Board approves for funding for an initial two years, subject to paragraphs 2 and 3 below, the Round 7 proposals recommended for funding by the Technical Review Panel (TRP) and listed in Annex 2 to the Report of the TRP and Secretariat on Round 7 Proposals (GF/B16/5) as:<ol type="i"><li>'Category 1';</li><li>'Category 2'; and</li><li>'Category 2B',</li></ol><br/>with the clear understanding that the grant amounts requested for the "Phase 1 Period" in such Annex are maximum upper ceilings subject to TRP clarifications and grant negotiations rather than final approved grant amounts.</li><li> The applicants whose proposals are recommended for funding as 'Category 1' shall conclude the TRP clarifications process, as indicated by the written approval of the Chair and/or Vice Chair of the TRP, not later than eight weeks after receipt of notification in writing by the Secretariat to the applicant of the Board's decision.</li><li> The applicants whose proposals are recommended for funding as 'Category 2 and Category 2B' shall:<ol type="i"><li>provide an initial detailed written response to the requested TRP clarifications and adjustments by not later than six weeks after receipt of notification in writing by the Secretariat to the applicant of the Board's decision; and</li><li>conclude the TRP clarifications process, as indicated by the written approval of the Chair and Vice Chair of the TRP, not later than three months from the Secretariat's receipt of the applicant's initial detailed response to the issues raised for clarification and/or adjustment.</li></ol></li><li>The Board declines to approve for funding those proposals categorized by the TRP as 'Category 3' as indicated in Annex 2 to GF/B16/5, although such applicants are encouraged to resubmit a proposal in a future funding round after major revision of the relevant proposal.</li><li>The Board declines to approve for funding those proposals categorized by the TRP as 'Category 4' as indicated in Annex 2 to GF/B16/5.</li></ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for the country disease components, and its constituent grant, as listed in the Table 1 of GF/B41/ER06 (“Table 1”);</li> <li>Acknowledges the country disease components’ constituent grant will be implemented by the proposed Principal Recipient listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for the country disease component, and its constituent grant, as listed in the Table 1 of GF/B41/ER09 (“Table 1”);</li> <li>Acknowledges the country disease component’s constituent grant will be implemented by the proposed Principal Recipient listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> </ol> <p>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for the country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</p>

<p>Based on the recommendation of the Audit and Finance Committee, the Board approves the Amended and Restated Policy on Restricted Financial Contributions, as set forth in Annex 1 to GF/B41/06 – Revision 1, which shall supersede the Amended and Restated Policy on Restricted Financial Contributions approved by the Global Fund Board in May 2017 under decision point GF/B37/DP08.</p>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Table 1 of GF/B41/ER01 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>Based on the recommendation of the Strategy Committee described in GF/B41/ER04, the Board:</p> <ol> <li>Notes that the Eligibility Policy (GF/B39/02) provides that certain non-eligible countries may be recommended to be eligible for malaria in the event of a significant resurgence in malaria cases;</li> <li>Acknowledging the Secretariat and technical partners’ recommendation described in GF/B41/ER04, decides that Venezuela’s malaria component will be eligible for funding for the 2020-2022 allocation period due to significant resurgence; and</li> <li>Notes that any resultant grant(s) will be subject to and governed by existing policy and processes.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 2 of GF/B41/ER05 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<ol> <li>The Board approves (i) the proposed amendments to the Operating Procedures of the Board and Committees of the Global Fund (“BCOP”) set out in Annex 1 of GF/B41/ER11; and (ii) the proposed amendments to the Charter of the Ethics and Governance Committee (“EGC Charter”) set out in Annex 2 of GF/B41/ER11.</li> <li>The Board endorses the due diligence process overview set out in Annex 4 of GF/B41/ER11.</li> <li>The proposed amendments to the BCOP shall enter into force upon the adoption of this decision point. The proposed amendments to the EGC Charter shall enter into force upon the expiry of the term of the current EGC in May 2020.</li> </ol>

<p>1.2 Set forth below is the Secretariat’s recommendation to approve grant extensions.</p> <p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 2 of GF/B38/ER05 (“Table 2”);</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 2, and (b) is subject to the availability of funding.</li> </ol>

<p><span>The Board:</span></p> <ol> <li><span>Approves the revised budget recommended for each grant listed in Table 2 of GF/B41/ER13 (“Table 2”);</span></li> <li><span>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</span></li> <li><span>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</span></li> </ol>

<p>1. Based on the recommendation of the Audit and Finance Committee, the Board approves the 2018 performance target for Key Performance Indicator 12b as presented in GF/B38/ER13A.</p>

<ol> <li>The Board: <ol type="a"> <li>Welcomes the invitation of the government of the Former Yugoslav Republic of Macedonia to host the Global Fund’s 39th Board Meeting on 9-10 May 2018; and</li> <li>Acknowledges the recommendation set forth in GF/B38/ER07.                              </li> </ol> </li> </ol> <ol start="2"> <li>Accordingly, the Board agrees to convene the 39th Board Meeting in Skopje, Former Yugoslav Republic of Macedonia.</li> </ol>

<p>Based on the recommendation of the Ethics and Governance Committee, the Board:</p> <ol> <li>Amends Article 7.1 of the Global Fund Bylaws by deleting the text which states “One Swiss citizen with his or her domicile in Switzerland authorized to act on behalf of the Global Fund to the extent required by Swiss law; and”, and replacing it with the following text: “One representative of the public donors which are not part of a voting donor constituency but have each pledged a contribution of at least $10 million in the current replenishment cycle; and”;</li> <li>Requests that the Secretariat invite the public donors included in the group which are not part of a voting donor constituency but have each pledged a contribution of at least $10 million in the current replenishment cycle to join this new non-voting Board constituency and develop a process for selecting its Board representation in accordance with the Bylaws and the Operating Procedures of the Board and Committees of the Global Fund; and</li> <li>Requests the Donor Voting Group report at the 39th meeting of the Global Fund Board on its revised process for public donor seat allocation, which will ensure that new public donors, who commit to the principles in the Framework Document of the Global Fund and contribute/pledge more than a defined threshold amount for two consecutive replenishment periods, will be integrated into a voting public donor constituency.</li> </ol>

<ul> <li>Set forth below is the Secretariat’s recommendation to approve funding up to an amount of US$ 2,317,504,873 and EUR 434,148,572; this includes country allocation funding as well as US$46,519,790 and EUR 1,782,000 of catalytic investments for matching funds.</li> </ul> <p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 to GF/B38/EDP02 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 2 of GF/B38/EDP17 (“Table 2”); and</li> <li>Affirms that any additional funding provided to fund the revised budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 2, and (b) is subject to the availability of funding. </li> </ol>

<p>Set forth below is the Secretariat’s recommendation to approve grant extensions.             </p> <p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 2 of GF/B38/EDP09 (“Table 2”);</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 2, and (b) is subject to the availability of funding.</li> </ol>

<p>The Board wishes to sincerely thank Dr. Marijke Wijnroks for her leadership of the Global Fund as Interim Executive Director.</p> <p>Dr. Wijnroks has led the Secretariat’s work to begin implementing the Global Fund Strategy 2017-2022, while overseeing a tremendous volume of grant-making and also inspiring colleagues to continue innovative work that is focused on achieving impact. The Board extends its gratitude for Dr. Wijnroks’ ongoing work to prepare for the arrival of the incoming Executive Director, paving the way for the new leader to move forward with a strong and committed team.</p> <p>The Board commends Dr. Wijnroks for her longstanding dedication and contribution to the Global Fund. Prior to her leadership as Interim Executive Director, Dr. Wijnroks served as Board Member for the Point 7 constituency, and as Chief of Staff from 2013 to 2017.</p> <p>Throughout this time, her passion for the organization’s mission, her commitment to those most in need of advocacy and support, and her unwavering optimism have inspired many. The Board wishes Dr. Wijnroks continued success in all endeavors.</p>

<ol> <li>The Board acknowledges the update on resource mobilization (GF/B38/19), and in that context, the Global Fund’s Sixth Replenishment as a key strategic priority.</li> <li>The Board requests its new Executive Director to develop a framework for a Resource Mobilization Action Plan (2018-2019), in consultation with partners and the Audit and Finance Committee, for the 39th Board meeting, followed by a detailed and fully costed plan to the relevant Committees in June 2018.</li> </ol>

<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of GF/B38/ER02 (“Table 2”);</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 to GF/B38/EDP15 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board expresses its deep appreciation to Aida Kurtović for her leadership as Chair of the Board. Over her time working with the Global Fund as Board Member for the Eastern Europe and Central Asia Constituency, Vice-Chair and Chair of the Board, Aida has shown a high degree of personal commitment, willingness to devote time and energy to the work of the Global Fund, and particular attention to engagement with constituencies. The Board recognizes her significant contribution to the priorities of the Global Fund over many years.</p> <p>The Board also expresses sincere gratitude to Amb. John Simon for his leadership as ViceChair of the Board. He has served the Global Fund with dedication, and has been an active driver of governance effectiveness, relationship building and collaboration that will have a lasting impact on the Global Fund.</p> <p>During their tenure, the outgoing Chair and Vice-Chair have presided over significant deliberations and decisions that will continue to shape the future of the Global Fund. Under their leadership, the Board appointed the Executive Director, guided resource mobilization efforts, adopted key decisions, including, the Revised Eligibility Policy and criteria regarding potential engagement with on-eligible countries in crisis, a strengthened Board Leadership Selection Process, the CCM evolution initiative, the Allocation Methodology and Catalytic Investments for the 2020-2022 Allocation Period, and integrated additional public donors into the Global Fund Governance Structure.</p> <p>The Board wishes Aida and John every success in their future endeavors and bestows upon them the honorary titles of Chair Emeritus and Vice-Chair Emeritus of the Board, respectively</p>

<p>Allan Maleche from the Developing Country NGO constituency is designated as Rapporteur for the 41st Board Meeting.</p>

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2018 Statutory Financial Statements, which have been audited by KPMG SA, as set forth in Annex 2 to GF/B41/04.</p>

The Board approves the outstanding Category 2 of Kenyan NGO Round 1 Proposals for HIV/AIDS as endorsed by the CCM.

<ul><li>Mandates the Committee to work with the Secretariat to develop a comprehensive proposal for the Partnership Forum for the June Board Meeting.</li></ul><ul><li>Decides, exceptionally, to hold the Forum during the first half of 2004.</li></ul><ul><li>Recommends to the Committee to link the Forum with another meeting, preferably a Board Meeting, to minimize costs.</li></ul><ul><li>Requests the Secretariat to research similar events and establish lessons learned (e.g. from GAVI).</li></ul><ul><li>Requests the Secretariat to provide a list of events for 2004 for consideration at the June Board Meeting.</li></ul>

<ul> <li>While the methodology for identifying the neediest and poorest countries is being developed, the Secretariat will supply information on needy and poor countries that have not received funding in Rounds 1 and 2 to the 4^thBoard meeting. The information presented to the 4^thBoard meeting on needy and poor countries will also be provided to partners to encourage them to support these countries in the process of applying to the Global Fund.</li> </ul> <ul> <li>(Deferred)For the Fifth Board meeting, the PMPC will provide recommendations on mechanisms for ensuring that the neediest and poorest are not systematically excluded from funding.</li> </ul>

<p>Based on the recommendation of the Audit and Finance Committee, the Board approves:</p> <ol> <li>the wording revision for Key Performance Indicator 10 as presented in GF/B41/ER12</li> <li>the indicator revision and performance target for Key Performance Indicator 12a as presented in GF/B41/ER12</li> <li>the 2020 performance target for Key Performance Indicator 12b as presented in GF/B41/ER12</li> </ol>

<p><span>The Board:</span></p> <ol> <li><span>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B41/ER13 (“Table 1”);</span></li> <li><span>Acknowledges each country’s disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</span></li> <li><span>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</span></li> <li><span>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</span></li> </ol>

<p>Based on the recommendation of the Strategy Committee (the “SC”), as presented in GF/B41/03 - Revision 1, the Board:</p> <ol> <li>Acknowledges that the total amount of sources of funds for allocation for the 2020-2022 allocation period will be decided by the Board in November 2019, based on the recommendation of the Audit and Finance Committee following announced replenishment results from the 6th Replenishment;</li> <li>Approves that the total amount of funding for catalytic investments in the 2020-2022 allocation period, as described in the Allocation Methodology approved under GF/B41/DP03, will be determined by the total amount of sources of funds for allocation for the 2020-2022 allocation period;</li> <li>Approves catalytic investments for the 2020 – 2022 allocation period as set forth in the scenarios described below: <ol type="i"> <li>USD 900 million scenario: If sources of funds for allocation for the 2020 – 2022 allocation period are greater than or equal to USD 13.1 billion, USD 900 million will be made available for catalytic investments, in accordance with the priorities and associated costs set forth in Table 1 of Annex 1 of GF/B41/03 - Revision 1 (“Annex 1”);</li> <li>USD 800 million scenario: If sources of funds for allocation for the 2020 – 2022 allocation period are below USD 13.1 billion and greater than or equal to USD 12.1 billion, USD 800 million will be made available for catalytic investments, in accordance with the priorities and associated costs set forth in Table 2 of Annex 1;</li> <li>USD 600 million scenario: If sources of funds for allocation for the 2020 – 2022 allocation period are below USD 12.1 billion and greater than or equal to USD 11.1 billion, USD 600 million will be made available for catalytic investments, in accordance with the priorities and associated costs set forth in Table 3 of Annex 1;</li> <li>USD 400 million scenario: If sources of funds for allocation for the 2020 – 2022 allocation period are below USD 11.1 billion and greater than or equal to USD 10.6 billion, USD 400 million will be made available for catalytic investments, in accordance with the priorities and associated costs set forth in Table 4 of Annex 1; and</li> <li>USD 200 million scenario: If sources of funds for allocation for the 2020 – 2022 allocation period are below USD 10.6 billion and greater than or equal to USD 10.1 billion, USD 200 million will be made available for catalytic investments, in accordance with the priorities and associated costs set forth in Table 5 of Annex 1.</li> </ol> </li> <li>Requests the Secretariat to return to the SC with a new recommendation on catalytic investments if sources of funds for allocation for the 2020 – 2022 allocation period are below USD 10.1 billion, for SC recommendation to the Board;</li> <li>Agrees that in the event that sources of funds for allocation for the 2020-2022 allocation period are above the midpoint of the funding range specified for a scenario above, the Secretariat may recommend the Board to approve an additional total amount up to USD 100 million for catalytic investments, to be invested in the priority areas for the scenario immediately preceding the applicable scenario in the list above;</li> <li>Requests the Secretariat to (i) implement a rigorous approval process for all catalytic investments, including strategic initiatives, by a review body with clear and transparent management of conflicts of interest to maintain the integrity of decision making, whether financial or programmatic; (ii) execute a credible, robust technical review process on the activities, mechanisms, and the requested amounts; and (iii) report regularly to the SC on all catalytic investments; and</li> <li>Notes the Secretariat will (i) have flexibility to operationalize catalytic investments; (ii) update the SC and Board on such operationalization; (iii) have flexibility to reallocate associated costs among the approved priorities under any applicable scenario, within 10% of the approved amount of associated costs for a specific priority; and (iv) present any reallocations of associated costs exceeding 10% for a specific priority for the SC’s approval.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Table 1 of GF/B41/ER05 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and<br />Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 2 of GF/B41/ER09 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 1 of GF/B41/ER07 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 2 of GF/B41/ER01 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p class="x_MsoNormal"><span>The Board approves the Report of the 41st Board Meeting, as set forth in GF/B41/18.</span></p>

<ol> <li>The Board notes: <ol type="a"> <li>Its decision in April 2016 (GF/B35/DP10) that (i) established the allocation methodology for the 2017 - 2019 allocation period; (ii) acknowledged the technical parameters for the 2017 - 2019 allocation period; and (iii) affirmed the restatement of core parts of the principles and framework for the allocation-based funding model (the “Core Funding Model Principles”); and</li> <li>The decision by the Strategy Committee (the “SC”) in March 2019 (GF/SC09/DP02), under authority delegated by the Board, to establish technical parameters for the 2020 – 2022 allocation period (the “Technical Parameters”).</li> </ol> </li> <li>Accordingly, based on the recommendations of the SC, as presented in GF/B41/02, the Board: <ol type="a"> <li>Approves the allocation methodology presented in Annex 1 to GF/B41/02 (the “Allocation Methodology”);</li> <li>Acknowledges the Technical Parameters for the 2020 – 2022 allocation period, as presented in Annex 2 to GF/B41/02;</li> <li>Approves that no more than USD 800 million of sources of funds available for country allocations be used to ensure scale-up, impact and paced reductions, as<br />described in paragraph 4.c of the Allocation Methodology; and</li> <li>Reaffirms the Core Funding Model Principles, as presented in Annex 3 to GF/B35/05 – Revision 1.</li> </ol> </li> <li>Accordingly, the Board:<br /> <ol type="a"> <li>Requests the SC to review and approve, at its July 2019 meeting, the method by which the Secretariat will apply and report on the qualitative adjustment process; and</li> <li>Acknowledges that the Allocation Methodology and Technical Parameters shall apply for the 2020 – 2022 allocation period and supersede the 2017 – 2019 allocation methodology and technical parameters presented in GF/B35/05 – Revision 1.</li> </ol> </li> </ol>

<ol> <li>The Board approves the revised Governance Performance Assessment Framework as set forth in Annex 1 to GF/B41/ER01 (“Framework”), which shall enter into force upon Board approval of this decision point.</li> <li>The revised Framework shall supersede all prior versions of the Governance Performance Assessment Framework.</li> <li>The Board mandates the Ethics and Governance Committee (“EGC”) to regularly review the Framework and delegates decision-making powers to the EGC for any future changes to the Framework and any supporting materials related to it.</li> </ol>

<p><span>The Board:</span><span></span></p> <ol> <li><span>Approves the revised budget recommended for each grant listed in Table 1 of GF/B41/ER03 (“Table 1”);</span><span></span></li> <li><span>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</span><span></span></li> <li><span>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</span></li> </ol>

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2018 Annual Financial Report, which includes the 2018 Consolidated Financial Statements that have been audited by KPMG SA, as set forth in Annex 1 to GF/B41/04.</p>

<p>The Board:</p> <ol> <li>Expresses continuing concern about the public health crisis in Venezuela, a country that has been made eligible for Global Fund funding for malaria only for the 2020-2022 allocation period, under GF/B41/EDP06, and its adverse impact on the fight against HIV, tuberculosis and malaria in Venezuela and the region;</li> <li>Acknowledges the new proposal for exceptional funding presented by the Secretariat, and developed in consultation with partners and civil society, in accordance with the approach for potential engagement with non-eligible countries in crisis approved by the Board through GF/B39/DP04;</li> <li>Recognizes that the emergency circumstances in Venezuela continue to require unique implementation and management arrangements, which differ substantially from the standard Global Fund funding model and applicable policies, as described in GF/B41/ER10 and Annex 1;</li> <li>Accepts that the proposed implementation and management arrangements continue to entail unique risks, as described in GF/B41/ER10 and Annex 1, including that the Office of the Inspector General will not be able to provide the Board with assurance, whether through audit or investigation work, over the funds disbursed under the proposed funding arrangements and that civil society oversight may not be able to provide adequate assurance as envisaged in GF/B41/ER10 and Annex 1;</li> <li>Based on the recommendation of the Strategy Committee, approves the investment and terms set forth in Annex 1, to provide an additional USD 6,000,000, for the year 2020, to support the procurement of critical HIV, TB and malaria health products for Venezuela and social monitoring of the investment; and</li> <li>Calls for continuous engagement from relevant partners, donors and other stakeholders to further support a regional response to the health crisis in Venezuela.</li> </ol>

<p>The Board approves the appointment of Dr. Mohsen Asadi-Lari, representing the Eastern Mediterranean Region Constituency, as a voting member of the Audit and Finance Committee for a term that will expire in May 2020.</p>

<p>Based on the recommendation of the Audit and Finance Committee, as set forth in GF/AFC09/DP03, the Board authorizes the reappointment of KPMG SA as the Global Fund’s independent external auditor for a second term of three years beginning with the 2019 financial year.</p>

<p>The agenda for the 41st Board Meeting (GF/B40/01) is approved.</p>

<p>Mr. Rico Gustav from the Communities constituency is designated as Rapporteur for the 38th Board Meeting.</p>

<p>The Board:</p> <ol> <li>Based on the recommendation of the Ethics and Governance Committee, the Board approves the Guideline for Annual Performance Assessment of Board Direct Reports as set forth in Annex 1 to GF/B38/ER04. This Guideline shall apply to the assessment of the performance of the Executive Director and the Inspector General during 2018 and onward.</li> <li>The Board directs the Ethics and Governance Committee (EGC) to review the guideline every three years, starting in 2020, to ensure its continued relevance.</li> <li>The Board delegates to the EGC the authority to approve revisions to the Guideline for Annual Performance Assessment to Board Direct Reports and to report such changes to the Board.</li> <li>The Board delegates to the EGC the authority to appoint a member of the EGC in replacement of the Board Chair or Vice Chair for the purposes of the performance assessment of the Executive Director or Inspector General in the event of a recusal of any of the said officials.</li> </ol>

<ol> <li>Based on the recommendation of the Ethics and Governance Committee, the Board approves the Global Fund Policy to Combat Fraud and Corruption as set forth in Annex 4 to GF/B38/06 – Revision 2;</li> <li>The Board directs the Executive Director to develop an implementation plan, and to periodically report to the Board through the Ethics and Governance Committee on its implementation of the Policy to Combat Fraud and Corruption, as part of regular updates pursuant to the Ethics and Integrity Framework; </li> <li>Consistent with his/her authority to implement the Policy to Combat Fraud and Corruption, the Executive Director shall have delegated authority to approve exceptions to the Policy. This provision does not apply to access rights of the Office of the Inspector General for which the Inspector General shall have such delegated authority; and</li> <li>The Board further directs that appropriate and regular reporting be made by the Executive Director and Inspector General to the Ethics and Governance Committee or the Audit and Finance Committee on the exercise of the authority delegated under paragraph 3 of this Decision Point; and</li> <li>The authority delegated to the Executive Director and the Inspector General, as the case may be, under paragraph 3 of this Decision Point expires at the moment when the Board has adopted the framework the Board has requested the Secretariat to develop in GF/B37/DP07.</li> </ol>

<p>Approves the Global Fund Honorarium Framework, as set forth in Annex 1 to GF/B38/ER09.</p>

<ol> <li>Based on the recommendation of the Strategy Committee, the Board approves: <ol type="a"> <li>the revisions for Key Performance Indicator 6a as presented in GF/B43/ER06;</li> <li>the performance target for Key Performance Indicator 6f as presented in GF/B43/ER06; and</li> <li>the revisions for Key Performance Indicator 9c as presented in GF/B43/ER06.</li> </ol> </li> <li>Based on the recommendation of the Audit and Finance Committee, the Board approves the revision to the 2020 performance target for Key Performance Indicator 12b as presented in GF/B43/ER06.</li> </ol>

<p>The agenda for the 43rd Board Meeting (GF/B43/01) is approved.</p>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 1 of GF/B43/ER01 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li> </ol>

<ol> <li class="x_MsoNormal">Based on the recommendation of the Ethics and Governance Committee (GF/EGC12/EDP02), the Board approves the amended and restated Policy on Conflict of Interest, as set forth in Annex 1 to GF/B43/ER04;</li> <li class="x_MsoNormal"><span></span>Accordingly, the Board acknowledges that this decision point and the amended and restated Policy on Conflict of Interest shall supersede the decision point GF/B27/DP05, the previous Policy on Ethics and Conflicts of Interest for Global Fund Institutions as set forth in Annex 1 to GF/B27/07 and the previous Declaration of Interest Form set forth in Annex 2 to GF/B27/07.</li> </ol>

<ol> <ol> <li>The Board recognizes that the COVID-19 pandemic remains a global public health emergency and that failure to control the pandemic threatens to derail the Global Fund’s mission to fight HIV/AIDS, tuberculosis, and malaria and to strengthen systems for health. The Board further recognizes the importance of ensuring rapid availability of quality COVID-19 products as part of the global response to COVID-19, and the significant benefits that beneficiaries in Global Fund-eligible and transitioned countries could potentially gain from improved access to pooled procurement volumes of these products.</li> <li>The Board notes the Secretariat is engaging with partners, notably WHO, UNICEF, UNITAID, GDF, FIND, Africa CDC and the newly-created Africa Medical Supply Platform, and taking an active role in the ACT-A partnership and the Diagnostics Consortium, to ensure collaboration, coherence and flexibility in providing procurement options and solutions for countries to address the challenges of managing supply constraints and access to quality health products in the context of COVID-19. In this rapidly evolving context, the Board wishes to leverage wambo.org, and the pilot for non-Global Fund-financed transactions as defined in GF/B42/DP05 (the Pilot) to facilitate broader access to COVID-19 product.</li> <li>The Board notes that the Secretariat is using the wambo.org platform to facilitate the procurement of certain COVID-19 products purchased by Global Fund Principal Recipients. The Board further notes that the framework of eligibility and quality assurance defined in GF/B42/EDP11 for COVID-19 products is being proposed to apply to products available to all eligible buyers on wambo.org.</li> <li>In order to allow broader access to these products, as presented in GF/B43/ER07, the Board decides to formally extend the scope of the Pilot to include for eligible buyers as defined in GF/B42/DP05, the purchase of all COVID-19 products available in wambo.org for procurement by Global Fund Principal Recipients.</li> <li>Such non-Global Fund-financed transactions for COVID-19 products will:<br />- be individually subject to agreement by the Global Fund and, if applicable, to agreement by the product catalogue owners or manufacturers; <br />- not count towards the cap of USD 50 million of transactions for the Pilot otherwise applicable to non-COVID-19 products;<br />- be issued as Purchase Orders by wambo.org within the period ending in 31 December 2020, unless extended by the Board following recommendation by the Strategy Committee.</li> <li>As with the Pilot, use of the wambo.org platform for non-Global Fund-financed transactions will remain optional for eligible buyers of COVID-19 products.</li> <li>Recognizing the extraordinary conditions due to the COVID-19 pandemic under which non-Global Fund-financed transactions for COVID-19 products will be processed, and the importance of maintaining the integrity of the Pilot as currently established, the Board further decides:<br />a. reporting of transactions for COVID-19 products will be included in the biannual reporting on the Pilot to the Strategy Committee, following the same principles as other transactions, in particular with respect to the determination of metrics for reporting, which will be agreed by the Strategy Committee in October 2020. However, COVID-19 product transactions will be disaggregated from reporting on other Pilot transactions, so as to enable integration with overall reporting on the COVID-19 response, and to avoid distorting reporting on the original Pilot.<br />b. these COVID-19 transactions, disaggregated from other Pilot transactions, will be included in the final independent evaluation of the Pilot, to be delivered no later than end of 2022.<br />c. with the Strategy Committee, to resume broader discussions of wambo.org’s future strategy for the Pilot and its role and market influence within the development of the Phase 2 of the Market Shaping Strategy and the next Global Fund Strategy in 2020-2021.</li> </ol> </ol>

<p class="x_MsoNormal"><span>The Board approves the Report of the 43^rd Board Meeting, as set forth in GF/B43/13.</span></p>

<p>The Board:</p> <ol> <li>Notes its responsibilities with regard to the recruitment process of the Inspector General as set out in Article 36 of the Operating Procedures of the Board and Committees of the Global Fund to Fight AIDS, Tuberculosis and Malaria;</li> <li>Based on the recommendation of the Chair and Vice-Chair of the Board (the “Board Leadership”), in consultation with the Ethics and Governance Committee, and its review of the contents of GF/B43/12 – Revision 1 approves: <ol type="a"> <li>The terms of reference of the 2020 Inspector General Nomination Committee, as set out in Annex 1 to GF/B43/12 – Revision 1; and,</li> <li>The revised terms of reference of the Inspector General, as presented in Annex 2 to GF/B43/12 – Revision 1, which shall enter into force upon the commencement of the term of the next Inspector General.</li> </ol> </li> <li>Requests the Board Leadership to submit a Chair, Vice-Chair and the membership of the nomination committee to the Board for approval.</li> </ol>

<ol start="1" type="1"> <li class="x_MsoListParagraphCxSpLast"><span>Based on the recommendation of the Ethics and Governance Committee (GF/EGC12/EDP01), the Board approves the revisions to the Code of Conduct for Governance Officials, as set forth in Annex 1 and 2 to GF/B43/ER05, developed in furtherance of the Ethics and Integrity Framework adopted by the Board at its 32nd Meeting (GF/B32/DP09);</span></li> <li class="x_MsoListParagraphCxSpLast">Accordingly, the Board acknowledges that this decision point and the revisions to the Code of Conduct for Governance Officials shall supersede the approval of the previous Code of Ethical Conduct for Governance Officials, as set forth in Annex A to GF/B33/15 – Revision 2, pursuant to paragraph 2 of the decision point GF/B33/DP10.</li> </ol>

<p>Ambassador Stéphanie Seydoux from the France constituency is designated as Rapporteur for the 43rd Board Meeting.</p>

<ul> <li>The report of the Eighth Board Meeting is approved.</li> </ul>

<p>The Board replaces the phrase "Option (c) is applicable only until December 31, 2004" in the Board decision on quality assurance (compliance with quality standards) from the Third Board Meeting (GF/B4/2, p. 23) with "Option (c) is applicable only until December 31, 2005</p><p>The Board invites the World Health Organization to work with the Secretariat to assess the impact of the expiry of the transition period established in Option (c) and to develop options on the quality assurance of single- and limited-source products, and to report back to the PMPC in time for the development of recommendations for the Tenth Board Meeting.</p>

The Board approves the nomination of Mr Kofi Annan, Secretary-General of the United Nations, as Chair and Mr Sven Sandström as Vice Chair of the Voluntary Replenishment Mechanism of the Global Fund. The Board expresses its appreciation to both Mr Annan and Mr Sandström for their commitment and their willingness to undertake this important task.

<ul type="disc"><li>Ms. Lucia Fiori from the Italian Constituency is designated as Rapporteur for the Ninth Board Meeting.</li></ul>

<p>Decision Point 1</p> <p>The Board adopts the following requirements for CCMs:</p> <ol type="a"> <li>All CCMs are required to show evidence of membership of people living with and/or affected by the diseases;</li> <li>CCM members representing the non-government sectors must be selected by their own sector(s) based on a documented, transparent process, developed within each sector;</li> <li>CCMs are required to put in place and maintain a transparent, documented process to: <ol type="i"> <li>Solicit and review submissions for possible integration into the proposal;</li> <li>Nominate the Principal Recipient and oversee program implementation;</li> <li>Ensure the input of a broad range of stakeholders, including CCM members and non-members, in the proposal development and oversight process</li> </ol> </li> </ol> <p>There are no material budgetary implications of this decision.</p> <p>Decision Point 2</p> <p>The Board agrees to make the following word substitution in the CCM Guidelines:</p> <p>When the PRs and Chair or Vice Chairs of the CCM are the same entity, the CCM must should have a written plan in place to mitigate against this inherent conflict of interest.</p> <p>There are no material budgetary implications of this decision.</p>

<p>Decision Point 1:</p> <p>The Board approves the Board Calendar for 2005 as attached.</p> <p>Decision Point 2:</p> <p>The Board accepts with gratitude the offer from Sweden to host the 1^st Replenishment Conference in Stockholm.</p> <p>Decision Point 3:</p> <p>The Board accepts with gratitude the offer from the United Kingdom to host the 2^nd Replenishment Conference.</p> <p>Decision Point 4:</p> <p>The Board accepts the invitation of Morocco to host the Twelfth Board meeting, and Latin America and the Caribbean to host a Board Meeting in 2008.</p>

The Board extends the deadline for the signing of a grant agreement for the Andean Regional Project - Malaria control in cross border areas of the Andean countries for three months to 19 June 2005.

The Board approves the Guidelines for the Fifth Call for Proposals.

<p>Decision Point 1</p> <p>The Board approves the list of persons contained in Annex 3 of the Report of the Portfolio Management and Procurement Committee (GF/B9/9) who have been recommended by the Portfolio Management and Procurement Committee and the Executive Director to fill the vacancies on the Technical Review Panel.</p> <p>There are no material budgetary implications for this decision point. </p> <p>Decision Point 2</p> <p>The Board approves the list of persons contained in Annex 4 that have been recommended by the PMPC and the Executive Director to comprise the TRP Support Group.</p> <p>There are no material budgetary implications for this decision point. </p> <p>Decision Point 3</p> <p>Board decides that the language used in its decisions for the approval of Category 2 proposals shall be modified to read as follows:</p> <p>"Recommended proposals provided adjustments and clarifications are met within a limited timeframe (the initial reply to TRP adjustments and clarifications should be received within 6 weeks of the applicant's receipt of the initial decision of the Board, and any further adjustments and clarifications should be completed within 4 months from the receipt of the initial reply from the applicant). The TRP Chair and/or Vice-Chair shall give final approval based on consultations with the primary and secondary reviewers."</p> <p>There are no material budgetary implications for this decision point. </p>

<p>Decision Point 1</p> <p>The Board decides to use the following language in its decisions for the approval of Category 1 and 2 proposals in order to recognize that the Secretariat may ask the Technical Review Panel to re-review proposals in the course of implementation:</p> <p>"This approval is subject to re-review by the Technical Review Panel if, after consultation with the recipient but in the sole discretion of the Global Fund, changes in scientific evidence (as identified in collaboration with WHO and other technical partners) materially affect the proposal."</p> <p>The Board further decides that following such re-review, should the TRP recommend that, in light of the new scientific evidence, the approach taken in the proposal should be changed, the Board should reconsider the approval of the proposal. The recipient will have the opportunity to submit a revised version of the relevant parts of the proposal prior to the Board's decision.</p> <p>There are no material budgetary implications for this decision point. </p> <p>Decision Point 2</p> <p>The Board expands the circumstances in which the Phase 2 decision-making process can be accelerated by modifying the existing decision on the Phase 2 process, as set forth in GF/B8/2, page 7, to read as follows:</p> <p>"The decision may be taken earlier in cases of (i) accelerated implementation; (ii) severe exchange rate fluctuations; or (iii) additional financing needs resulting from changes in scientific evidence."</p> <p>There are no material budgetary implications for this decision point.</p>

<p>The Board appoints the following individuals to serve as members of the Inspector General Nomination Committee (Nomination Committee) in accordance with the terms of reference of the Nomination Committee approved under decision point GF/B43/DP03 and set out in Annex 1 to GF/B43/12 – Revision 1:</p> <ul> <li>Grace Rwakarema, Chair</li> <li>Thomas Alexander, Vice-Chair</li> <li>Allan Maleche, Member;</li> <li>Thomas Morrow, Member;</li> <li>David Webb, Member;</li> <li>Diana Isiye; Independent Member and,</li> <li>Norbert Hauser, Independent Member.</li> </ul>

<p> Ratification of Board Committee leadership and composition: Approved to defer the ratification of Board Committee Chairs and Vice Chairs and committee composition until Friday, 31 January 2003, after the election of Board Chair and Vice Chair and after the committee reports have been heard.</p> <p>Report of the Third Board Meeting (GF/B4/2): The Board approves the Report of the Third Board Meeting with the deletion of the reference to any Article number in section 9.2.1, so that the last sentence reads, "(Legal advice will be sought on whether the implementation of this decision requires a change of the By-Laws)".</p>

<p>The Board hereby notes the Executive Director’s appointment of the following senior management official of the Global Fund:</p> <ol type="i"> <li>Adda Faye, as Chief Financial Officer.</li> </ol>

<p>In response to the exceptional circumstances related to the current Covid-19 pandemic, the Board:</p> <ol> <li>Extends its recognition to Dr Donald Kaberuka, Chair of the Board, and Lady Roslyn Morauta, Vice-Chair of the Board, for their service since May 2019;</li> <li>Thanks the Ethics and Governance Committee for their recommendation and notes the analysis and review process preceding this decision; and</li> <li>Extends the terms of Dr Donald Kaberuka, as Chair of the Board, and Lady Roslyn Morauta, as Vice-Chair of the Board, to the adjournment of the first Board Meeting in 2022.</li> </ol>

<p>The Board, taking into account the specific nature of Local Fund Agent (the “LFA”) services as described in GF/B38/ER01 decides to:</p> <ol> <li>Replace its prior decision on Re-tendering Local Fund Agent Contracts (GF/B15/DP50) with the Principles of the LFA Procurement Method: Differentiation; Ensuring value-for-money through monitoring LFA performance and cost; Encouraging the diversity of LFA service providers; and Unique contracting arrangements, as set forth in Part 6 of GF/B38/EDP01 (the “Principles of the LFA Procurement Method”);</li> <li>Delegate to the AFC the authority to approve modifications to the Principles of the LFA Procurement Method; and</li> <li>Delegate to the Secretariat the authority to approve the procedures for procurement of LFA services in accordance with the Principles of the LFA Procurement Method Budgetary implications: no additional resources required</li> </ol>

<p>The agenda for the 38th Board Meeting (GF/B38/01) is approved.</p>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 to GF/B38/EDP12 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<ol> <li>The Board approves the appointment of: <ol type="i"> <li>Beatrijs Stikkers-Muller as Chair of the Audit and Finance Committee;</li> <li>Anthony Garnett as Vice-Chair of the Audit and Finance Committee;</li> <li>Sandra Thurman as Chair of the Ethics and Governance Committee;</li> <li>Grace Rwakarema as Vice-Chair of the Ethics and Governance Committee;</li> <li>Kieran Daly as Chair of the Strategy Committee; and</li> <li>Abdalla Osman as Vice-Chair of the Strategy Committee.</li> </ol> </li> </ol> <ol start="2"> <li>The Board notes each Committee Chair and Vice-Chair appointed under this decision point shall begin their term on 11 May 2018 and serve for two years or until the appointment of their successor.</li> </ol>

<p>Based on the recommendation of the Audit and Finance Committee, the Board approves the following:</p> <ol> <li>2018 Corporate Work Plan and Budget Narrative, as set forth in GF/B38/04B; and </li> <li>2018 Operating Expenses Budget in the amount of up to USD 312.0 million, as set forth in GF/B38/04A- Revision 1 (the “2018 OPEX Budget”), which includes USD 15.92 million for the Office of the Inspector General’s 2018 operating expenses and up to USD 12.0 million as exceptional, one-off impact of the Global Health Campus infrastructure investment.</li> </ol> <p>However, the Board reaffirms the agreement that the total operating expenses over the 2017-2019 period will remain within USD 900.0 million and requires that the Secretariat undertake a comprehensive review of both the operating expense budget for 2019 and the operating expenses required to meet the Global Fund’s strategic objectives, in connection with the presentation of the 2019 operating expense budget.</p>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 to <span>GF/B38/EDP08</span> (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>Set forth below is the Secretariat’s recommendation to approve funding up to an amount of US$ 1,321,996,861 and EUR 52,050,991; this includes country allocation funding as well as US$ 32,737,727 of catalytic investments for matching funds.</p> <p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 to GF/B38/EDP04 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>Report of the 38th Board Meeting</p>

<ol> <li>The Board approves the appointment of Madame Estelle Tiphonnet-Diawara, representing the French Constituency, as a voting member of the Strategy Committee (“SC”) for a term that will expire in May 2018, or until the appointment of her successor.</li> </ol>

<p>The Board appoints Peter Sands to serve as the next Executive Director of the Global Fund for a four-year term.</p>

<ol> <li>Based on the recommendation of the Audit and Finance Committee contained in GF/AFC05/DP01, the Board approves the 2018 performance target for Key<br />Performance Indicator 12b as presented in GF/B38/05A and notes the review of the 2018 target planned for Q1 2018.</li> <li>Based on the recommendation of the Strategy Committee contained in GF/SC05/DP04, the Board: <ol type="a"> <li>Approves the performance targets for Key Performance Indicators 3, 6a i, 6a ii, 6b and 6e as presented in GF/B38/05A; and</li> <li>Agrees to postpone its review and approval of the performance target for Key Performance Indicator 6a iii, until such time as a baseline is available.</li> </ol> </li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Tables 1a and 1b to GF/B38/EDP16 (“Table 1a” and “Table 1b”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a and Table 1b,or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li> </ol>

<ol> <li>The Board approves the appointment of the following individuals to serve as non-voting independent members of the Audit and Finance Committee (the “AFC”) listed below, in the areas of expertise listed by their name: <ol type="i"> <li>Robert Samels, financial audit; and</li> <li>Diana Isiye, forensic investigation.</li> </ol> </li> <li>The Board approves the appointment of the following individual to serve as non-voting independent member of the Ethics and Governance Committee (the “EGC”) listed below, in the area of expertise listed by his name: <ol type="i"> <li>Mohammad Ali Mubarak Kisubi, ethics.</li> </ol> </li> <li>The Board notes each independent committee member appointed under this decision point is entitled to receive honoraria in accordance with the Global Fund’s Honorarium Framework.</li> <li>The Board notes each independent committee members appointed under this decision point shall begin their term on 24 June 2020 and serve for two years or until the appointment of their respective successors.</li> </ol> <p> </p>

<p>The Board:</p> <ol> <li>Expresses continuing concern about the public health crisis in Venezuela, a country that has been made eligible for Global Fund funding for malaria only for the 2020-2022 allocation period, under GF/B41/EDP06, and its adverse impact on the fight against HIV, tuberculosis and malaria in Venezuela and the region;</li> <li>Acknowledges the new proposal for exceptional funding in 2021 presented by the Secretariat, and developed in consultation with partners and civil society, in accordance with the approach for potential engagement with non-eligible countries in crisis approved by the Board through GF/B39/DP04;</li> <li>Recognizes that the emergency circumstances in Venezuela continue to require unique implementation and management arrangements, which differ substantially from the standard Global Fund funding model and applicable policies, as described in GF/B44/ER16 and Annex 1;</li> <li>Accepts that the proposed implementation and management arrangements continue to entail unique risks, as described in GF/B44/ER16 and Annex 1, including that the Office of the Inspector General will not be able to provide the Board with assurance, whether through audit or investigation work, over the funds disbursed under the proposed funding arrangements and that civil society oversight may not be able to provide adequate assurance as envisaged in GF/B44/ER16 and Annex 1;</li> <li>Based on the recommendation of the Strategy Committee, approves the investment and terms set forth in Annex 1, to provide an additional US$ 6,000,000, for the year 2021, to support the procurement of critical HIV &amp; TB health products for Venezuela and social monitoring of the investment; and</li> <li>Calls for continuous engagement from relevant partners, donors and other stakeholders to further support a regional response to the health crisis in Venezuela.</li> </ol>

<ol> <li>The Board approves the appointment of Ms Shirley Carruthers, representing the Canada, Switzerland and Australia Constituency, as a voting member of the Audit and Finance Committee for a term that will expire in May 2022, or until the appointment of her successor.</li> <li>The Board approves the appointment of Mr Chimi Dorji, representing the South East Asia Constituency, as a voting member of the Audit and Finance Committee for a term that will expire in May 2022, or until the appointment of his successor.</li> <li>The Board approves the appointment of Ms Nathalie Olijslager, representing the Point Seven Constituency, as a voting member of the Ethics and Governance Committee for a term that will expire in May 2022, or until the appointment of her successor.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B43/ER14 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B43/ER18 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p class="p1">The Board</p> <p class="p1">Mandates the Chair of the Board and the Vice-Chair of the Board, acting jointly</p> <ol class="ol1"> <li class="li2">to negotiate the terms of an employment agreement with each of the final candidates identified by the Inspector General Nomination Committee for the position of Inspector General</li> <li class="li2">to execute on behalf of the Global Fund the employment agreement with the Inspector General ultimately appointed by the Board, and</li> <li class="li2">to set the annual salary of the Inspector General within the salary scale applicable for the position of Inspector General, as set out in the Amended and Restated Global Fund Human Resources Policy Framework.</li> </ol>

<p>The Board:</p> <ol> <li>Recalls GF/B43/EDP07 where it decided to extend the scope of the wambo.org pilot to allow for eligible buyers, as defined in GF/B42/DP05, to purchase all COVID-19 products available in wambo.org for procurement by Global Fund Principal Recipients and specified that such non-Global Fund financed transactions for COVID-19 products will be issued as purchase orders by wambo.org within the period ending 31 December 2020, unless extended by the Board following a recommendation by the Strategy Committee; and</li> <li>Based on the recommendation of the Strategy Committee (GF/SC14/DP05), the Board approves the change in the end date of such period through which non-Global Fund financed transactions for COVID-19 products may be issued as purchase orders by wambo.org to 31 May 2021 and confirms that all other conditions and flexibilities set forth in GF/B43/EDP07 shall continue to apply.</li> </ol>

<p>The Board agrees that COVID-19 continues to pose a grave threat to the Global Fund’s mission to fight HIV/AIDS, tuberculosis, and malaria and strengthen systems for health, and that continued support for country responses to COVID-19 is critical to safeguard Global Fund programs and country health systems. The Board acknowledges its previous decisions establishing the Global Fund COVID-19 Response Mechanism (C19RM) to provide additional support for country responses to COVID-19 (GF/B42/EDP11), and approving certain time-bound operational flexibilities to ensure the continued delivery of the Global Fund mission during the pandemic (GF/B42/EDP10). Noting that COVID-19 continues to jeopardize country health systems and impede progress in the Global Fund’s mission, and that additional funds may become available for C19RM, the Board:</p> <ol> <li>Approves that the Secretariat may approve requests for C19RM funds through 15 April 2021;</li> <li>Affirms that all other previously approved principles under GF/B42/EDP11 will continue to apply to C19RM;</li> <li>Requests the Secretariat to return to the Board, through its Committees as relevant, for additional consideration and approval should further extensions of C19RM be required as the pandemic continues to evolve, or if total additional funding for C19RM exceeds USD 500 million; and</li> <li>Approves that the operational flexibility under paragraph 3 of GF/B42/EDP10, delegating authority to the Secretariat to grant limited exceptions to the Quality Assurance Policies to waive the requirement for pre-shipment sampling and testing for Expert Review Panel-approved products, vector control products, and condoms, where such testing may delay the delivery of products to countries, will apply through 15 April 2021.</li> </ol>

<p><b>Decision Point:</b> </p><p>1.1 The choice of currency will apply only to new proposals submitted after 1 January 2005. Specifically:</p><p>1.2 Grants approved in Rounds 1 through 4 which have not been signed by 1 January 2005 will continue to be denominated in USD (i.e. the currency choice applies from Round 5 onwards)</p><p>1.3 Phase 2 renewals are not regarded as new proposals and hence will continue to be denominated in the currency chosen for Phase 1.</p><p>1.4 The currency choice must be made at the time of submission of the Proposal. Specifically, the applicant cannot change its chosen currency at any time after submission of the Proposal (including during implementation). </p>

<ul><li>Requests the Chairs of the Governance and Partnership Committee and the Portfolio and Procurement Committee consult together with the Executive Director to identify inputs on this issue for the Revised Proposal Guidelines for Round 3;</li></ul><ul><li>Requests the Committee to revisit the issue of CCMs, based on inputs from Board Members, and prepare recommendations for the next Board meeting;</li></ul>

<p>1. The Board of the Global Fund accepts the procedure for the conduct of the current Election for Chair and Vice Chair of the Board as presented in the Proposed Election Procedure to the Board on 31 January 2003.</p><p>2. The Board of the Global Fund mandates the Governance and Partnership Committee to constitute a sub-group to develop election procedures for future elections and a success policy and to revise the Board Operating Procedures accordingly.</p>

<p>1.Based on the recommendation of the Strategy, Investment and Impact Committee, the Board approves the Sustainability, Transition and Co- Financing Policy, as set forth in Annex 1 to GF/B35/04 - Revision 1 (the "STC Policy").</p> <p>2.Accordingly, the Board:</p> <p>a.Acknowledges this decision point and the new co-financing policy set forth in the STC Policy supersede Board decision point GF/B30/DP05 and the previous Counterpart Financing Policy as set forth in Attachment 1 to GF/B30/6 - Revision 1 (the "Counterpart Financing Policy"); and</p> <p>b.Notes that notwithstanding paragraph 2.a. of this decision point, the Counterpart Financing Policy remains applicable to grant programs originating from the 2014 - 2016 allocation period.</p>

<p>The report of the Fifth Board Meeting was approved with the following changes:</p> <ul> <li>Page 5 - The Board asks the Governance and Partnership Committee …</li> </ul> <p>For the Board 6 meeting, that the constituencies of the Chair and Vice Chair be permitted to designate two Alternate Members, based on the condition that the delegate from those constituencies sitting as Chair or Vice Chair recuse themselves from all votes.</p>

<p>The Board approved the following decisions:</p> <p>Decision Point 1</p> <p>Resource-mobilization should use a periodic replenishment model on a voluntary basis for all public donors, complemented by additional ad hoc contributions for all donors, including new public donors, the private sector, and individuals.</p> <p>Decision Point 2</p> <p>TRP-recommended proposals should be approved up to the total of resources available.</p> <p>Decision Point 3</p> <p>Proposals are approved for the entire term of the proposal (up to five years) with a financial commitment for the initial two years with the possibility of renewal for up to an additional three years, with the following conditions: </p> <p>a. The Board may approve proposals and commit funds for two years up to the cumulative uncommitted amount pledged through the calendar year of the Board decision;</p> <p>b. A sufficient amount of assets to meet the full cost of two years of implementation of approved grants must be deposited with the Trustee or readily available on demand prior to the Secretariat signing a grant agreement;</p> <p>c.    Based on successful implementation of a grant, funding beyond its first 2 years receives priority over the funding of new proposals;</p> <p>d. No funds for appeals should be reserved. Successful appeals should be funded immediately if resources are available or as soon as new resources become available. </p> <p>Decision Point 4</p> <p>Both cash and demand public promissory notes should be considered as assets. </p> <p>Decision Point 5</p> <p>The Board will announce a minimum of one Call for Proposals per calendar year.</p> <p>The Board can adjust this based on need and on resources available. </p> <p>A forecast of the resources available for the Round will be announced at the time that the Call for Proposals is issued. </p> <p>Decision Point 6</p> <p>At the final Board meeting of each year, beginning with the 2004 budget, the Global Fund will forecast resources and estimate demand for the next year. </p> <p>This estimate will show clearly the funds available for commitment. </p> <p>This estimate should be attached to the annual budget.</p> <p>This estimate should be updated at each Board meeting. </p> <p>Decision Point 7</p> <p>Technical merit will be the criteria used to determine proposal approval.</p> <p>The Technical Review Panel should refine its recommendations in category 2 in a way that will facilitate the Board's prioritization of proposals for approval. </p> <p>If it is necessary to further prioritize within these sub-categories, the following additional criteria will be used by the Board: poverty, disease burden, repeated failures for the same component and other criteria which the Board deems appropriate. </p> <p>Decision Point 8</p> <p>The Board will not partially approve components. </p> <p>Decision Point 9</p> <p>The Secretariat will work with the Trustee, the MEFA Committee, and other partners such as WHO and UNAIDS to develop financial models that provide regular estimates of resources available for commitment and of demand for Global Fund financing, to be presented to the Board at its seventh meeting. </p> <p>Decision Point 10</p> <p>The Secretariat will work with the Trustee and the MEFA Committee to determine the specific criteria on promissory notes to be considered as assets, to be presented to the Board at its seventh meeting.</p> <p>Decision Point 11</p> <p>The Secretariat will work with the MEFA Committee and with PMPC to determine the process for the extension of two-year grants, to be presented to the Board at its seventh meeting. </p> <p>Decision Point 12</p> <p>The Secretariat will work with PMPC to operationalize the principles for prioritization among TRP-recommended proposals, to be presented to the Board at its seventh meeting. </p> <p>Decision Point 13</p> <p>The Secretariat will work with the MEFA Committee to identify a set of indicators for assessing the performance of the Global Fund's financial policies, to be presented to the Board at its seventh meeting. </p>

<ol> <li>The Board approved that the RMCC and the PMPC form a joint working group to develop proposals on the issue of in-kind donations.</li> <li>The RMCC will urgently develop a resource mobilization strategy, in full consultation with other partners, consistent with the comprehensive funding policy to raise funds sufficient to meet future needs. This strategy will include the sustainable mechanism for the agreed voluntary replenishment process.</li> <li>The Secretariat working closely with the RMCC will develop a workplan to implement this strategy.</li> <li>The RMCC and Secretariat will call upon outside experts to advise and assist them in the design and implementation of this strategy and workplan.</li> <li>The RMCC will report by one month before each Board Meeting on the Global Fund's progress in implementing this strategy.</li> </ol>

<p>The Board approves the recommendations of the Governance and Partnership Committee as follows: </p> <ol> <li>To adopt the Revised Bylaws and Revised Board Operating Procedures as proposed by the Governance and Partnership Committee.</li> <li>To approve the Committee Rules and Procedures as proposed by the Governance and Partnership Committee.</li> <li>Mandate the Board Chair to convene the Ethics Committee and approve the Ethics Committee and its terms of reference.</li> </ol> <p>Partnership Forum</p> <ol> <li>To adopt the approach to the Partnership Forum process and event as proposed by the Governance and Partnership Committee;</li> <li>To agree specifically to hold the 2004 Partnership Forum event contiguous with the IAC AIDS 2004 Conference inBangkok;</li> <li>To agree to hold the Second Board meeting of 2004 in Geneva and not in connection with the Partnership Forum event;</li> <li>To mandate the Board Chair to convene the Steering Committee immediately to begin planning the Partnership Forum process and event; and</li> <li>To approve the Steering Committee and its Terms of Reference as proposed.</li> </ol>

<ol><li>The Board directs the MEFA Committee in its December 2003 meeting to finalize its review and recommendations of the 2004 budget, including comments made by the Board and to bring its final recommendation to the Board at its next meeting in 2004.</li><li>The Board authorizes the Secretariat to continue to operate with the ceiling of the 2003 budget until the 2004 budget can be adopted by the Board. During this interim period, in the event the Secretariat must incur specific expenses not included in the 2003 budget (e.g. Partnership forum venue costs), it shall do so with the understanding that the expense will be covered within the finally adopted 2004 budget. The Secretariat will present a report of its first quarter expenses to the Board in March.</li><li>The Board directs the MEFA Committee to finalize the review of the budget for 2005 and report to the Board for their decision in 2004.</li></ol>

<p>During the 6^thBoard meeting, the Board took the following decision:</p> <p>"The Board approves proposals in TRP category 2B, subject to the completion of TRP clarifications. This decision would become effective upon Board confirmation by email in January 2004. Meanwhile the Secretariat can proceed with resolving TRP clarifications for these proposals." </p> <p>The Board reviewed and confirmed its approval of the decision on category 2B proposals for a total amount of US$138,463,324.</p> <p>The Board noted that as of january 2004, US$604 million is forecastto be available for the Fourth Call for Proposals.</p> <p>The Board noted that this amount will be reducedby the aggregate amount of successful appeals of Third round decisions.</p> <p>The Board noted that the total amount of funds requested in proposals submitted to the AppealsPanel following round 3 and deemed eligible for review is US$101.5million.</p>

<ol> <li>The Board approves for funding the Round 3 categories 1 and 2A today, (15 October) subject to the completion of TRP clarifications.</li> <li>The Board approves proposals in TRP category 2B, subject to the completion of TRP clarifications. This decision would become effective upon Board confirmation by email in January 2004. Meanwhile the Secretariat can proceed with resolving TRP clarifications for these proposals.</li> <li>The completion of TRP clarifications in Category 1 should be completed within 4 weeks of the applicant's receipt of the initial decision of the Board, and given final approval by the TRP Chair and/or Vice Chair.</li> <li>The initial reply to TRP clarifications for proposals in Category 2 should be received within 6 weeks of the applicant's receipt of the initial decision of the Board, and any further clarifications should be completed within 4 months from the receipt of the initial reply from the applicant. The TRP Chair and/or Vice Chair shall give final approval based on consultations with the primary and secondary reviewers.</li> <li>Proposals in Category 3 are not recommended in their current form but are encouraged to resubmit.</li> <li>Proposals in Category 4 are not recommended for funding.</li> <li>The Board requests the PMPC and GPC to examine the issue of non-CCM proposals that have been approved by the Board and that may be against the criteria for non-CCM proposals, and report to the Seventh Board Meeting.</li> <li>The Board requests the PMPC and GPC to review the applicability of the eligibility criteria to future non-CCM applications.</li> <li>The Board requests the GPC todevelop with reference to the Framework Document guidelinesrecommendations for alternative funding mechanisms where particular constraints exist about funding the proposed Principal Recipients and sub recipients. These recommendations should reflect the humanitarian spirit of the Global Fund and the desire to direct funds quickly and accountably to affected populations. These modalities, subject to approval by the Board, should also apply to all approved proposals in Round 3.</li> <li>The Board requests the GPC to examine the possible conflicts of interest between the Chairs of CCMs and the Principal Recipients, particularly in the process of selecting Principal Recipients.</li> <li>The Board requests the GPC to examine the eligibility of CCM applications when the composition of CCMs lacks representation of communities affected by the three diseases and civil society.</li> </ol>

1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B35/ER10 ("Table 1);<br/><br/>2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/><br/>3. Acknowledges the original grant duration, manifested in the form of either the implementation or budgeted period, of each country disease component and its constituent grants listed in Table 2 of Section IV ("Table 2") is shortened according to the operational flexibility granted to the Secretariat pursuant to GF/B31/DP09;<br/><br/>4. Approves the additional incremental funding and implementation period recommended for the Uganda HIV disease component, and the component's constituent grants, as listed in Table 2, based on the available funding that the Finance and Operational Performance Committee (the "FOPC") validated pursuant to GF/FOPC17/DP02;<br/><br/>5. Affirms the (additional) incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br/><br/>6. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and

<ol> <li>The Board endorses the Global Fund's Monitoring and Evaluation strategy as described by the MEFA Committee [the Monitoring and Evaluation Strategy document GF/B6/1 and annex 1 GF/B6/11.1 which describes the management arrangements for the Fund's M&amp;E].</li> <li>The Board approves the correction of the Round 1 grant amounts previously recorded as approved by the Board, in these cases, to reflect the Board's overall decision to approve the first two years of each proposal, thus endorsing the amounts agreed to in the grant agreements.</li> </ol>

<p>The Board:</p> <ol> <li>Notes that the two-year term of the current Board Members began on 28 January 2002 (the appointment of Board Members is recorded in the minutes of the First Board Meeting), the current term of office of Board Members appointed to the first Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria will expire this week. Therefore, Board membership must be confirmed by 28 January 2004.<br /><br /></li> <li><span></span>The final nominations for Board membership were received on 27 January 2004, by the Secretariat and are therefore proposed to the Board for approval in accordance with Article 7.4 of the Bylaws namely:<br /><br /><u>7.4 Functions</u><br /><br />Appoint Board Members selected in accordance with Article 7.2.<br /><br /></li> <li>Notes that Article 7.2 states:<br /><br /><u>7.2 Appointment of Foundation Board Members</u><br /><br />Each group mentioned in Article 7.1 of these Bylaws will determine a process for selecting its Foundation Board representation. Board Members will serve as representatives of their constituencies. Foundation Board members will serve on the Foundation Board for two years or such other term that the Foundation Board may determine.<br /><br />Board members shall be deemed to act in their capacity as representatives of their respective governments, organizations, constituencies and other entities.<br /><br /></li> <li>Approves the new Global Fund Board as listed in the attached document.</li> </ol>

<ol> <li>The Board requested the GPC to address all outstanding issues of the Conflict of Interest Policy for submission to the Board.</li> <li>The Board endorsed the Memorandum of Understanding between the Fund and the Inter-American Development Bank and delegated the Stop TB and Roll Back Malaria Memoranda of Understanding to the GPC, after which they will both be presented for ratification by the Board at its subsequent meeting in 2004.</li> <li>The Board mandated the GPC to work further on the legal status of the Global Fund.</li> <li>The Board delegated authority to execute agreements on its behalf to the Chair, Vice Chair and Executive Director. As necessary and appropriate to maintain continuity of Secretariat operations, in the event the Executive Director is unavailable to exercise such authority the Chief Operating Officer or the Chief Fund Portfolio Director may do so.</li> <li>The Board requested the GPC to address the conditions under which the communities delegation can become a voting member without affecting the existing voting mechanism, and report back to the Seventh Board Meeting.</li> </ol>

<ol><li>The Board requests the PMPC, with the support of the Secretariat, WHO, and UNAIDS to revise the Guidelines for Proposals for the Fourth Round and subsequent Rounds as needed, including taking account of the principles of harmonization.</li><li>The Secretariat should track in their financial projections the pledges as defined by the donor.</li><li>The Fourth Call for Proposal will be launched onJanuary 10, 2004.</li><li>The Board will approve Round 4 proposals at its June Board Meeting.</li><li>The Board reasserts the principles of the governing policy of the Global Fund, asks each stakeholder of the Global Fund to deploy every possible effort to increase the resources available for 2004, and subsequent years and requests that donors specify before the end of 2003 their contributions for 2004.</li><li>The PMPC will revise the guidelines for proposals by January 1 with input from all Board Members.</li></ol>

<p>The Board:</p> <ol> <li>Having read the following message from the Board Chair dated 30 January 2004: <br /><br />"I have been asked by several Board Members to resolve certain issues related to the renewal of Board memberships. There appear to be ambiguities in our By-Laws and Board Operating Procedures related to the terms of Board Members. Specifically, the length of the terms of Board Members is not clearly defined. In the absence of clear guidelines, the Global Fund Secretariat determined that Board membership commenced on January 28. While reasonable, this interpretation has created a significant gap in leadership positions, in particular in the position of Vice Chair. Dr. Lieve Fransen, Chair of the Governance and Partnership Committee, as well as other Committee members, which met this week in Geneva, have suggested that a better interpretation is that new Board Members terms commence at the first Board meeting of the calendar year. I am inclined to agree with this interpretation. I would to ask the Committee to develop language to amend the Board Operating Procedures to resolve this ambiguity for Board review at the March meeting. <br /><br />To resolve the immediate issue, I would like the Board to agree by resolution that new Board members will take their seat on the morning of March 18, the first day of our first Board meeting of the year. Such a solution would allow our current leadership to continue its work in the weeks leading up to the March Board meeting. The terms of office of our new Board Members would therefore extend to the first Board meeting of calendar year 2006, so that incoming Board Members would not lose any net time of service. <br /><br />(...)<br /><br />Sincerely, <br />Tommy G. Thompson <br />Chair, Global Fund Board of Directors" <br /><br /></li> <li>The Board approves that: <br /><br /> <ol> <li>New Board members will take their seat at the start of the first Board Meeting of 2004. <br /><br /></li> <li>The terms of office of new Board Members will extend to the first Board meeting of calendar year 2006.</li> </ol> </li> </ol>

<p>Lennarth Hjelmåker was designated as Rapporteur for the Sixth Board Meeting.</p><ul type="disc"></ul>

<p>The agenda for the Sixth Board Meeting was approved.</p>

<p>The Board adopted the attached Calendar for Board Meetings for 2004 and 2005, with the understanding that the dates will be confirmed at the beginning of each year.</p>

<p>The Board</p><ol><li>The Board affirms its goal of raising US$ 15 billion so that it can effectively support countries in their fight against HIV/AIDS, tuberculosis and malaria in the 2014 – 2016 period. The available resources will be awarded to indicative and incentive funding to invest strategically in areas where there is high potential to achieve impact and value for money while rewarding ambitious, high-quality expressions of full demand, based on robust National Strategic Plans or investment cases. The 2014 – 2016 allocation period is the first where principles adopted under the new funding model (GF/B28/DP4) will be applied. The Board notes that the current replenishment cycle will result in unique actions in order to adjust investments in notionally over- and under-allocated countries. Accordingly, the Board acknowledges implementation methodology developed for the 2014 – 2016 allocation period will be reviewed and modified, as appropriate, for future allocation periods. <br/><br/></li><li>The Board decides: <br/><br/><ol><li type="a">For each allocation period, a fixed percentage of the amount of resources approved by the Board for initial allocation (the “Initial Allocation”), after deduction of the amount allocated to the Country Band corresponding to higher income (GNI per capita) and lower disease burden (“Band 4”), will be used for allocating Incentive Funding to Country Bands 1, 2 and 3. For the 2014 – 2016 allocation period, the Incentive Funding fixed percentage will be set, based on the following Initial Allocation scenarios: 10% for up to US$ 11 billion, 15% for over US$ 11 billion and up to US$ 13.5 billion, or 20% for over US$ 13.5 billion. The balance of the Initial Allocation will be used for Indicative Funding. <br/><br/></li><li type="a">No Incentive Funding will be allocated to the countries within Band 4 since Band 4 is subject to a separate allocation methodology approved by the Strategy, Investment and Impact Committee (the “SIIC”), which recognizes the particular needs of countries / disease components in Band 4. <br/><br/></li><li type="a">A graduated reduction will be applied to the funding levels of disease components that have received funding at levels above their notional shares under the allocation methodology. For 2014 – 2016, this graduated reduction will seek to reflect a target minimum reduction of 20% across the portfolio of impacted disease components relative to the most recent available three-year disbursement levels. The Secretariat shall have discretion to apply appropriate reductions for such disease components to reach the target reduction across the portfolio. <br/><br/></li><li type="a">Disease components that will, after the reduction referred to above, receive funding at levels that exceed their notional shares under the allocation methodology by more than 50% over the 2014 – 2016 allocation period will not be eligible for Incentive Funding during the 2014 – 2016 allocation period. <br/><br/></li><li type="a">Additional resources that become available after the initial allocation of available resources, including accelerations in the graduated reductions described in paragraph 3 of this decision and additional contributions from donors, will be apportioned to fund Unfunded Quality Demand in accordance with the methodology approved by the SIIC for which countries in all four Country Bands will be eligible. <br/><br/></li><li type="a">The SIIC will review this decision and propose appropriate modifications to the Board for approval prior to the 2017 – 2019 allocation period.</li></ol></li></ol>

<p>The Board adopts the following decisions:</p> <p>Decision 1</p> <ol type="a"> <li>Following TRP renewal, approximately one-quarter of the TRP members will be rotated each Round.</li> <li>Members appointed from 2003 onwards will be appointed to serve a term of up to four Rounds.</li> <li>After each Round, the Chair and Vice Chair of the TRP will recommend with specific explanation to the selection panel the members whom should be asked to remain on the TRP (up to a maximum of four Rounds' service for each TRP member).</li> <li>The selection panel will select replacement TRP members from among the TRP Support Pool.</li> </ol> <p>Decision 2</p> <p>For the Fourth and subsequent rounds of applications to the Global Fund:</p> <ol type="a"> <li>Countries classified as "Low Income" by the World Bank are fully eligible to apply for support from the Global Fund.</li> <li>Countries classified as "Lower-Middle Income" by the World Bank are eligible to apply for support from the Global Fund but must meet additional requirements, including co-financing, focusing on poor or vulnerable populations and moving over time towards greater reliance on domestic resources.</li> <li>Countries classified as "High Income" by the World Bank are not eligible to apply for support from the Global Fund.</li> <li>Regional proposals that include a majority of eligible countries may submit applications to the Global Fund.</li> </ol> <p>Decision 3:</p> <p>The Board approves Option One for Round Four.</p> <ol type="a"> <li>Option 1:Countries classified as "Upper-Middle Income" by the World Bank are eligible to apply forsupportfrom the Global Fund only if they face very high current disease burden. This is defined (based on technical input from WHO and UNAIDS) for each disease as follows:<br /> <ol type="i"> <li>HIV/AIDS: if the country's ratio of adult HIV seroprevalence (as reported by UNAIDS, multiplied by 1000) to GNI per capita (Atlas method, as reported by the World Bank) exceeds 5;</li> <li>Tuberculosis: if the country is included on the WHO list of 22 high-burden countries, or on the WHO list of the 36 countries that account for 95% of all new TB cases attributable to HIV/AIDS;</li> <li>Malaria: if the country experiences more than 1 death due to malaria per 1000 people (as reported by WHO).</li> </ol> </li> <li>Eligible countries must meet additional requirements, including co-financing, focusing on poor or vulnerable populations, and moving over time towards greater reliance on domestic resources.</li> <li>The Board requests that the PMPC review the issue of future applications focusing exclusively on vulnerable populations that do not receive significant funding from domestic or external sources from Upper-Middle Income countries ineligible under Option 1.</li> <li>The PMPC will present recommendations to the Board for consideration at the Seventh Board Meeting.</li> </ol> <p>PROCUREMENT AND SUPPLY MANAGEMENT</p> <p>Decision 4:</p> <p>National Drug Regulatory Authorities (NDRA) laboratories or laboratories recognized by the NDRA should be used for quality monitoring by the PR. To ensure the respective laboratories have adequate capacity for full pharmacopoeial testing, they must meet one of the following criteria:</p> <ol type="a"> <li>Acceptance for collaboration with WHO pre-qualification project;</li> <li>Accredited in accordance with ISO17025 and/or EN45002;</li> <li>Accepted by a stringent authority. For the purposes of this policy a stringent drug regulatory authority is defined as a regulatory authority in one of the 28 countries which is either a Pharmaceutical Inspection Cooperation Scheme and/or International Conference on Harmonization.</li> </ol> <p>Decision 5:</p> <ol type="a"> <li>The principles for procurement and quality assurance of pharmaceuticals that were adopted during the Third Board meeting of the Global Fund apply to diagnostics and other non-pharmaceuticals: namely that a Principal Recipient (PR) is responsible for procurement, and is required to conduct competitive purchasing in order to obtain the lowest possible price for products of assured quality:</li> <li>For non-durable products, the same principles as for pharmaceuticals should be followed, namely that a PR is required to select from lists of pre-qualified products, where they exist, or products accepted by stringent regulatory agencies or products accepted by national standards.</li> <li>For durable products the lowest possible price should take into account the Total Cost of Ownership (TCO), including the cost of reagents and other consumables as well as costs for annual maintenance.</li> <li>Procurement methods for durable products may include either lease or purchase. The PR must provide a plan for service and maintenance of the products.</li> <li>The Secretariat will work with technical partners such as WHO, UNAIDS and bilateral agencies to ensure availability of information to recipients in regards to quality assurance and procurement systems related to high priority consumables and durables such as condoms, HIV rapid testing kits, CD4+ T cell monitoring, bed nets, microscopes, etc.</li> </ol> <p>Decision 6</p> <ol type="a"> <li>The Board recognizes the potential role of in-kind donations in significantly expanding the impact of the GF and in making a significant contribution to resource mobilization efforts through providing leverage for cash resources. In-kind donations also constitute a significant means by which the private sector may be involved with the Global Fund and contribute to achieving its goals, thus reflecting the public - private partnership principles upon which the Global Fund is based.</li> <li>The Board recognizes the considerable challenges to be confronted in operationalizing in-kind donations. There are different issues involved in managing in-kind donations in the form of services, non-health products, or health products, particularly pharmaceuticals, at both the global and country level.</li> <li>The Board requests that the PMPC, on the basis of input from the PSM-AP, and working jointly with other Committees, particularly with the Resource Mobilization Committee, to consider further the different operational and other issues surrounding in-kind donations of services, non-health, and health products. These general issues include, inter alia: <ul> <li>Guarding against conflicts of interest;</li> <li>Potential legal liabilities;</li> <li>Long term sustainability;</li> <li>Valuation of contribution.</li> </ul> </li> <li>The Board requests that, on the basis of work done by the private sector and others, the PSMAP will propose strategic options, capturing issues relating to the diversity of products and services, the managerial capacity of the Global Fund Secretariat and Principal Recipients, and the advantages/costs of channeling donations through the Global Fund vis-à-vis other existing mechanisms.</li> </ol> <p>Decision 7: Board refers to the Governance and Partnership Committee the issue of potential conflict of interests when products are manufactured in a state-owned laboratory and the Principal Recipient is a public entity and when products are manufactured or purchased in a state-owned structure and the state is responsible for quality.</p>

The Board:<br/>1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Tables 1.a. and 1.b. of Section IV to GF/B35/ER12 ("Table 1");<br/>2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/>3. Acknowledges the original grant duration, manifested in the form of either the implementation or budgeted period, of each country disease component and its constituent grants listed in Table 2 of Section IV ("Table 2") is shortened according to the operational flexibility granted to the Secretariat pursuant to GF/B31/DP09;<br/>4. Approves the additional incremental funding and implementation period recommended for the Kenya malaria disease component, and the component's constituent grants, as listed in Table 2, based on the available funding that the Finance and Operational Performance Committee (the "FOPC") validated pursuant to GF/FOPC17/DP02;<br/>5. Affirms the (additional) incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br/>6. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Tables 1a and 1b of Section IV to GF/B35/ER16 (“Tables 1a and 1b”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Tables 1a and 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Acknowledges the grant duration and related funding originally approved by the Board for those country components that participated in the concept note process in 2013 as part of the transition to the allocation-based funding model authorized under GF/B28/DP05 (the "Early Applicants") will end on or before 31 December 2016 and accordingly will need additional funding to bridge the relevant program implementation until 31 December 2017, the typical end date of grant programs arising from the 2014 - 2016 allocation period;</li> <li>Approves the additional incremental funding and implementation period recommended for the EHRN regional grant, being an Early Applicant grant, as listed in Table 2 of Section IV to GF/B35/ER16 based on the available funding that the Finance and Operational Performance Committee (the “FOPC”) validated pursuant to GF/FOPC17/DP02;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:<br/>1. Approves the incremental funding recommended for each country and regional disease component, and its constituent grants, as listed in Table 1a and 1b, respectively, of Section IV to GF/B35/ER11 (collectively, "Table 1");<br/><br/>2. Acknowledges each country and regional disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/><br/>3. Approves the reinvestment of within-allocation efficiencies for the Zambia TB/HIV grant and its resultant total program budget, as listed in Table 2 of Section IV to GF/B35/ER11;<br/><br/>4. Acknowledges the grant duration and related funding originally approved by the Board for those country components that participated in the concept note process in 2013 as part of the transition to the allocation-based funding model authorized under GF/B28/DP05 (the "Early Applicants") will end on or before 31 December 2016 and accordingly will need additional funding to bridge the relevant program implementation until 31 December 2017, the typical end date of grant programs arising from the 2014 - 2016 allocation period;<br/><br/>5. Approves the additional incremental funding and implementation period recommended for the Philippines TB disease component, being an Early Applicant grant, as listed in Table 3 of Section IV to GF/B35/ER11, based on the available funding that the Finance and Operational Performance Committee (the "FOPC") validated pursuant to GF/FOPC17/DP02;<br/><br/>6. Affirms the (additional) incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country and regional disease component's constituent grants, (b) is subject to the availability of funding and (c) shall be committed in annual tranches; and<br/><br/>7. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country and regional disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</p><p>This decision does not have material budgetary implications for the 2016 Operating Expenses Budget.</p>

1. The Board acknowledges the process led by the Board Chair and Vice-Chair to identify candidates to serve as independent committee members on the Ethics and Governance Committee (the "EGC"), as set forth in GF/B35/ER13". <br/><br/>2. Accordingly, the Board approves the appointment of Joan Elise Dubinsky to serve as a non-voting independent member of the EGC with expertise in the area of ethics for a two-year term starting from the June 2016 initial meeting of the EGC, or until the appointment of her successor<br/><br/>3. In accordance with the EGC Charter, which provides that independent committee members may receive honoraria, the Board also decides to make available to the individual appointed as an independent committee member under this decision point an annual amount of USD 13,500.

<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B35/ER03 ("Table 1");</li> <li>Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>Based on the recommendation of the Strategy, Investment and Impact Committee, the Board approves the Challenging Operating Environments Policy, as set forth in Annex 1 to GF/B35/03.</p>

<p>1.The Board notes:</p><p>a.Its decisions in September 2012 (GF/B27/DP07) and November 2012 (GF/B28/DP04) that established the principles and framework for the allocation-based funding model (the "Funding Model Principles");</p><p>b.Its decisions in October 2013 (GF/B29/EDP10 and GF/B29/EDP11) and March 2014 (GF/B31/DP06, GF/B31/DP07, GF/B31/DP08, GF/B31/DP09 and GF/B31/DP10) to define certain elements for the 2014 - 2016 allocation period that would be reviewed and refined, as appropriate, prior to the 2017 - 2019 allocation period (the "2014 - 2016 Elements"); and</p><p>c.Decisions by the Strategy, Investment and Impact Committee (the "SIIC") in October 2013, under authority delegated by the Board, to establish technical parameters for the 2014 - 2016 allocation period (GF/SIIC09/DP01) and the process for managing and awarding incentive funding and unfunded quality demand (GF/SIIC09/DP02) (the "Prior SIIC Decisions").</p> <p>2. Accordingly, based on the recommendations of the SIIC, as presented in GF/B35/05 - Revision 1, the Board:</p><p>a. Approves the allocation methodology presented in Annex 1 to GF/B35/05 - Revision 1 (the "Allocation Methodology");</p> <p>b. Acknowledges the technical parameters for the 2017 - 2019 allocation period, as presented in Annex 2 to GF/B35/05 - Revision 1 and approved by the SIIC at its 17^thmeeting in March 2016 (the "Technical Aspects"); and</p> <p>c. Affirms the restatement of core parts of the Funding Model Principles, as presented in Annex 3 to GF/B35/05 - Revision 1 (the "Affirmed Principles").</p> <p>3. Accordingly, the Board:</p><p>a. Requests the Strategy Committee to review and approve, at its June 2016 meeting, the method by which the Secretariat will apply and report on the qualitative-factor adjustment process;</p> <p>b. Requests the Secretariat to present the priorities, activities or initiatives, including associated costs, that could be funded as catalytic investments, for the Strategy Committee to review at its June 2016 meeting and recommend to the Board; and</p> <p>c. Acknowledges that the Allocation Methodology, Technical Aspects and Affirmed Principles shall apply for the 2017 - 2019 allocation period and supersede the Funding Model Principles, 2014 - 2016 Elements and Prior SIIC Decision.</p><p><br/></p>

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund's 2015 Annual Financial Report, which includes the 2015 Consolidated Financial Statements that have been audited by Ernst &amp; Young SA, as set forth in GF/B35/09 Annex 1. </p>

The Board approves the appointment of Sanne Fournier-Wendes to serve as a non-voting member of the Audit and Finance Committee, representing the Partners Constituency, for a two-year term or until the appointment of her successor.

1. Approves extension of the relevant implementation period for each grant listed in Table 2 of Section IV to GF/B35/ER10.

1. The Board acknowledges the process led by the Board Chair and Vice-Chair to identify candidates to serve as independent committee members on the Audit and Finance Committee (the "AFC"), as set forth in GF/B35/ER04". 2. Accordingly, the Board approves the appointment of the following individuals to serve as non-voting independent members of the AFC listed below, in the areas of expertise listed by their name: i. Peter Maertens, audit ii. Jean-Michel Ferat, forensic investigation<br/>3. In accordance with the AFC Charter, which provides that independent committee members may receive honoraria, the Board also decides to make available to each of the individuals serving as independent committee members an annual amount of USD 13,500.<br/>4. The Board notes each independent committee member appointed under this decision point shall begin their term on 9 June 2016 and serve for two years or until the appointment of their respective successor.

<p>1.Based on the recommendation of the Strategy, Investment and Impact Committee, the Board approves the revised Eligibility Policy, as set forth in Annex 2 to GF/B35/06 - Revision 1 (the "Revised Eligibility Policy").</p> <p>2.Accordingly, the Board: </p> <p>a.Acknowledges this decision point and the Revised Eligibility Policy supersede Board decision point GF/B30/DP05 and the previous Eligibility Policy as set forth in Attachment 1 to GF/B30/6 - Revision 1 (the "Previous Eligibility Policy"); and</p> <p>b.Notes that notwithstanding paragraph 2.a. of this decision point, the Previous Eligibility Policy remains applicable to grant programs originating from the 2014 - 2016 allocation period. </p>

<p>Based on the recommendation of the Strategy, Investment and Impact Committee, the Board approves the Global Fund Strategy 2017 - 2022: Investing to End Epidemics, as presented in Annex 1 to GF/B35/02- Revision 1. </p>

<p>Siula Bulu from the Western Pacific Region constituency is designated as Rapporteur for the 35th Board Meeting.</p>

<p><b><i>1. The Board acknowledges the nominations for membership of the Board's Audit and Finance Committee (the "AFC"), Ethics and Governance Committee (the "EGC"), and Strategy Committee ("SC"), as set forth in GF/B35/ER02".</i></b> </p> <p><b><i>2. Accordingly, the Board approves the appointment of the following individuals to serve as voting members of the Committees listed below, representing the Board constituencies listed by their name:</i></b> </p> <p><b><i>a. Audit and Finance Committee</i></b> </p> <p><b><i>i. Gregoire Lacoin, European Commission Constituency;</i></b> </p> <p><b><i>ii. Sylvie Bourdenet, France Constituency;</i></b> </p> <p><b><i>iii. Erika Satterwhite, Private Sector Constituency;</i></b> </p> <p><b><i>iv. Anthony Richard Garnett, United Kingdom Constituency;</i></b> </p> <p><b><i>v. Michael Ruffner, United States Constituency;</i></b> </p> <p><b><i>vi. Soltan Mammadov, Eastern Europe &amp; Central Asia Constituency;</i></b> </p> <p><b><i>vii. Thamer Al Hilfi, Eastern Mediterranean Constituency;</i></b> </p> <p><b><i>viii. Grace Rwakarema, Eastern and Southern Africa Constituency;</i></b> </p> <p><b><i>ix. Sugata Ghosh Dastidar, South East Asia Constituency; and</i></b> </p> <p><b><i>x. Han Mengjie, Western Pacific Region Constituency.</i></b> </p> <p><b><i>b. Strategy Committee</i></b> </p> <p><b><i>i. Philippe Meunier, France Constituency;</i></b> </p> <p><b><i>ii. Heiko Warnken, Germany Constituency;</i></b> </p> <p><b><i>iii. Eiji Hinoshita, Japan Constituency;</i></b> </p> <p><b><i>iv. Lennarth Hjelmaker, Point Seven Constituency;</i></b> </p> <p><b><i>v. Kieran Daly, Private Foundations Constituency;</i></b> </p> <p><b><i>vi. Rico Gustav, Communities Constituency;</i></b> </p> <p><b><i>vii. Jorge Saavedra, Developing Country NGOs Constituency;</i></b> </p> <p><b><i>viii. Vinand Nantulya, Eastern and Southern Africa Constituency;</i></b> </p> <p><b><i>ix. Joel Mayowa, West and Central Africa Constituency; and</i></b> </p> <p><b><i>x. LV Fan, Western Pacific Region Constituency.</i></b> </p> <p><b><i>c. Noting that the Chairs of the Technical Review Panel and the Technical Evaluation Reference Group serve as non-voting members of the Strategy Committee, the Board appoints the following individuals to serve as additional non-voting members of the Strategy Committee, representing the Board constituencies listed by their name:</i></b> </p> <p><b><i>i. Sheikh Mubashar, WHO Constituency; and</i></b> </p> <p><b><i>ii. Melanie Renshaw, Partners Constituency.</i></b> </p> <p><b><i>d. Furthermore, the Board appoints Alexandru Cebotari to serve as a non-voting member of the Audit and Finance Committee</i></b> , <b><i>representing the World Bank, and notes that the remaining non-voting member of the Audit and Finance Committee that will represent one of the non-voting, ex-officio members of the Board will be subsequently appointed.</i></b></p> <p><b><i>3. Additionally, the Board approves the appointment of the following individuals, with their nominating Board constituency listed by their name, to serve in their personal capacity as voting members of the Ethics and Governance Committee:</i></b> </p> <p><b><i>a. Jacques Mader, Canada Switzerland Australia Constituency;</i></b> </p> <p><b><i>b. Sarah Boulton, United Kingdom Constituency;</i></b> </p> <p><b><i>c. Sandy Thurman, United States Constituency;</i></b> </p> <p><b><i>d. Jason Wright, Developed Country NGOs Constituency;</i></b> </p> <p><b><i>e. Archil Talakvadze, Eastern Europe &amp; Central Asia Constituency; and</i></b> </p> <p><b><i>f. Mirta Roses Periago, Latin America and Caribbean Constituency.</i></b> </p><p> <b><i>4. The Board notes each Committee Member appointed under this decision point shall begin their term upon approval of this decision point and serve for two years or until the appointment of their respective successor.</i></b></p>

<p>1.The Board notes its review and discussion of the: </p><p>a.Office of the Inspector General 2015 Annual Opinion on Governance, Risk Management and Internal Controls of the Global Fund, as set forth in GF/B35/11 (the "OIG Annual Opinion"); and</p><p>b.Risk Management Report and Assurance Statement, as set forth in GF/B35/23.</p><p>2.Accordingly, the Board acknowledges that while in-country partnerships are in place and significant initiatives and measures have been implemented to improve programmatic, fiduciary and risk-management processes, immediate and heightened efforts are needed to accelerate progress and advance risk management systems and processes. </p><p>3.The Board requests the Secretariat to:</p><p>a. Present a detailed action plan to advance risk management and internal controls, with measurable and time-bound targets, and a report on progress to the Board in June 2016 through the standing committees that were established under Board decision point GF/B34/EDP07 (the "Standing Committees"); and</p><p>b. In the context of the differentiation initiative, review the business model in high-risk countries and present possible options to the Board after review by the Standing Committees at their second meetings in 2016.</p>

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund's 2015 Statutory Financial Statements, which have been audited by Ernst &amp; Young SA, as set forth in GF/B35/09 Annex 2.</p>

<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B35/ER01 ("Table 1");</li> <li>Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Acknowledges the original grant duration, manifested in the form of either the implementation or budgeted period, of each country disease component and its constituent grants listed in Table 2 of Section IV to GF/B35/ER01 ("Table 2") isshortened according to the operational flexibility granted to the Secretariat pursuant to GF/B31/DP09.</li> <li>Approves the reinvestment of within-allocation efficiencies as well as the additional incremental funding and implementation period recommended for Sudan malaria disease component and its constituent grant, as listed in Table 2, based on the available funding that the Finance and Operational Performance Committee (the "FOPC") validated pursuant to GF/FOPC17/DP02;</li> <li>Affirms the (additional) incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<h3>Decision not approved.</h3>

The Board approves the Report of the 35th Board Meeting, as set forth in GF/B35/28 - Revision 1.

The Board:<br/><br/>1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1a of Section IV to GF/B35/ER07 ("Table 1a");<br/><br/>2. Approves the reinvestment of within-allocation efficiencies for the Iran HIV grant and its resultant total program budget, as listed in Table 1b of Section IV to GF/B35/ER07;<br/><br/>3. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/><br/>4. Acknowledges the original grant duration, manifested in the form of either the implementation or budgeted period, of each country disease component and its constituent grants listed in Table 2 of Section IV ("Table 2") is shortened according to the operational flexibility granted to the Secretariat pursuant to GF/B31/DP09;<br/><br/>5. Approves the additional incremental funding and implementation period recommended for (a) Ghana malaria, (b) Mozambique HIV, (c) Tanzania HIV and (d) Uganda malaria disease components, and each component's constituent grants, as listed in Table 2, based on the available funding that the Finance and Operational Performance Committee (the "FOPC") validated pursuant to GF/FOPC17/DP02;<br/><br/>6. Acknowledges the grant duration and related funding originally approved by the Board for those country components that participated in the concept note process in 2013 as part of the transition to the allocation-based funding model authorized under GF/B28/DP05 (the "Early Applicants") will end on or before 31 December 2016 and accordingly will need additional funding to bridge the relevant program implementation until 31 December 2017, the typical end date of grant programs arising from the 2014 - 2016 allocation period;<br/><br/>7. Approves the additional incremental funding and implementation period recommended for Zimbabwe HIV disease component, being an Early Applicant grant, as listed in Table 3, based on the available funding that the FOPC validated pursuant to GF/FOPC17/DP02;<br/><br/>8. Affirms the (additional) incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br/><br/>9. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

<p>Based on the recommendation of the Board Chair and Vice-Chair (“Board Leadership”), in consultation with the Ethics and Governance Committee (“EGC”) and the Governance Focal Points Network, the Board:</p> <ol> <li>Notes its responsibilities with regard to the recruitment process of the Executive Director as set out in Article 36 of the Operating Procedures of the Board and Committees <span>of the Global Fund to Fight AIDS, Tuberculosis and Malaria (“BCOP”).</span></li> <li>Notes the consultations of the Board Leadership and the Governance Focal Points Network with the EGC in relation to this process, including with respect to the establishment of the nomination committee referred to in the BCOP and the selection of an executive search firm, Russell Reynolds Associates, to provide support to the said nomination committee in carrying out its mandate.</li> <li>Approves the terms of reference of the 2016 Executive Director Nomination Committee as set out in Annex 1 to GF/B35/ER15.</li> <li>Invites the Board Leadership to submit in due course for Board approval, in accordance with Article 36 of the BCOP, a Chair and the membership of the nomination committee.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the appointment of the following individual to the Strategy, Investment and Impact Committee (‘SIIC’), to replace one out-going member:<br />a. Ambassador Philippe Meunier, representing France.</li> <li>Notes that Ambassador Philippe Meunier shall serve on the SIIC until the end of his predecessor’s term.</li> </ol>

The Board approves the 2012 Annual Report of the Global Fund, as set forth in GF/B29/11.

<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grant listed in Table 1 in the amount indicated for such grant, based on the understanding that the amount approved is the upper ceiling rather than the final funding amount for that period and that on-going implementation arrangements for such grant shall be pursued by the Secretariat consistent with the principles of the recommendation set forth in the related Memo submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that the funding for the renewal of such grant shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1)</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of such grant shall be the sum of the amount set out in Table 1 below for such grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 6,026,955 for the following grant: MYS-H-MAC</p>

<p>The Board decides:</p> <ol> <li>Prior to the initial allocation of available resources to Country Bands for the 2014 – 2016 allocation period, the Secretariat will apportion such resources among the three diseases based on the following distribution: 50% for HIV/AIDS, 32% for malaria, and 18% for tuberculosis.</li> <li>In accordance with Board Decision GF/B27/DP7, applicants will have flexibility in deciding how to allocate financing between the three diseases for their individual country programs.</li> <li>The Board reaffirms its prior decision to recognize the importance of core TB-HIV collaboration services to achieve successful outcomes in TB and HIV grants (GF/B18/DP12). Taking note of the insufficient progress in implementing this prior decision on TB-HIV collaboration services, the Board requests the Secretariat to ensure integrated TB-HIV services are addressed in the country-dialogue and concept-note development process for countries with high TB-HIV co-infection rates, as set forth in the WHO policy on collaborative TB/HIV activities: “Guidelines for National Programs and Other Stakeholder” (2012).</li> <li>The Strategy, Investment and Impact Committee will review this decision and propose appropriate modifications to the Board for approval prior to the 2017 – 2019 allocation period.</li> </ol>

<ol start="1" type="1"><li><b>(Deferred) </b> Agree that Board commitments should be fully covered by pledges, with agreement by donors that pledges for a given calendar year are callable on demand following commitments made in that or subsequent years.</li></ol><ol start="2" type="1"><li><b>(Deferred) </b> Agree that signed Grant Agreements should be fully covered by cash assets received in the Trustee Account, implying that payment of any unpaid pledges made for a current or previous calendar year must rapidly follow commitments.</li></ol><ol start="3" type="1"><li><b>(Not approved) </b> Endorse the financial targets and instruct the Executive Director and the proposed Board Resource Mobilization standing committee to pursue a corresponding resource mobilization strategy.</li></ol><ul><li><b>In 2003, a total of USD 2.5 billion is the minimum needed </b> to make commitments to high-quality proposals anticipated in Rounds Two and Three. This requires USD 1.6 billion of new pledges and payments in addition to payment of outstanding pledges for 2002 (equal to 90 million) and current pledges for 2003 (equal to 305 million).</li></ul><ul><li><b>In 2004, approximately USD 3.8 billion is needed </b> to make new commitments to high-quality proposals anticipated in Rounds Four and Five. New pledges of USD 3.5 billion are required in addition to payment of current pledges earmarked for 2004 (equal to 305 million).</li></ul>

<ul><li><b>(Deferred) </b> The Secretariat Procurement Policy was deferred until the next Board Meeting. The Secretariat was requested to discuss the policy with WHO in an attempt to reconcile the difficulties identified by WHO. The policy should be reviewed by the Committee before it is resubmitted to the Board.</li></ul><ul><li>Request the Secretariat to urgently put in place contracting guidelines; contracting review and documentation processes; and comprehensive conflict of interest policies.</li></ul><ul><li>Decide that until the Board agrees to its own policies and procedures on procurement of goods and servicesfor the Secretariat, the Fund Secretariat should abide by the spirit and letter of the policies and procedures of WHO in these matters.</li></ul><ul><li>Decide that the rights of Board Members to ask questions on any contracting issue on which they desire information and clarification should be affirmed within the Board Operating Procedures. The process for addressing inquiries of Board Members on contracting matters should be elaborated within the Board Operating Procedures.</li></ul><ul><li>Direct the Secretariat to provide the MEFA Committee with an independent consultant remuneration scale at their next meeting.</li></ul>

<p>The PMPC recommends that PSM Advisory Panel consider necessary policies for the Global Fund related to the procurement of diagnostics and other products related to the provision of medications. Refer to GF/B4/7) for further details.</p><p><b>(No options are approved by a 2/3 majority vote) </b> The PMPC requests that the Board adopt one of the three policies on domestic production as discussed GF/B4/7).</p><ul><li><b>Option 1:</b> Zero Price Premium</li><li><ul><li>Donors: Yes: 7 No: 2</li><li>Recipients: Yes: 2 No: 6 Abstain: 1 </li></ul></li><li><b>Option 2:</b> 15% Price Premium over the lowest price imported generics </li><li><ul><li>Donors: Yes: 1 No: 7 Abstain: 1  </li><li>Recipient: Yes: 0 No: 8 Abstain: 1</li></ul></li><li><b>Option 3:</b> 15% Price Premium over lowest imported product </li><li><ul><li>Donors: Yes: 2 No: 6 Abstain: 1</li><li>Recipients: Yes: 6 No: 2 Abstain: 1</li></ul></li></ul> <p>The PMPC recommends that the Board amend the policy adopted on exemption on duties, tariffs and taxes to allow but not to encourage that Fund resources be used to pay possible product duties, tariffs and taxes. The amended policy should read as follows: "The Fund strongly encourages the relevant national authorities in recipient countries to exempt from duties and taxes all products financed by Global Fund grants and procured by NGOs or any other Principal Recipient or sub-recipient."</p><p>The Board is invited to acknowledge PMPC's decisions 4.a - 4.l on pages 6-10.</p><ul><li>4a: The PMPC has agreed to the creation of a PSM Advisory Panel, according to the Terms of Reference in Part 1 Annex II, to provide technical advice to the PMPC as required</li><li>4b: The PMPC has agreed to consider the subject of product quality monitoring processes, on the basis of both WHO input and advice by the PSM Advisory Panel, and make appropriate recommendations to the Fifth Board Meeting.</li><li>4c: The PMPC has agreed to consider how the Global Fund should ensure the assessment of NDRA recognized laboratories for product quality monitoring, drawing on the advice of the PSM Advisory Panel, and make appropriate recommendations to the Fifth Board Meeting.</li><li>4d: The PMPC has agreed to consider potential PSM-related conflicts of interest based on advice of the PSM Advisory Panel and make appropriate recommendations to the Fifth Board Meeting.</li><li>4e: The PMPC has agreed to consider issues related to global bidding mechanisms based on advice from the PSM Advisory Panel and make appropriate recommendations to the Fifth Board Meeting.</li><li>4f: The PMPC has agreed to approve the importance of capacity building for procurement and supply management as proposed by the PSM Task Force and request the Secretariat to ensure that information on the subject be made available to potential grantees and Principal Recipients.</li><li>4g: The PMPC has agreed on the Terms of Reference for a Pricing Reporting Mechanism design study, as attached in Part 1 Annex III, and has directed the Secretariat to commission this study and implement the resulting system for collecting and reporting prices paid for pharmaceutical products by Global Fund recipients by September 2003.</li><li>4h: The PMPC has agreed to refer the issueof the direct payment of suppliers to the Secretariat,with further analysis by the Advisory Panel as necessary.</li><li>4i: The PMPC has agreed to refer the issueof product prices used for budgeting proposals to the Secretariatfor operationalization, with further analysis by the Advisory Panel as necessary.</li><li>4j: The PMPC has agreed to consider issues related to in-kind contributions, if they are considered eligible by the Board of the Global Fund for resource mobilization, based on advice from the PSM Advisory Panel and make appropriate recommendations to the Fifth Board Meeting.</li><li>4k: The PMPC has agreed to consider the previous recommendation made to the Third Board Meeting on the issue of international and national law, based on advice from the PSM Advisory Panel and make appropriate recommendations to the Fifth Board Meeting.</li><li>4l: The PMPC has agreed to consider the previous recommendation made to the Third Board Meeting on the issue of supply chain management, based on advice from the PSM Advisory Panel and make appropriate recommendations to the Fifth Board Meeting.</li></ul>

<p>1. Request the Secretariat to pursue a legal status with the Swiss authorities that provides for the Global Fund with those privileges and immunities that are necessary for it to effectively fulfil its mandate. This status and its associated practical arrangements should ensure that the Global Fund's administration is efficient and no more costly than the current arrangements.</p><p>2. The Secretariat is asked to present to the Fifth Meeting of the Board, precise recommendations for change of status with all associated information.</p>

<p>1. Approve the Global Fund work plan and budget for 2003 with the proposed changes as presented in Part 2 of this report, with the understanding that some degree of flexibility is required in the specific allocation of resources during the year.</p> <p>2. Request the MEFA Committee to continuously work with the Secretariat to monitor budget implementation in relation to priority and end product accomplishment and report to the Board on budget performance semi-annually.</p> <p>3. Request the Secretariat, with MEFA Committee approval, to adjust this approved 2003 budget to reflect decisions made at the January 2003 Board meeting if those decisions impact the 2003 budget.</p>

<ul><li><b>(Not Approved)</b> Acknowledge the approach to partnerships outlined in the paper and authorizes the Secretariat to pursue such partnerships as appropriate.</li></ul><ul><li>Asks the Governance Committee to examine and comment on partnership arrangements negotiated by the Secretariat in light of the framework and present them to the following Board for acknowledgement, or as appropriate, for approval.</li></ul><ul><li>Requests the Executive Director to provide ongoing updates of Global Fund partnership activity in his communications with the Board.</li></ul><ul><li>Board takes note with satisfaction of the MOU with UNAIDS.</li></ul>

<ol start="1" type="1"> <li>Requests the Board to endorse the approaches to Communications outlined in the Communications Report GF/B4/10.</li> </ol> <ol start="2" type="1"> <li>Requests the Board to work with the Secretariat and to assist them in their need for additional spokespeople and partners in Communications.</li> </ol> <ol start="3" type="1"> <li>(Deferred) Requests the Board to endorse the logo and the Logo Policy and to instruct the Secretariat to continue the process of legal registrations of the logo.</li> </ol> <ol start="4" type="1"> <li>Recommends that the Resource Mobilization Committee Terms of Reference be revised to include communications, as recorded in the document below.</li> </ol>

1.<b> </b> Chair and Vice Chair of the Board will discuss with the Executive Director on issues related to committee leadership and composition and revert to the Board as soon as possible.

<p>One additional item is added to the Board’s agenda, proposed at 1800 today. The Board approves the revised Agenda.</p>

The Board approves the outstanding Category 2 of Indonesia Round 1 Proposals for HIV/AIDS and Malaria.

<ul><li>Direct the Secretariat to draft a Monitoring and Evaluation Plan, which will be reviewed by the MEFA Committee and presented to the Board for approval by the June Board meeting.</li></ul><ul><li>Direct MEFA torecommend to the Board for approvala qualified external auditor to audit the Global Fund's financial statements in time to report the audit findings at the June 2003 Board meeting.</li></ul><ul><li>Direct MEFA to discuss the advantages and disadvantages of an independent Monitoring and Evaluation unit versus the use of external auditors to assure objective evaluation and recommend to the Board the preferred method for independent review.</li></ul>

Regarding the election of Board Chair and Vice Chair, it is approved that this decision will be deferred until Friday, 31 January 2003. Nominations will be accepted by 1200 noon and announced at 1400 on Thursday, 30 January 2003.

<ul><li>Acknowledge the evaluation of the Global Fund fiduciary arrangements undertaken by the Committee and direct the MEFA Committee to continue to improve the Fund's fiduciary arrangements that should include reviewing LFA performance and fees, developing a LFA conflicting of interest policy, together with the Governance and Partnership Committee, and report on the results of the Round 2 LFA selection. These actions should be reported to the Board in June 2003.</li></ul>

<ul> <li>The PMPC unanimously agreed the appeal mechanism should be impartial, objective, independent, simple, speedy and well accepted by all stakeholders. However, strict criteria must be applied to minimize the number of appeal proposals.</li> </ul> <ul> <li>The PMPC decided that proposals rejected through the Secretariat screening, due to clear cut ineligibility criteria, are not eligible for appeal. Only those proposals in category three and four in both the current and the last Round (repeated failure cases) can appeal. The PMPC also agreed that CCMs only submit a new proposal on a different disease component than the one going through the appeal process (non-CCM proposals could only be submitted for a different disease component than the one going through the Appeal Process.)</li> </ul> <ul> <li>The PMPC member unanimously agreed on the following criteria:<br /><br /> <ul> <li>Appeals must have CCM endorsement, except in the event in which a non-CCM proposal was initially deemed eligible for TRP review by the Secretariat, in which non-CCM endorsement is required.</li> <li>Applicant shall provide the specific grounds upon which it claims the TRP was in error regarding information contained in the proposal. It is not permitted to provide additional information or justification additional to that contained in its proposal.</li> <li>The appeal panel should assess appeals using the same assessment criteria as used by the TRP.</li> <li>To prevent unfair treatment to other failed applicants who do not appeal, and to safeguard appeal panel independence from unnecessary pressure, a face-to-face discussion, negotiation between appeal panel and applicants is not allowed.</li> <li>The GF Board should endorse/reject the recommendation of the appeal panel via email.</li> <li>GF Board decision on the appeal is final.</li> <li>Appeal can be made only once.</li> </ul> </li> </ul> <ul> <li>The PMPC also endorsed a timeline for appeals, which allows CCMs to appeal within four weeks of notification, appeal process to be finalised within four weeks and Board endorsement within two weeks after the receipt of Panel recommendations.</li> </ul> <ul> <li>The PMPC endorsed a fourth option (see below): Appeal Panel to be composed by three high level experts to be proposed by WHO, UNAIDS and the World Bank and two TRP members, one disease expert and one cross-cutting expert, who were not either the primary or secondary reviewer of that specific proposal.<br /><br /> <ul> <li>Option 4: Appeal Panel <ul> <li>To be comprised by three high level experts to be proposed by WHO, UNAIDS and the World Bank. These would be joined by two TRP members, one disease expert and one cross cutting expert who were not either the primary or secondary reviewer of that specific proposal. The TRP members will change based on the proposal to be reviewed.</li> </ul> </li> </ul> </li> </ul> <ul> <li>(Deferred)  The PMPC asks the Board to acknowledge the need for increased contextual information to support the Technical Review process. Recognizing the need for more robust information and TRP deliberation, the PMPC will recommend to the Fifth Board meeting mechanisms to address this need.</li> </ul> <ul> <li>(Deferred)  The PMPC asks the Board to acknowledge the need for clarification of what the Global Fund means by "additionality". The PMPC will come up with suggested definitions for the Fifth Board meeting.</li> </ul> <ul> <li>Request the Board to allow the PMPC to revise the Guidelines for Proposals for the Third Round without further endorsement from the Board.</li> </ul>

<ul><li>Adopts the revised Conflicts of Interest Policy (amendments on gifts and institutional definition) as presented.</li></ul><ul><li>Ask the Governance and Partnerships Committee to address the additional issues raised by the Board members, which the members shall put in writing.</li></ul><ul><li>Adopts the revised Disclosure of Interest Form and requests all covered individuals to submit the form by the deadline specified.</li></ul><ul><li>Requests the Board Chair to identify three of its members to form the Conflicts (or Ethics) Committee and mandates the Governance and Partnership Committee to establish procedures for the functioning.</li></ul><ul><li>Instructs the Executive Director to appoint an Ethics Officer from the Secretariat</li></ul>

Dr. Julian Lob-Levyt is designated rapporteur of the 4^th Board meeting.

<p>1. The Board endorses the following Committee Calendar:</p><ul><li>Chairs and Vice Chairs meet together on 3 April 2003</li><li>Committees meet on:<ul><li>Resource Mobilization and Communications - 1, 2 April 2003</li><li>Governance and Partnership - 2, 3 April 2003</li><li>Monitoring, Evaluation, Finance and Audit - 3, 4 April 2003</li><li>Portfolio Management and Procurement Committee - 3, 4 April 2003</li></ul></li></ul><p>2. Decide that the Calendar regarding Board meeting dates and Round 3 as proposed for 2003 is appropriate and instruct the Secretariat to plan accordingly.</p><p>3. <b>(Deferred)</b> Decide that the generic Calendar is a good model for future planning and instruct the Secretariat to use this generic Calendar as a basis for planning.</p>

Mr. Seiji Morimoto, Vice Chair will chair this meeting as approved by the Board.

<ol start="1" type="1"><li><b>(Deferred) </b> The Board is requested to instruct the Secretariat to pursue a resource mobilization strategy to achieve the fundraising targets for 2003 and 2004 identified in the Financial Prospectus (GF/B4/6a).</li></ol><ol start="2" type="1"><li><b>(Deferred) </b> The Board is requested to instruct the Resource Mobilization Committee to work with the Secretariat in the pursuit of these targets, particularly by identifying specific ways that Board Members can support the Fund's resource mobilization efforts.</li></ol><ol start="3" type="1"><li><b>(Deferred) </b> The Board is requested to encourage the Private Sector Board Delegation to prepare for the Resource Mobilization Committee a framework for options and processes by which the Fund can accept and/or channel in-kind donations in support of efforts to mobilize resources for its grantees.</li></ol>

<ul> <li>(Deferred) The PMPC recommends that the Board endorse upper and lower limits for proposals submitted to the Global Fund.<br /><br /> <ul> <li>The PMPC recommends that the Board endorse the strongly preferred recommendation to use a lower limit of US$2 million per year per proposal.</li> <li>Alternatively, the minority option supports the use of a lower limit of US$2 million per year per proposal on all CCM applications, and a lower limit of $1 million per year per proposal on all non-CCM applications.</li> </ul> </li> </ul> <ul> <li>The Board encourages the Secretariat, working with the Portfolio Management and Procurement Committee, to include in the revised Guidelines for Proposals for the Third Round language regarding the preferred scale of grant applications. This should provide guidance to applicants to ensure that proposals are neither excessively large, in view of both national programmatic capacity and the limited resources of the Global Fund, nor excessively small, in view of both the Global Fund's goal to scale-up country responses and the administrative costs of processing applications.</li> </ul> <ul> <li>(Not Approved) The PMPC recommends that the Board endorse the strongly preferred recommendation to use a lower limit of US$2 million per year per proposal. Alternatively, the minority option supports the use of a lower limit of US$2 million per year per proposal on all CCM applications, and a lower limit of US 1 million per year per proposal on all non-CCM applications. The PMPC recommends that the Board endorse an upper limit on all proposals of US$50 million per year and of 50% of total public health sector expenditure per year (whichever figure is the lower).</li> </ul>

<p>The PMPC in order to ensure the sustainability and continuity of the TRP and to have a good proportional balance among the different experts recommends that:</p><ul><li>TRP membership should be expanded from 22 to 25 members, by adding 3 cross cutting experts.</li><li>The new membership should consist of 11 cross-cutters, 7 HIV/AIDS experts, 4 Malaria experts and 3 TB experts. While there is to be a maximum of 25 members of the TRP and 11 members must be cross-cutters, the chair and vice chair of the TRP may, at their discretion, adjust the number of experts from the different fields of disease expertise, with reference to the proposals submitted and the needs of the TRP.</li><li>The current Chair and Vice-Chair retain their positions as Chair and Vice-Chair and the 5 members who joined for Round 2 retain their positions on the panel on a voluntary basis</li><li>The remaining 18 seats be filled through an open, transparent, criteria-based selection process</li><li>7 of the seats be reserved for original members who may reapply (assuming 7 or more of them do so). If more than 7 reapply, those performing best against the criteria will be selected</li><li>Members of the Secretariat are ineligible to serve as TRP experts</li><li>Board/Alternate/Focal Points and CCM members must stand down from these roles if selected</li><li>Members would serve in their personal capacities</li></ul><ul><li>A qualified member from the PLWA (Persons Living with AIDS) community should be actively recruited among applicants.</li><li>Following TRP renewal, approximately one-third of the TRP members will be rotated each year. Members appointed from 2003 onwards will be appointed to serve a term of three years.</li><li>By April 2003, the PMPC and the Executive Director will recommend to the Board the candidates for the TRP for approval. The PMPC may decide to call on external and/or multi-lateral agencies (WJHO, UNAIDS, World Bank) for assistance as required. Further working methods will be developed on the 28^thof January 2003.</li><li>By the 3^rdround of TRP 64% of the TRP members will be new in comparison to the TRP appointed in March 2002</li><li>TRP members must not attend Board or Committee meetings as members of their constituency</li></ul><p>Staff from multilateral organizations will be allowed to serve on the TRP.</p>

<ul><li>Adopts the Guidelines on Constituency Processes as a useful compilation of best practice.</li></ul><ul><li>Adopts the Constituency Operations Statement as a transparent tool for understanding the processes of stakeholder groups and requests Board Members to complete the statement for their constituency, understanding that this statement will be made public.</li></ul><ul><li>Notes the importance of the role of focal points and supports the facilitation of the attendance of focal points for recipient country constituencies in attending Board and Committee Meetings.</li></ul>

<p>1. The Board is asked to approve for funding proposals recommended by the Technical Review Panel and according to the categories listed below, with the clear understanding that budgets requested are upper ceilings rather than final budgets and the Secretariat will report to the Board the results of the negotiations with the Principal Recipient on the final budget for acknowledgement.</p> <ul> <li>Category 1: Recommended proposals with no or minor modifications, which should easily be answered within 6 weeks and given the final approval by the TRP Chair and Co-Chair.</li> <li>Category 2: Recommended proposals provided clarifications are met within a limited timeframe (6 weeks for the applicant to respond, at most 6 months to obtain the final TRP approval should further clarifications be requested). The primary reviewer, secondary reviewer as well as TRP Chair and /or Co-Chair need to give final approval.</li> <li>Category 3: Not recommended in its present form but strongly encourage to re-submit.</li> <li>Category 4: Not recommended for funding.</li> </ul> <p>2. The Board is asked to acknowledge the lessons learnt of the Secretariat and the TRP during this process and allow adequate measures to be taken to improve Round 3. </p>

<p>The Board:</p> <p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), incremental funding in the amount listed for the interim-applicant grants in Table 2 (as indicated in the “Recommended Incremental Funding under the New Funding Model” column), which will be in addition to the relevant grants’ total budget amounts that the Board has already approved for the implementation period. The Recommended Incremental Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for each grant shall be committed in annual tranches.</p> <p>See attached tabledetailing total recommended funding amount of US$ 8,941,930 for the following grants: PHL-607-G08-H ; SLB-810-G01-T ;ZAM-708-G19-M ; ZAM-711-G26-T</p>

<p>The agenda for the Twenty-Ninth Board Meeting (GF/B29/1) is approved.</p>

<ol> <li>The Board approves the appointment of Mr. Mohamed Abdellatif as an independent member of the Audit and Ethics Committee (the “AEC”) to fill one current vacancy.</li> <li>Mr. Mohamed Abdellatif shall serve on the AEC until the end of his predecessor’s term.</li> </ol>

<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that funding for renewals of existing grants shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for each listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 842,017,272 for the following grants: CIV-809-G09-M ; GEO-H-GPIC ; GEO-T-GPIC ; GYA-304-G01-H ; LBR-M-PII ; LBR-M-MOH ; MKD-011-G04-T ; MEA-011-G01-H ; MEI-011-G01-H ; NGA-H-NACA ; NGA-H-ARFH ; NGA-H-SFHNG ; SAF-H-RTC ; SAF-910-G09-H ; SAF-304-G04-H ; SAF-H-NDOH ; SAF-H-NACOSA ; South Africa Grant TBD ; TNZ-M-MOFEA ; TNZ-809-G11-M ; TNZ-102-G01-M ; ZAM-811-G28-H ; ZAM-011-G29-H</p>

<p>The report of the Twenty-Eighth Board Meeting (GF/B29/2) is approved.</p>

<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that funding for renewals of existing grants shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1)</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for each listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 401,799,230 for the following grants: AGO-911-G05-T ; CIV-910-G12-H ; CIV-910-G13-H ; ZAR-M-MOH ; ZAR-M-SANRU ; ZAR-M-PSI ; GHN-809-G11-H ; GUA-311-G05-H ; GUA-311-G06-H ; MLW-H-NAC ; MSA-910-G01-H ; NMB-T-MoHSS ; THA-M-DDC</p>

<p>The Board:</p> <p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), incremental funding in the amount listed for the interim-applicant grants in Table 3 (the “Recommended Incremental Funding under the New Funding Model”), which will be in addition to the relevant grants’ total budget amounts that the Board has already approved for the implementation period. The Recommended Incremental Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for each grant shall be committed in annual tranches.</p> <p>See attached tabledetailing total recommended funding amount of US$ 56,526,508 for the following grants: BAN-T-NTP ; BAN-T-BRAC ; IDA-708-G14-H ; IDA-708-G15-H ; IND-M-MOH ; JAM-708-G02-H ; RUS-506-G05-H ; SUD-708-G10-M ; ZIM-809-G12-T</p>

<p>The Board approves the revised Declaration of Interest Form attached as Annex 1 of GF/B29/ER1.</p>

Based on the recommendation of the Audit and Ethics Committee, the Board approves the appointment of Ernst &amp; Young as the Global Fund’s external auditor for the 2013 fiscal year.

<p>The Board expresses its deep appreciation to Simon Bland for his leadership as Chair of the Board. He has served the Global Fund with a high degree of personal commitment and passion. During his tenure, Simon has successfully guided the Board through significant challenges and important decisions that will continue to shape the future of the Global Fund.</p> <p>The Board also expresses sincere gratitude to Mphu Ramatlapeng for her leadership as Vice-Chair of the Board. She has served the Global Fund with dedication and distinction. During her tenure, Mphu has been instrumental in driving governance reform, coordinating important deliberations, and facilitating decisions of the Board that will have a lasting impact on the Global Fund.</p> <p>Their stewardship of the Board through the Consolidated Transformation Plan, the development of a new funding model, and the appointments of the Executive Director and the Inspector General have pointed the Global Fund towards continued success and efficiency in achieving its mission.</p> <p>The Board wishes Simon and Mphu all the success in their future endeavors and bestows upon them the honorary titles of Chair Emeritus and Vice-Chair Emeritus of the Board, respectively.</p>

Dr. Aziza Bennani from the Eastern Mediterranean Region constituency is designated as Rapporteur for the Twenty-Ninth Board Meeting.

<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related Program Score Card submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that funding for renewals of existing grants shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for each listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 602,905,795 for the following grants: BLR-S10-G04-T ; CAM-H-NCHADS ; CAF-810-G08-M ; ECU-910-G06-H ; ECU-910-G07-H ; GIN-T-MSHP ; GYA-M-MOH ; HND-H-CHF ; HND-T-UECFSS ; IND-T-MOH ; IND-809-G10-T ; LAO-T-GFMOH ; MAL-809-G07-H ; MON-T-MOH ; MOZ-911-G09-H ; MOZ-911-G10-H ; NGA-809-G11-M ; NGA-809-G14-M ; STP-M-UNDP ; SNG-T-PLAN ; SNG-T-PNT ; SRL-911-G15-S</p>

<p>The Board:</p> <p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), incremental funding in the amount listed for the interim-applicant grant in Table 2 (the “Recommended Incremental Funding under the New Funding Model”), which will be in addition to the relevant grants’ total budget amounts that the Board has already approved for the implementation period. The Recommended Incremental Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for the relevant grant shall be committed in annual tranches.</p> <p>See attached tabledetailing total recommended funding amount of US$ 285,226 for the following grant: SWZ-809-G06-M</p>

<p>The Board:</p> <p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), incremental funding in the amount listed for the interim-applicant grants in Table 3 (the “Recommended Incremental Funding under the New Funding Model”), which will be in addition to the relevant grants’ total budget amounts that the Board has already approved for the implementation period. The Recommended Incremental Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for each grant shall be committed in annual tranches.</p> <p>See attached tabledetailing total recommended funding amount of US$ 27,934,678 for the following grants: CMR-011-G11-H ; NGR-708-G08-H ; RUS-304-G01-H ; YEM-708-G06-M</p>

<p>The Board:</p> <ol> <li>Selects Martin O'Malley to serve as the next Inspector General of the Global Fund for a six-year term beginning on or around September 2013</li> <li>Requests the Board Chair and Vice-Chair to facilitate the appointment of Martin O'Malley to the position of Inspector General.</li> </ol>

<p>1. The nomination of Secretary Tommy G. Thompson of the United States of America for Chair of the Board of the Global Fund to Fight AIDS, Tuberculosis &amp; Malaria.</p><p>2. The nomination of Doctor Suwit Wibulpolprasert of Thailand for Vice Chair of the Board of The Global Fund to Fight AIDS, Tuberculosis &amp; Malaria.</p>

<p>The PMPC, after considering the report from the Secretariat recommends the following to the Board regarding the revision of eligibility criteria:</p> <ul> <li>Poverty and disease-related need (which encompasses both current disease burden and risk of growth) are the criteria that will be used to determine eligibility to apply for financing from the Global Fund.</li> </ul> <ul> <li>For the Third Round of applications to the Global Fund:</li> </ul> <p>a. Countries classified as "Low Income" by the World Bank are fully eligible to apply for support from the Global Fund;</p> <p>b. Countries classified as "Lower-Middle Income" by the World Bank are eligible to apply for support from the Global Fund but must meet additional requirements, including co-financing, focusing on poor or vulnerable populations, and moving over time towards greater reliance on domestic resources;</p> <p>c. Countries classified as "Upper-Middle Income" by the World Bank are eligible to apply for support if they face a very high current disease burden (a list of such countries will be provided to the Board and included in the Guidelines for Proposals) and they meet the additional requirements, including co-financing, focusing on poor or vulnerable populations, and moving over time towards greater reliance on domestic resources;</p> <p>d. Countries classified as "High Income" by the World Bank are not eligible to apply for support from the Global Fund;</p> <ul> <li>For the fourth and subsequent Rounds of applications to the Global Fund, WHO and UNAIDS will be asked to provide matrices categorizing countries based on disease-related need and poverty. These matrices will be used as the basis for categorization of eligible countries for each disease and will be presented to the Fifth Board meeting for use beginning with the Fourth Round of applications to the Global Fund.</li> </ul>

<ul> <li>Recommend approval of the 2003 Secretariat Work Plan and Budget as present in Board Document GF/B4/11.</li> </ul> <ul> <li>(Deferred to GF/B4/11 report decisions) Direct the MEFA Committee to review the performance of the Secretariat on the 2003 Work Plan and Budget and report their findings at the June and October meetings of the Board in 2003.</li> </ul> <ul> <li>Direct the MEFA Committee to review the trustee agreement and performance and direct the Secretariat to negotiate new terms and fees for the trustee basedon emerging Global Fund needs.</li> </ul>

<ul><li>Current numbers of Board delegates from recipient countries,NGO's and Communities Living With the Diseases offered funding by the Secretariat for travel should be maintained.</li></ul><ul><li>Class of air travel guided by the current Secretariat travel policy and consistent with the WHO policy on class of air travel should be continued with emphasis placed on using the most economical available fares within those policies.</li></ul>

<ul><li>Adopts the revisions to the Board Operating Procedures as proposed, except for paragraphs 22 and 23.</li></ul><ul><li>The Board has recognized the need for a revision of the By Laws and asks the Governance and Partnership Committee and Secretariat to review the By Laws and report back to the Board at their June 2003 meeting.</li></ul>

<p>1. The Board notes that under its previous decision in May 2009 (GF/B19/DP11) to create a non-voting seat on the Board to represent the constituency of key partners whose mission is directly related to the Global Fund and who are not currently represented on the Board (the "Partners Constituency"), any key partner that wishes to be represented on the Global Fund Board through the Partners Constituency should make a formal request to the Board for their inclusion in the Partners constituency.</p> <p>2. The Board also notes that the Partnership for Maternal, Newborn &amp; Child Health ("PMNCH") have fully responded to the criteria for accepting new constituency members, developed by the Partners Constituency, and have received unanimous support from the current Partners Constituency Members to be incorporated into the Constituency.</p> <p>3. Based on the request submitted by the Partners Constituency, as outlined in GF/B35/27, the Board decides to invite the PMNCH to be a member of the Partners Constituency.</p>

<p><b>Decision Point 1</b> </p><p>The Board approves the 2005 Secretariat Budget and associated Secretariat staffing as attached in Annex 6 to the report of the October 12 - 13 MEFA meeting and as informed by that report. </p><p><b>Decision Point 2</b> </p><p>The Board takes note that the additional budgetary costs associated with any new rounds of proposals are excluded from the base 2005 budget and are highlighted separately.</p><p><b>Decision Point 3</b> </p><p>The Board approves that the agreed costs associated with Rounds 5 and 6 will be treated by the Board as an integral part of the decision to launch the relevant Round.</p>

<p>Decision Point 1:</p> <p>The Board revokes, until the Thirteenth Board meeting, Decision 3* of Agenda Item 5 of the Seventh Board Meeting (reference GF/B8/2), and decides that Phase 2 decisions shall be made by the Board in accordance with the processes and subject to the policies set out in Annex 3 to Board Document GF/B9/8. </p> <p>The Board approves, until the Thirteenth Board meeting, the amendments to the Bylaws and Board Operating Procedures set out in Annex 4 to Board Document GF/B9/8.</p> <p>Budgetary implications for this decision point:</p> <p>The additional cost of this decision point is estimated at US$140,000, reflecting assumptions around the need for a) some level of periodic Fund Portfolio Manager effort to work with CCMs and grant recipients to answer questions and provide clarifications to the Board in response to situations where the Board does not endorse Secretariat recommendations for Phase 2 funding; and b) costs incurred to handle the communications protocol described above, including the development of the web pages to hold the Phase 2 materials, the compilation and posting of all materials in a timely manner, and the correspondence with Board constituencies as required by the process.</p> <p>Decision Point 2:</p> <p>The Board approves, at the final Board Meeting of each year, a maximum amount for Phase 2 commitments during the next calendar year; and</p> <p>The Board asks the Secretariat to report back to the Board at every Board Meeting on the Phase 2 decisions taken since the previous Board Meeting, including the cumulative amount approved to date in the current calendar year.</p> <p>There are no material budgetary implications for this decision point. </p>

<p>The Board:</p> <ol> <li>Approvesextension of the relevant implementation period and, where applicable, theadditional funding requested for the grant listed in Table 1.</li> </ol> <p>See attached table detailing total recommended funding amount of US$ 11,300,472 for the following grant: ZAR-911-G14-T for Democratic Republic of Congo (DRC).</p>

<p>TheBoard:</p> <p>Approvesextension of the relevant implementation period and, where applicable, theadditional funding requested for the grant listed in Table 3.</p> <p>See attached table detailing total recommended funding amount of US$ 12,973,121 for the following grant: SUD-011-G15-H for Sudan.</p>

<p>The Board:</p> <p>Approves extension of the relevant implementation period for the grant listed in Table 3 of Attachment 1 to GF/B31/ER26.</p> <p>Table 3: Secretariat’s Recommendations on Grant Extension (see attached: Burundi, BRN-202-G05-M (BRN-M-SEPCNLS))</p>

<p>The agenda for the Thirty-First Board Meeting (GF/B31/01) is approved.</p>

<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grant listed in Table 1, based on the understanding that the amount approved is upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for the grant listed shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of the additional funding requested and to the provision that such additional funding if available shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of the proposed grant shall be the sum of the amount set out in Table 1 below for the listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>Table 1: Secretariat’s Funding Recommendation</p> <p>See attached table detailing total recommended funding amount of EUR 971,313 for CAF-911-G09-T (Central African Republic).</p>

<p>The report of the Thirtieth Board Meeting (GF/B31/02) is approved.</p>

<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grant listed in Table 1, based on the understanding that the amount approved is upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for the grant listed shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of the additional funding requested and to the provision that such additional funding if available shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of the proposed grant shall be the sum of the amount set out in Table 1 below for the listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>Table 1: Secretariat’s Funding Recommendation for a Grant Renewal</p> <p>See attached table detailing total recommended funding amount of EUR 981,882 for KOS-911-G05-T (Kosovo).</p>

<ol> <li>The Board notes that a portion of sources of funds may be excluded from the allocation to Country Bands for future utilization towards initiatives that are not adequately accommodated through the allocation of resources to Country Bands (Annex 1 to GF/B27/DP7) (the “Special Initiatives”). </li> <li>Based on the recommendation of the Strategy, Investment and Impact Committee (the “SIIC”), the Board decides that up to USD 100 million will be available over the 2014 – 2016 allocation period for the following Special Initiatives, as described in GF/B31/08A – Revision 1, in the amounts listed below: <ol type="a"> <li>USD 30 million for the Humanitarian Emergency Fund;</li> <li>USD 17 million for Country Data Systems; </li> <li>USD 29 million for Technical Assistance for Strong Concept Notes and PR Grant-making Capacity Building; </li> <li>USD 15 million for Technical Assistance on Community, Rights and Gender; and</li> <li>USD 9 million for Enhancing Value for Money and Financial Sustainability of Global Fund Supported Programs.</li> </ol> </li> <li>The funds available for Special Initiatives may be reallocated by the Secretariat among the Special Initiatives set forth under paragraph 2 above, upon the SIIC’s approval, in consultation with the Finance and Operational Performance Committee (the “FOPC”), of an updated budget and plan to implement such initiatives.</li> <li>The Secretariat shall recover investments towards Special Initiatives from funding provided through grant programs whenever possible.</li> <li>With respect to the use of funds available for the Special Initiatives, the Board requests the Secretariat to report to the FOPC on the financial implications and to the SIIC on the operational and strategic implications. </li> </ol>

<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Attachment 1 to GF/B31/ER26 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Find policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Table 1: Secretariat’s Funding Recommendation on Additional Funding from the 2014 Allocation. (see attached: Moldova, HIV/AIDS, MDA-H-PAS, MDA-H-PCIMU).</p>

<ol> <li>The Board acknowledges the recommendations set forth in GF/B31/10 outlining the membership appointment recommendations for the Board’s Audit and Ethics Committee (the “AEC”).</li> <li>Accordingly, the Board approves the appointment of the following individuals to the AEC for a term that will expire on 9 March 2016, or until the appointment of their respective successors: <ol type="a"> <li>Graham Jocelyne as independent Chair of the AEC;</li> <li>Mohammed Abdellatif as independent member of the AEC;</li> <li>Gabor Amon as independent member of the AEC;</li> <li>Wendy Harrison as independent member of the AEC; and</li> <li>Christopher Kassami as a constituency-nominated member from the Eastern and Southern Africa Constituency.</li> </ol> </li> </ol>

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2013 Annual Financial Report, which includes the 2013 Consolidated Financial Statements that have been audited by Ernst &amp;amp; Young Ltd, as set forth in GF/B31/ER02 Annex 1.</p>

<ol> <li>Based on the recommendation of the Audit and Ethics Committee, the Board approves the Policy for Disclosure of Reports Issued by the Inspector General, as revised and set forth in Annex 1 to GF/B31/12, which supersedes and replaces the disclosure policy adopted by the Board under GF/B20/DP23.</li> <li>Accordingly, the Board approves the following revision to Section 15 of the Charter of the Office of the Inspector General <a>[1]</a>(the “OIG Charter”) to align the OIG Charter with the revised Policy for Disclosure of Reports Issued by the Inspector General:</li> </ol> <blockquote> <p>“15. Reporting: Final reports of Office of the Inspector General regarding its <span style="text-decoration: line-through;">external</span> assurance and investigations work will be posted on the Global Fund’s public internet site in accordance with the Board-approved ‘Policy for Disclosure of Reports Issued by the Inspector General’<span style="text-decoration: line-through;">. Internal assurance findings will be promptly reported to the Executive Director and the AEC for internal action.</span>”</p> </blockquote>

<ol> <li>The Board acknowledges the nominations for membership of the Board’s Strategy, Investment and Impact Committee (the “SIIC”), as set forth in GF/B31/10”.</li> <li>Accordingly, the Board approves the appointment of the following individuals to serve as voting members of the SIIC, representing the Board constituencies listed by their name, for a term that will expire on 9 March 2016, or until the appointment of their respective successors: <ol type="a"> <li>Aida Kurtovic, Eastern Europe and Central Asia;</li> <li>Vinand Nantulya, Eastern and Southern Africa;</li> <li>Abdalla Osman, Eastern Mediterranean Region;</li> <li>Mirta Roses, Latin America and the Caribbean;</li> <li>Asia Russell, Developed Country NGO;</li> <li>Helga Fogstad, Point 7;</li> <li>Jason Lane, UK-Australia;</li> <li>Julia Martin, USA;</li> <li>Philippe Meunier, France; and</li> <li>Jan Paehler, European Commission.</li> </ol> </li> <li>Noting that the Chair of the Technical Review Panel and the Technical Evaluation Reference Group serve as non-voting members of the SIIC, the Board appoints the following individuals to serve as additional non-voting members of the SIIC, representing the Board constituencies listed by their name, for a term that will expire on 9 March 2016, or until the appointment of their respective successors: <ol type="a"> <li>Lucica Ditiu, Partners; and</li> <li>Mbulawa Mugabe, UNAIDS.</li> </ol> </li> <li>The Board decides to launch a new call for nominations for the Finance and Operational Performance Committee (the “FOPC”) with a due date for nominations by 26 March 2014. The Chair and Vice-Chair of the Board will present its recommendation of candidates to the Board for approval by 15 April 2014.</li> <li>The Board notes that qualified candidates that have already been nominated, but not appointed, for a Committee role will remain in consideration for FOPC membership.</li> <li>The Board urges constituencies to nominate additional candidates that clearly demonstrate the competencies and skills that are required to perform the responsibilities of FOPC members. </li> </ol>

<ol> <li>Based on the recommendation of the Finance andOperational Performance Committee, the Board approves the amended and restatedComprehensive Funding Policy, as set forth in GF/B31/04 – Annex 1 (the “Amendedand Restated CFP”). </li> <li>The Amended and Restated CFP supersedes all priorversions of the Comprehensive Funding Policy, and any related decisionspreviously adopted by the Board or its Committees that are inconsistent withthe Amended and Restated CFP. </li> </ol>

<p>The Board approves the appointment of Ms. Jeya Wilson as an independent member of the Audit and Ethics Committee (the “AEC”) for a term that will expire on 9 March 2016, or until the appointment of her successor.</p>

<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation periods and, where applicable, the additional funding requested for the relevant grant listed in Table 1.</li> </ol> <p>Table 1: Secretariat’s Recommendations on Grant Extensions</p> <p>See attached table detailing total recommended funding amount of US$ 3,561,367 for US$ 3,561,367 (Ethiopia) and US$ 3,561,367 for US$ 3,561,367 (Syrian Arab Republic).</p>

<ol> <li>The Board decides: <ol type="a"> <li>The Secretariat is authorized to extend a grant’s implementation period by a maximum of 12 months beyond the end date set forth in the relevant grant agreement: <ol type="i"> <li>When the extension does not require funding in addition to the amounts approved by the Board for such implementation period ; or</li> <li>When any portion of the extension requires funding in addition to the amounts approved by the Board for such implementation period, provided the period of additional funding does not exceed six months and the amount of additional funding does not exceed USD 10 million.</li> </ol> </li> <li>Any other circumstances warranting an extension will be recommended by the Secretariat to the Board for approval. </li> <li>The Secretariat will develop a framework for exercising the authority delegated under this decision, and report to the Board the extensions approved by the Secretariat under such authority through the monthly Grant Approvals Committee Report on funding recommendations.</li> <li>The Secretariat will review the implementation of this decision and present any recommended modifications to the Strategy, Investment and Impact Committee for approval.</li> </ol> </li> <li>The Board also decides that as of the date of this decision, the extension framework adoptedunder this decision supersedes all prior policies and decisions concerningextensions whether in whole or with respect to relevant parts, including thefollowing Board Decision Points:</li> <li>B24/EDP/5: Procedure forRolling Continuation Channel Mid-Term Performance Reviews and Extensions;</li> <li>GF/B20/DP31: ArchitectureReview – Transition Provisions;</li> <li>GF/B16/DP7, GF/B14/DP27 and GF/B13/DP2: Phase 2Decision-Making Policies and Procedures; and</li> <li>GF/B26/DP5: Delegation of Authority to Secretariat forGrant Operations. </li> </ol>

<p>The Board:</p> <ol> <li>Approves extension of the relevantimplementation periods and, where applicable, the additional funding requested forthe grants listed in Table 1.</li> </ol> <p>See attached table detailing total recommended funding amount of US$ 35,730,528 for the following Ukraine grants: UKR-011-G08-H, UKR-011-G09-H and UKR-011-G10-H.</p>

<ol> <li>The Board acknowledges: <ol type="a"> <li>The Finance and Operational Performance Committee’s recommendation on the amount of announced replenishment results for the 2014 – 2016 Replenishment Period, net of certain adjustments and qualifying deductions, that will be allocated to Country Bands at the start of the Allocation Period (the “Initial Allocation”), as set forth in GF/B31/06, in accordance with the Comprehensive Funding Policy, as amended and restated under decision point GF/B31/DP05; and</li> <li>The Board’s approval of the Strategy, Investment and Impact Committee’s recommendation to apportion USD 100 million to finance Special Initiatives and USD 200 million to finance Regional Programs over the 2014 – 2016 period (GF/B31/DP06 and GF/B31/DP07 respectively).</li> </ol> </li> <li>Accordingly, the Board decides the Initial Allocation for the 2014 – 2016 Replenishment Period is USD 10.22 billion.</li> </ol>

<ol> <li>The Board acknowledges the current political context and challenging implementation environment in Iraq due to ongoing conflicts. and</li> <li>Accordingly, the Board approves the following policy exceptions for processing IRQ-T-UNDP related transition funding application: <ol type="a"> <li>Maintaining the counterpart financing threshold at the level of 40%;</li> <li>Waiver of the “willingness to pay” requirement; and</li> <li>Waiver of the CCM eligibility requirements to access transition funding.</li> </ol> </li> </ol>

<p>The Board:</p> <p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), incremental funding in the amount listed for the interim-applicant grant in Table 2 (the “Recommended Incremental Funding under the New Funding Model”), which will be in addition to the relevant grant’s total budget amounts that the Board has already approved for the implementation period. The Recommended Incremental Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for the relevant grants shall be committed in annual tranches.</p> <p>See attached table detailing total recommended funding amount of EUR 731,918 for the following grant: MOL-H-PCIMU for Moldova.</p>

<p>The Board:</p><ol><li>Declines approval of additional funding for the next implementation period for the Round 10 Jordan TB grant (JOR-011-G04-T).</li></ol><p>Table 1: Secretariat’s Recommendation for Discontinuation of Funding for a Renewal </p><p><i>See attached table.</i></p>

<p>The Board decides to renew the appointment and extend the term of Peter Sands, as the Executive Director of the Global Fund, for an additional four years. In accordance with Article 36.1 of the Operating Procedures of the Board and Committees, the Board has taken such decision with due consideration of performance over his first term, and following discussion of key priorities for the extended term.</p> <p>The Board extends its appreciation and recognition to Mr. Sands for his service during his first term, and expresses support and encouragement to take forward this mandate to implement the organization’s strategic vision in pursuit of the mission.</p>

<ol> <li>Based on the recommendation of the Strategy Committee, the Board approves the revisions for Key Performance Indicators 3, 5, 6a, 6b and 9b as presented in GF/B44/ER04.</li> <li>Based on the recommendation of the Audit and Finance Committee, the Board approves the 2021 target for Key Performance Indicator 12b as presented in GF/B44/ER04; and</li> <li>Based on the recommendation of the Audit and Finance Committee, the Board approves the revision of the formula for Key Performance Indicator 7a as presented in GF/B44/ER04. </li> </ol>

<ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B44/ER08 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li> </ol>

<ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B44/ER07 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grant listed in Table 2 of GF/B44/ER08 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the TRP validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 3 of GF/B44/ER08 (“Table 3”);</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 3, and (b) is subject to the availability of funding.</li> </ol>

<ol> <li>Approves the revised budget recommended for the grant listed in Table 2 of GF/B44/ER06 (“Table 2”);</li> <li>Affirms that the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period for the grant listed in Table 2, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component within the grant, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B44/ER06 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li> </ol>

<p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 2 of GF/B44/ER02 (“Table 2”);</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 2, and (b) is subject to the availability of funding.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B43/ER03 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B44/ER02 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <p>Approves the extension budget and revised implementation period recommended for each grant listed in Table 2 of GF/B44/ER02 (“Table 2”);</p> <p>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 2, and (b) is subject to the availability of funding.</p>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B44/ER01 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board appoints Tracy Staines to serve as the next Inspector General of the Global Fund for a six-year term to begin not later than 1 January 2021.</p>

<p>Robin Montgomery from the Developed Country NGOs constituency is designated as Rapporteur for the 44th Board Meeting.</p>

<p>The agenda for the 44th Board Meeting (GF/B44/01 – Revision 1) is approved.</p>

<ol> <li>Based on the recommendation of the Audit and Finance Committee, the Board approves the following: <ol type="a"> <li>2021 Work Plan and Budget Narrative, as set forth in GF/B44/02A; and</li> <li>The 2021 Operating Expenses Budget in the amount of US$315 million, as set forth in GF/B44/02B (the “2021 OPEX Budget”), which includes US$ 14.90 million for the Office of the Inspector General’s 2021 operating expenses.</li> </ol> </li> </ol>

<p>The Board approves the Terms of Reference for the 2014 Ad-Hoc Working Group on Governance, as set forth in Annex 1 to GF/B31/ER06.</p>

<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Attachment 1 to GF/B31/ER30 ( “Table 1”); provided, however, that the disbursement of any and all funding for the grant “KAZ-T-NCTP” is subject to satisfactory resolution in line with the Global Fund policies by the Republic of Kazakhstan of all recoveries and other OIG matters now pending in draft or final forms;</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>GF/B32/EDP26 - Table 1: Secretariat’s Funding Recommendation on Additional Funding from the 2014 Allocation (see Annex for details)</p> <p>Indonesia (IDN-M-PERDHAK and IDN-M-MOH), Kazakhstan (KAZ-T-HOPE and KAZ-T-NCTP), Timor Leste (TLS-M-MOH), Philippines (PHL-M-PSFI), Swaziland (SWZ-M-NERCHA), Zambia (ZMB-C-CHAZ, ZMB-C-MOH, ZMB-M-CHAZ and ZMB-M-MOH)</p>

<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that funding for renewals of existing grants shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for each listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached table detailing total recommended funding amount of US$ US$ 309,646,766 for the following grants: ETH-T-FMOH for Ethiopia, KEN-H-KRC and KEN-H-MOF for Kenya, MOR-011-G04-H and MOR-011-G05-T for Morocco, UGD-T-MoFPED for Uganda.</p> <p>NOTES:</p> <ol type="a"> <li>Discrepancies between the CCM Request figures and the Program Scorecard result from the clarifications process with the CCM after the Request for Renewal was submitted and/or from corrections and adjustments made by the Global Fund Secretariat at the time of grant renewal review. Based on Board Decision GF/B26/DP7 on the Modification of Rules Governing Grant Renewals dated 11 May 2012, a modified ceiling of 90% of the TRP adjusted Phase 2 amount is applied to the Grant Renewals. This also takes into account discrepancies between the CCM Request figures and the Secretariat’s recommendation.</li> </ol>

<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grant listed in Table 2 of Attachment 1 to GF/B31/ER26 (“Table 2”) in the amount indicated, based on the understanding that the amount approved is the upper ceiling rather than the final funding amount for that period and that on-going implementation arrangements for the listed grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that funding for the renewal of such existing grant shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of the grant shall be the sum of the amount set out in Table 2 for the listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>Table 2: Secretariat’s Funding Recommendation for a Grant Renewal (see attached: Macedonia, MKD-H-MOH)</p>

<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grant listed in Table 2, based on the understanding that the amount approved is upper ceilings rather than final funding amount for that period and that on-going implementation arrangements for the grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of the additional funding requested and to the provision that such additional funding if available shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of the proposed grant shall be the sum of the amount set out in Table 2 below for the listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>Table 2: Secretariat’s Funding Recommendation for an Interim Applicant.</p> <p>See attached table detailing total recommended funding amount of EUR 21,336,770 for NGR-708-G07-M (Niger).</p>

<p>The Board:</p> <p>Approves extension of the relevant implementation period for the grant listed in Table 2 of Attachment 1 to GF/B31/ER30.</p> <p>Table 2: Secretariat’s Recommendations on Grant Extension (see Annex for details)</p> <p>Tanzania (TNZ-607-G09-T)</p>

<p>Decision Point 1:</p> <p>The Board approves for funding the proposals recommended by the Technical Review Panel, and according to the categories listed below, with the clear understanding that budgets requested are upper ceilings rather than final budgets and the Secretariat should report to the Board the results of the negotiations with Principal Recipients on the final budget for acknowledgement (Report of the Technical Review Panel and the Secretariat on Round Four Proposals: Annex II).</p> <ul> <li>Category 1: Recommended proposals with no or minor clarifications, which should be met within 4 weeks and given the final approval by the TRP Chair and/or Vice-Chair.</li> <li>Category 2: Recommended proposals provided clarifications are met within a limited timeframe (the initial reply to TRP clarifications should be received within 6 weeks of the applicant's receipt of the initial decision of the Board, and any further clarifications should be completed within 4 months from the receipt of the initial reply from the applicant). The TRP Chair and/or Vice-Chair shall give final approval based on consultations with the primary and secondary reviewers</li> <li>Category 3: Not recommended in their present form but are encouraged to resubmit.</li> <li>Category 4: Not recommended for funding.</li> </ul> <p>Decision Point 2:</p> <p>The Board acknowledges the lessons learned by the Secretariat and the TRP during the Round 4 process and requests the PMPC to further consider the Report of the TRP and to recommend specific actions to address the issues raised by the TRP, and to address the length of time TRP members are permitted to serve on the TRP at the Ninth Board Meeting.</p>

<p><span>Revised Decision Point 4: </span></p> <p>The Board recognizes the importance of sustaining ongoing treatment, as well as prevention, care and support services.</p> <p>The Board requests the Secretariat urgently to explore internal mechanisms and to work with partners to develop options for the continuity of services through broader country partnerships associated with common national strategic framework for the three diseases. The Board requests the Secretariat to report back to MEFA, PMPC and the Ethics Committee on these issues in time for the development of recommendations by the Ninth Board Meeting.</p> <p>Up to the Ninth Board Meeting, Secretariat priority shall be given to addressing issues related to discontinuation of treatment within Global Fund grant programs</p> <p>Budgetary implications of this decision point:</p> <p>The additional cost of implementing this decision is approximately US $67,500.</p> <p>Decision Point 5:</p> <p>With regard to the legal concerns and fiduciary policy constraints raised by some Board Constituencies, the Board decides to revisit the issue of approval authority of the agreed procedure for decision making on Phase 2 renewals.</p> <p>MEFA, in cooperation with the PMPC, is requested to explore options for incorporating in the agreed Phase 2 renewal process provision for the exercise by the Board of an appropriate decision making role that meets legal and fiduciary policy requirements of Board constituencies and make recommendations to the Ninth Board Meeting.</p> <p>As an interim arrangement, the Board authorizes the Secretariat to extend the terms of grants up to six months for those grants where Phase 2 decision is required prior to the Ninth Board Meeting, and to provide bridge funding for such grants as appropriate based on program needs during this extension period. The Board approves an amount of up to USD 30 million to be used for this purpose.<br /><br />Decision Point 6:</p> <p>The Board recognizes the urgent need to allow recipients to change to new, more expensive artemisinin-based combination therapy in line with the latest scientific evidence, following the recommendations of the malaria experts of the Technical Review Panel.</p> <p>As an interim measure, the Board authorizes the Secretariat to commit as necessary up to USD 90 million for the projected costs of reprogramming 28 programs, which would be financed by utilizing resources from the Phase 2 renewal funding of these programs.</p> <p>The Board requests PMPC to consider the issue of reprogramming in the context of changing scientific evidence, and report back to the Ninth Board Meeting.</p>

The Board agrees to have a retreat of Board Members and Alternates to discuss the core business model of the Global Fund, to be held in Arusha, Tanzania on Saturday 20 November 2004.

<p>The Board resolves to expand the membership of the Ethics Committee from four members to six voting members. Desiring to achieve appropriate balances between geographic representation, gender, and government and civil society participation, 3 members shall come from the voting group encompassing the donor and private sector constituencies and 3 from the recipient, NGO and Communities constituencies.</p><p>The Board resolves that the Ethics Committee shall also appoint one independent, nonvoting expert to advise the Committee.</p>

<p>The report of the Seventh Board Meeting is approved.</p>

<p>Decision Point 1:</p> <p>The Board exempts the Round 3 proposals from the Angola CCM on malaria and from the Benin CCM on malaria from the requirement that all TRP clarifications for proposals in Category 2 should be received within 6 weeks of the applicant's receipt of the initial decision of the Board, and any further clarifications should be completed within 4 months from the receipt of the initial reply from the applicant, in light of the evidence presented by the TRP that this timeframe was impossible to meet due to delays caused by the unavailability of TRP reviewers.</p> <p>There are no material budgetary implications for this decision point.</p> <p>Decision Point 2:</p> <p>The Board exempts the incoming Chair of the TRP, Jonathan Broomberg, from the requirement that TRP members leave the TRP after four Rounds of proposal review, in light of the need for continuity in the leadership of the TRP.</p> <p>There are no material budgetary implications for this decision point.</p> <p>Decision Point 3:</p> <p>The Board commends the Technical Review Panel for its dedicated efforts to ensure that Global Fund financing targets only technically sound proposals. Special recognition is given to the outgoing chair of the Technical Review Panel, Michel Kazatchkine, for his leadership, vision, and dedication to the development of the Technical Review Panel.</p> <p>There are no material budgetary implications for this decision point.</p>

<p>The Board replaces the current eligibility criteria of "co-financing" and "moving over time to an increasing reliance on domestic resources" with a single criterion termed "counterpart financing." The Board adopts the following definition of counterpart financing:</p><ol type="a"><li>Counterpart financing encompasses all domestic resources (including contributions from governments, loans from external sources or private creditors, debt relief proceeds, and private contributions such as from nongovernmental organizations, faith-based organizations, other domestic partners, and user fees) dedicated to the disease program;</li><li>Counterpart financing is in the form of parallel financing.</li></ol><p>The Board requests the Secretariat to only deem eligible proposals from Upper-Middle Income countries that demonstrate 20% counterpart financing, and from Lower-Middle Income countries that demonstrate 10% counterpart financing for the first year of proposed Global Fund grant implementation.</p><p>The Board requests proposals to demonstrate a progressive increase in counterpart financing over the proposed duration of a Global Fund proposal from 20% to 40% for Upper Middle Income countries and from 10% to 20% for Lower-Middle Income countries.</p><p>The Board exempts non-CCM proposals from the counterpart financing requirement.</p><p>The Board will not further define the eligibility criterion "focusing on poor or vulnerable populations" and instead will allow applicants to use their own definitions of poor or vulnerable populations. The Board requests the Secretariat to work with partners such as the World Health Organization, UNAIDS, and the World Bank to further refine this term in order to provide guidance to applicants.</p>

<p>The Board recommends the following:</p><ul><li>From 2005, proposals submitted to the Global Fund may be denominated in USD as well as in Euro</li><li>Grant agreements may be signed in USD or Euro, depending on a recipient's preference. Disbursements will be made in the denominated currency of the grant agreement.</li><li>The Board requests the Trustee to incorporate in its data processing system for the Global Fund, the capacity to cater for grants denominated in USD as well as in Euro.</li><li>The Board authorizes the Secretariat to incur costs not exceeding USD 150,000, for this purpose. The Secretariat may use the contingency to cover this expenditure.</li><li>The Board mandates the MEFA Committee with the Secretariat to prepare the operational implications for the Ninth Board Meeting.<br/>Budgetary implications of this decision point.</li></ul>

<p><b>Decision Point 1:</b> </p><p>The Board of The Global Fund to Fight AIDS, Tuberculosis and Malaria decided to renew Professor Richard Feachem's contract as Executive Director of the Global Fund on the same terms and for a period of two years beginning 15 July 2004.</p><p><b>Decision Point 2:<br/></b> </p><p>The Board approved the Terms of Reference for the Executive Director as amended.</p>

<p>At the occasion of the issue on July 1st of the first stamp dedicated to the Global Fund to Fight AIDS, Tuberculosis and Malaria by the French Post Office, the Board of the Global Fund expresses its profound gratitude to the French Post Office. The issue of this first stamp dedicated to the Global Fund will increase the awareness of the urgency of the fight against these three diseases and on the key role of the Global Fund in this fight.</p><p>A l'occasion de l'émission de le 1er juillet 2004 du premier timbre dédié au Fonds Mondial de Lutte contre le SIDA, la Tuberculose et le Paludisme para la Poste française, le Conseil du Fonds Mondial exprime a la poste française sa profonde gratitude. L'émission de ce premier timbre dédié au Fonds mondial contribuera à accroître a prise de conscience sur l'urgence du combat a mener contre ces trois maladies et sur le rôle clé du Fonds mondial dans ce combat.</p>

<p>The Ethics and Conflict of Interest Policy is amended by inserting the following as section seven, and re-numbering the policy accordingly:</p><ol><li value="7">Any individual who has served as a Board member, Alternate, a member of a Board committee, or as Chair or Vice Chair of the Technical Review Panel shall not be eligible for employment by the Global Fund Secretariat until one year following their last date of service in such a position. The Ethics Committee may waive this provision as appropriate.</li></ol><p>There are no material budgetary implications for this decision point.</p>

<p><span>The Board authorizes the signing of the Headquarters Agreement based on the text attached as Annex 4a to the Report of the Governance and Partnership Committee.</span></p>

<p><span><b>Decision Point 1:</b> </span></p><p><span>The Board recommends that a maximum time limit is needed for a proposal to result in one or a few grant agreements to set performance incentives for all actors involved in this process. This includes the Secretariat, the TRP, LFAs, CCMs and PRs, with responsibilities to be clearly defined. Based on these specified responsibilities, all actors are accountable for completing the necessary work between Board approval of a proposal and grant agreement signing as swiftly as possible.<br/></span></p><p><span>There are no material budgetary implications for this decision point.<br/></span></p><p><span><b>Decision Point 2:<br/></b> </span></p><p><span>The Board recommends that the normal time from Board approval of a proposal to grant agreement signing should be approximately 6 months. If a grant agreement has not been signed 12 months after Board approval, the proposal should no longer be considered approved unless the Board decides to allow a further exceptional time extension based on information received from the Secretariat and CCMs. This time extension will be limited to a maximum of 3 months.<br/></span></p><p><span>Based on further experiences with Global Fund processes, the Secretariat will provide improved estimates on the time required to complete the work between Board approval and grant signing to MEFA before the November Board meeting. At this time, the Boarf may decide to shorten the maximum time limit specified in decision point 2.<br/></span></p><p><span>The resources allocated to a Board-approved proposal that has no signed grant agreement within the specified time period shall be made available for other priority uses according to the Global Fund financial policies.<br/></span></p><p><span>This policy shall not apply for Rounds 1 and 2.<br/></span></p><p><span>There are no material budgetary implications for this decision point.<br/><br/><b>Decision Point 3:<br/></b></span></p><p><span>The Board recommends that the Secretariat analyze possible implications for proposals approved in Round 3 for which grant agreements have not been signed within the maximum time limit specified.<br/></span></p><p><span></span></p>

<p>The Board notes and shares the concerns expressed in the report of the Executive Director as to the situation with regard to Portfolio Management staffing, in view of the anticipated rapid acceleration of workload in July - December 2004 and beyond.</p><p>MEFA will call a special meeting of a Finance sub-group in advance of the 7 - 8 October MEFA meeting to further review and analyze the staffing situation and the budget implications for 2004 and 2005. This meeting will also review the 2005 and 2006 draft budget details to ensure that the preparation of the budget is completed in accordance with the agreed schedule and to deliver fully developed proposals to Board members by<br/>October 22, 2004.</p><p>As an exceptional measure, the Board authorizes an increase in the 2004 Secretariat budget of up to $2.0 million, representing + 29 positions, a maximum staffing of 118 positions. This translates into a 2005 commitment of $ 4.8 million (annual basis).</p><p>This will be financed in 2004 by a $ 1.7 million transfer from the 2004 LFA budget and the use of up to $ 300,000 from the contingency provision, after exploring other 2004 savings options.</p>

<p><b>Decision Point 1: </b> </p><p>The Board approves the action plan for the recruitment of the Executive Director set forth in Annex 2 to the Report of the Executive Director Transition (GF/B13/14) as revised at the Thirteenth Board meeting.</p><p><b>Decision Point 2:</b> </p><p>The timeline set by the Board for the selection of the new Executive Director is based on the expectation that he or she would be able to take office by January 2007. However, given that this is not certain to happen, the Board requests WHO to extend the contract of Professor Feachem to March 31, 2007. The Board acknowledges Professor Feachem's statement that, notwithstanding the end date of his contract, he is able to leave office at the time his successor is ready to assume it, as determined by the Chair and Vice Chair of the Board.</p>

The Board approves the proposed 15 Key Performance Indicators for the Executive Director and associated 2006 targets as presented in Annex 1 of GF/B13/12.

<p>The Board recognizes that the funding under the Continuity of Services Policy should apply to ongoing courses of treatment, whether the treatment is for a limited duration (such as tuberculosis) or is life-long (such as anti-retroviral therapy). To address this, the Board amends the decision at the Twelfth Board Meeting on Continuity of Services as set out in Annex 4 to the Report of the Policy and Strategy Committee (GF/B13/7).</p>

The agenda for the Thirteenth Board Meeting (GF/B13/1) is approved, as amended at the Thirteenth Board Meeting.

The Board approves additional funding of up to USD5,729,444 for the Round 3 South Africa grant for the HIV/AIDS program entitled “Strengthening and Expanding the Western Cape HIV/AIDS prevention, treatment and care programmes” (Grant No SAF-304-G04-H) to ensure program continuation until January 31, 2007.

The Board recommends that the option of top-up grants should not be pursued as mechanisms to protect against exchange rate fluctuations.

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B44/ER09 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The agenda for the Eighth Board Meeting is approved.</p>

Dr. Carol Jacobs from the Latin America and Caribbean Constituency is designated as Rapporteur for the Eighth Board Meeting.

<p>The Board:</p> <ol> <li>Approves the establishment of a seven-member ad hoc nominations committee to assist the Board with its appointment of the next Inspector General (the “IG AHNC”) according to the Terms of Reference set out in Annex 1 of the Electronic Report to the Board that is numbered GF/B31/ER22.</li> <li>Appoints the following five individuals, based on nominations by the voting constituencies of the Board as well as the World Bank, to serve as members of the IG AHNC, each serving in his or her personal capacity: <ul> <li>Jan PAEHLER, who will also serve as Chair of the IG AHNC</li> <li>Pavel AKSENOV</li> <li>Galina MIKHLIN-OLIVER</li> <li>Navin RUGHOONUNUN</li> <li>Timothy ZIEMER</li> </ul> </li> <li>Delegates authority to the Board Chair, in consultation with the Board Vice Chair, and Chair and Vice Chair of the Audit and Ethics Committee, to appoint by 5 September 2014, the two remaining members of the IG AHNC that are not affiliated with a Board constituency, as stipulated in the Terms of Reference of the IG AHNC.</li> </ol>

<p>The Board authorizes the appointment of Ernst &amp; Young Ltd as the Global Fund’s external auditor for the 2014 fiscal year. </p>

<ol> <li>Based on the recommendation of the Finance and Operational PerformanceCommittee (the “FOPC”), the Board approves the 2014 operating expenses budgetin the amount of USD 298.8 million, as set forth in GF/B31/03 Part A (the “2014Operating Expenses Budget”), which includes USD 20.5 million for the Office ofthe Inspector General’s 2014 operating expenses.</li> <li>As previously decided by the Board (GF/B22/DP18), the Secretariat willmanage the 2014 Operating Expenses Budget’s exposure to foreign-exchange ratevolatility and include in its periodic reporting to the FOPC on budget mattersany measures taken to minimize such exposure.</li> </ol>

<ol> <li>Based on the recommendations of the Strategy, Investment and Impact Committee (the “SIIC”), the Board approves the composition of Country Bands for the 2014 – 2016 allocation period, as defined and set forth in Annex 1 to GF/B31/09 – Revision 1.</li> <li>In accordance with its decision to approve the transition framework recommended by the Finance and Operational Performance Committee and the SIIC (GF/B31/DP09), the Board acknowledges USD 15.8 billion is available for allocation to Country Bands for the 2014 – 2016 allocation period, consisting of the following: <ol type="a"> <li> USD 14.8 billion for indicative funding; and</li> <li> USD 950 million for incentive funding.</li> </ol> </li> <li>The Board approves the following allocation of indicative funding for the 2014 – 2016 allocation period: <ol type="a"> <li> Country Band 1: USD 11,250 million;</li> <li> Country Band 2: USD 915 million;</li> <li> Country Band 3: USD 1,530 million; and</li> <li> Country Band 4: USD 1,105 million.</li> </ol> </li> <li>The Board also decides incentive funding, in the amount of USD 950 million, will be apportioned across and within Country Bands 1, 2 and 3 in accordance with the methodology approved by the SIIC under authority delegated by the Board (GF/SIIC09/DP2). </li> </ol>

<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation periods and, where applicable, the additional funding requested for the relevant grant listed in Table 3.</li> </ol> <p>See attached table detailing total recommended funding amount of EUR 12,794,690 for BUR-H-SPCNLS (Burkina Faso) and US$ 1,277,361 for NEP-M-EDCD (Nepal).</p>

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2013 Statutory Financial Statements, which have been audited by Ernst &amp; Young Ltd, as set forth in GF/B31/ER02 Annex 2. </p>

<p>The Board approves the Report of the Thirty-First Board Meeting (GF/B31/19).</p>

<ol> <li>The Board acknowledges the nominations for membership of the Board’s Finance and Operational Performance Committee (the “FOPC”), as set forth in GF/B31/ER03 Revision 1”.</li> <li>Accordingly, the Board approves the appointment of the following individuals to serve as voting members of the FOPC, representing the Board constituencies listed by their name, for a term that will expire on 1 May 2016 or until the appointment of their respective successors: <ul> <li>Hristijan Jankuloski, Developing Country NGO;</li> <li>Ren Minghui, Western Pacific Region;</li> <li>Nilaya Mitash, South East Asia;</li> <li>Rachel Ong, Communities;</li> <li>Safiatou Thiam, West and Central Africa;</li> <li>Kieran Daly, Private Foundations;</li> <li>Arun Thangaraj, Canada and Switzerland;</li> <li>Reinhard Tittel-Gronefeld, Germany;</li> <li>Nazzereno Todini, Private Sector; and</li> <li>Takeshi Osuga, Japan.</li> </ul> </li> <li>The Board appoints the following individuals to serve as non-voting members of the FOPC, representing the Board constituencies listed by their name, for a term that will expire on 1 May 2016, or until the appointment of their respective successors: <ul> <li>Alexandru Cebotari, World Bank; and</li> <li>Martins Pavelsons, Partners.</li> </ul> </li> </ol>

Based on the need to accommodate both the Board retreat and meeting, the Board agrees to convene the Thirty-Second Board Meeting in Montreux, Switzerland as an exception to article B.6.1 of the Operating Procedures of the Board and Committees.

<ol> <li>The Board notes its prior decision to approve the Amended and Restated Comprehensive Funding Policy (GF/B31/DP05) (the “CFP”) as a standard financial management framework, and acknowledges unique measures are required to facilitate the 2014 allocation of resources to Country Bands, the first under the allocation-based funding model, to manage the transition from the rounds-based system.</li> <li>Accordingly, based on the joint recommendation of the Finance and Operational Performance Committee (the “FOPC”) and the Strategy, Investment and Impact Committee (the “SIIC”), the Board adopts the following transition framework: <ol type="a"> <li>The total amount that will be allocated to Country Bands (the “Total Allocation”) using the allocation methodology will be comprised of the following amounts: <ol type="i"> <li>The Initial Allocation, in the amount of USD 10.22 billion, as approved under decision point GF/B31/DP08, which will determine the amount of incentive funding; and</li> <li>The amount of Sources of Funds, as defined in the CFP, originating from the Third Replenishment Period (2011 – 2013), or earlier, which have not been disbursed as at 31 December 2013 (the “Existing Funds”), in the amount of USD 5.55 billion, as recommended by the FOPC.</li> </ol> </li> <li>While each grant applicant’s portion of the Total Allocation must be requested by the applicant and approved by the Board prior to 31 December 2016, it may be utilized beyond such date in accordance with the terms of the relevant grant agreement;</li> <li>The Total Allocation will address the remaining pipeline of grant funding due to Board-approved proposals or other Board decisions originating from the Third Replenishment Period, or earlier, as at 31 December 2013, (the “Existing Grants Pipeline”) while taking a comprehensive approach such that performance and strategic impact are reflected in the investment of the entirety of funds;</li> <li>While each disease component’s portion of the Total Allocation will typically cover a period of four years starting from 1 January 2014, the Secretariat, working together with countries and/or regions, has the operational flexibility to structure longer or shorter grant implementation periods while applying the principles of the allocation model (GF/B28/DP4) to guide funding levels towards the amounts derived from the allocation formula;</li> <li>Accordingly, a 25-percent target minimum reduction compared to the most recent available four-year disbursement levels (the “Graduated Reduction”) will be applied across the portfolio of disease components that have funding levels above their notional shares under the allocation methodology; and</li> <li>If a disease component’s Existing Grants Pipeline exceeds the amount that would result from applying the Graduated Reduction described in paragraph 2.e. above, then instead of applying the Graduated Reduction, the disease component’s Existing Grants Pipeline will serve as a basis to determine its total allocation starting from 1 January 2014.</li> </ol> </li> <li>The Board notes the transition framework established under this decision represents measures tailored to address the unique circumstances and challenges of transitioning from the rounds-based system to the allocation-based funding model and shall not apply to subsequent allocations and Replenishment Periods.</li> </ol>

<ol> <li>The Board notes that a portion of sources of funds may be excluded from the allocation to Country Bands for future utilization towards investments that are not adequately accommodated through the allocation of resources to Country Bands (Annex 1 to GF/B27/DP7). </li> <li>Based on the recommendation of the Strategy, Investment and Impact Committee, as set forth in GF/B31/08B, the Board: <ol type="a"> <li>Decides that USD 200 million will be available for new Regional Programs over the 2014 – 2016 allocation period;</li> <li>Recognizes that Regional Programs will be presented to the Board for funding approval throughout the 2014 – 2016 allocation period; and</li> <li>Acknowledges funding applications that are submitted by a group of small island economies or other small countries that typically would not apply as individual countries due to inherent administrative inefficiencies (the “Multi-Country Applications”) will be funded from amounts allocated to the individual disease components participating in each Multi-Country Application. </li> </ol> </li> </ol>

The Board notes the Audit and Ethics Committee’s (the “AEC”) responsibility to oversee financial accounting and reporting matters and requests that, following a limited review by the Global Fund’s external auditor, the AEC reviews and authorizes the publication of interim condensed consolidated financial statements which have been prepared by the Secretariat.

<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation periods and, where applicable, the additional funding requested for the relevant grant listed in Table 1.</li> </ol> <p>Table 1: Secretariat’s Recommendations on Grant Extensions</p> <p>See attached table detailing total recommended funding amount of US$ 69,353,613 for UGD-708-G07-H and US$ 1,200,000 for UGD-708-G13-H (Uganda).</p>

Minister Benedict Xaba from the Eastern and Southern Africa constituency is designated as Rapporteur for the Thirty-First Board Meeting.

<p><span>The Board requests the Secretariat to begin preparations for the Fifth Call for Proposals, to enable a decision at the Ninth Board Meeting on the Fifth Call for Proposals.</span></p><p><span>There are no material budgetary implications for this decision point.</span></p>

<p>The Board adopts the requirements and recommendations as proposed in Annex 3a, and treats all requirements in this document as recommendations, in order to improve the functioning of Country Coordinating Mechanisms as public-private partnerships of all relevant stakeholders.</p> <p>With regards to HIV/AIDS, coordination efforts should be done within the overall framework of the "Three Ones".</p> <p>The Board decided to table Option 1 of Recommendation 9.</p> <p>The Board decided to replace Recommendation 13 with the following:</p> <ul> <li>The Board takes note of the recommendation contained in the reports of GPC, MEFA and TRP concerning the need to strengthen technical assistance and capacity development. Considering the urgency and cross-cutting nature, the Board recommends the formation of a special Ad Hoc Working Group to assess needs and make policy recommendations to facilitate the provision of technical assistance and capacity development for and through Country Coordinating Mechanisms, Principal Recipients, Sub-Recipients, inclusive of all phases of the Fund's grant cycle. The Ad Hoc Working Group will present recommendations for approval at the Ninth Board Meeting.</li> </ul> <p>The Board decided to replace Recommendation 15a with the following:</p> <ul> <li>The Board further directs the Secretariat, in consultation with the TERG, to develop a pilot set of auditable standards for benchmarking the performance of CCMs and report back through the GPC by the Ninth Board Meeting.</li> </ul>

<p>The Board adopts the paper describing the operational modalities to implement the process of Voluntary Replenishment (as outlined in Annex 3 of the Report of the Resource Mobilization and Communication Committee (RMCC)).</p>

<p>The Global Fund strongly endorses the "Three Ones Framework".</p><p>In this context the Board welcomes the recent initiative led by Chairman Thompson, U.S. Ambassador Tobias and European Union leaders to call together key stakeholders -including WHO, UNAIDS, the World Bank, the Global Fund and major donors, to take forward practically the 'Three Ones" agenda.</p><p>We commit the Global Fund, both now and in the future, to work practically and concretely with others to improve and measure coordination and make a success of harmonization as outlined in the "Three Ones Framework".</p><p>Specifically, the Secretariat should explore as part of the CCM indicator framework and other processes, the monitoring of the Global Fund's performance in harmonizing its own processes and procedures with other in-country national frameworks and coordination mechanisms.</p>

<p><span>The Board approves, with immediate effect, the amendments to the Bylaws and Board Operating Procedures (as outlined below) that add a constituency represented by a representative of an NGO who is a person living with HIV/AIDS or from a community living with tuberculosis or malaria (the "Communities delegation") as a full voting member of the Board.</span></p><p><span>The Board announces its intention to add an additional and balancing donor seat when new donor resources become available which meet an appropriate financial threshold.</span></p><p><span>Amendments:</span></p><p><span>Article 7.1 of the Bylaws is amended as follows:</span></p><p><span>7.1. Composition</span></p><p><span>The Foundation Board shall consist of <u>nineteen voting members and four nonvoting members</u>. Each voting member shall have one vote.</span></p><p><span>Voting members of the Foundation Board shall consist of:</span></p><ul><li><span>Seven representatives from developing countries, one representative based o each of the six World Health Organization ("WHO") regions and one additional representative from Africa.</span></li><li><span> Seven representatives from donors.</span></li><li><span><u>Five</u> representatives from civil society and the private sector (one representativ of a non-governmental organization ("NGO") from a developing country, one representative of an NGO from a developed country, one representative of th private sector, one representative of a private foundation, <u>and one representative of an NGO who is a person living with HIV/AIDS or from a community living with tuberculosis or malaria)</u>.</span></li></ul><p><span>The <u>four</u> ex-officio nonvoting members of the Foundation Board shall consist of:</span></p><ul><li><span>One representative from the W HO;One representative from the Joint United Nations Programme on HIV/AIDS ("UNAIDS");</span></li><li><span>One representative from the trustee; and</span></li><li><span> One Swiss citizen with his or her domicile in Switzerland authorized to act on behalf of the Foundation to the extent required by Swiss law.</span></li></ul><p><span>Members of the Foundation Board ("Board Members") may each appoint one Alternate Member to serve in their stead, under policies and procedures determined by the Foundation Board.</span></p><p><span>The third paragraph of Article 7.6 is amended as follows:</span></p><p><span>7.6 Operations</span></p><p><span>The Foundation Board shall use best efforts to make all decisions by consensus. If all practical efforts by the Foundation Board and the Chair have not led to consensus, any member of the Foundation Board with voting privileges may call for a vote. In order to pass, motions require a two-thirds majority of those present of both: a) the group encompassing the seven donor seats and the two private sector seats and b) the group encompassing the seven developing country seats, the two non-governmental organization seats, <u>and the representative of an NGO who is a person living with HIV/AIDS or from a community living with tuberculosis or malaria</u>.</span></p><p><span>Section 10 of the Board Operating Procedures is amended as follows:</span></p><p><span>10. Decision-making</span></p><p><span>The Board shall use best efforts to reach all decisions by consensus. If all practical efforts by the Board and the Chair have not led to consensus, any member of the Board with voting privileges may call for a vote. In order to pass, motions require a two-third majority of those present of both: a) the group encompassing the 7 donor seats and the 2 private sector seats and b) the group encompassing the 7 developing country seats, the 2 non-governmental organization seats, <u>and the representative of an NGO who is person living with HIV/AIDS or from a community living with tuberculosis or malaria</u>. </span></p><p><span>There are no material budgetary implications for this decision point.</span></p>

<p><span>Decision Point 1: </span></p> <p><span>1.1 The Board decides that special policies and procedures are required in the event o insufficient resources during a certain calendar year to fund all Phase 2 grant renewals. Such a situation of resource constraints would become evident at the final </span><span>Board meeting of the previous year.</span></p> <p><span>1.2 The Board decides that provided funding is available for at least one year of renewals, available resources will be allocated among all grants that satisfy the Global Fund's renewal criteria according to a time-limited partial allocation system.</span></p> <ol type="a"> <li><span>A time-limit for renewed grants should be established by the Board at the final Board meeting of the year prior to the year of renewals. This time limit will be based on conservative estimates of resource needs for renewals as compared to resources available for the calendar year of resource constraints.</span></li> <li><span>Initial amounts committed during the year may be adjusted at the end of the year based on actual resource needs for renewals as compared to resources available.</span></li> </ol> <p><span>There are no material budgetary implications for this decision point.</span></p> <p><span>Decision Point 2:</span></p> <p><span>The Board decides that for subsequent year(s), the following priority system will apply in the event of resource constraints:</span></p> <p><span><u>First funding priority</u>: Unfunded portions of prior year(s) renewals.</span></p> <p><span><u>Second funding priority</u>: Renewals due in the current year. A time limited partial allocation system will be established as necessary (seeDecision Point 1.)</span></p> <p><span><u>Third funding priority</u>: New proposal rounds (as already established in the Comprehensive Funding Policy).</span></p> <p><span>There are no material budgetary implications for this decision point.</span></p> <p><span>Decision Point 3:</span></p> <p><span>The Board recommends that if funding is not available for at least one year of Phase 2 grant renewals during a certain calendar year, special procedures will be decided by the Board at the final Board meeting of the previous year.</span></p> <p><span>There are no material budgetary implications for this decision point.</span></p> <p><span>Decision Point 4:</span></p> <p><span>The Board recognizes the importance of sustaining ongoing treatment, as well as prevention, care and support services.</span></p> <p><span>The Board requests the Secretariat urgently to explore internal mechanisms and to work with partners to develop options for the continuity of services through broader country partnerships associated with common national strategic framework for the three diseases. The Board requests the Secretariat to report back to MEFA, PMPC and the Ethics Committee on these issues in time for the development of recommendations by the Ninth Board Meeting.</span></p> <p><span>Budgetary implications of this decision point:</span></p> <p><span>The additional cost of implementing this decision is approximately US $135,000.</span></p>

<p>The Board approves the Memorandum of Understanding with Roll Back Malaria attached as Annex 3 to the Report of the Governance and Partnership Committee (GF/B9/7), and requests the Secretariat to provide periodic reports on cooperation between the Fund and RBM under the agreements.</p> <p>There are no material budgetary implications of this decision.</p>

<p>The Board approves the Report of the 44th Board Meeting, as set forth in GF/B44/18.</p>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B44/ER11 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<span>The Board extends the deadline for the signingof a grant agreement for the Timor Leste Round 5 HIV proposal for three monthsto 16 March 2007.</span>

The Board approves the 2007 Corporate Key Performance Indicators and associated 2007 targets contained which will also serve as the Key Performance Indicators/Targets for the Executive Director.

<p>The Board recognizes that, in exceptional circumstances, there may be a need to provide funding for the continuation of treatment in grants where funding ends. </p> <p>The Board wishes to revise its policy on continuity of services for treatment (as amended at the Twelfth and Thirteenth Board Meetings) to reflect the differing circumstances of grants that end because of suspension, force majeure situations, a decision not to provide Phase 2 funding, or other unforeseen causes ("unanticipated terminations") and grants which reach the end of their term ("anticipated expirations"). </p> <p>The Board accordingly revokes the Continuity of Services decision, as amended at the Thirteenth Board Meeting (GF/B14/2) and replaces it with this decision:</p> <p>The Board adopts the following system for addressing continuity of services following both unanticipated termination and anticipated expiration of grants: </p> <p>i. A recipient (typically a CCM) whose funding has ended may submit an Extraordinary Request for Continued Funding for Treatment.</p> <p>ii. The Extraordinary Request will be limited to expenses directly related to the continuation of courses of treatment (including medicines [which, in the case of discontinuation of anti-retroviral therapy, includes drugs for HIV-related opportunistic infections], diagnostics, and, as appropriate, costs for medical staff and other personnel directly involved in care of the patients on treatment) for those people already placed on courses of treatment under the existing proposal at the time of the Extraordinary Request. "Courses of treatment" includes treatment that is for a limited duration (such as for tuberculosis), or is life-long (such as for antiretroviral therapy).</p> <p>iii. The Extraordinary Request will be limited to the amount required to provide services directly related to the continuation of courses of treatment for up to two years (taking into account any amount which remains available under the existing grant).</p> <p>iv. The Extraordinary Request shall contain a description of the steps taken to find sustainable sources of financing for the people on courses of treatment, and to ensure the recipients are delivering courses of treatment effectively. To be eligible for funding under this provision, the CCM (or, in the case of non-CCM proposals, the grant applicant) must demonstrate that it has used its best efforts to identify other sources of funding to provide continuity of services, but has been unsuccessful.</p> <p>v. The Secretariat will review the Extraordinary Request, and provide a funding recommendation to the Board for its approval. The Secretariat will take into account performance issues, as appropriate, and shall make any adjustments to existing implementation arrangements necessary to ensure the effective use of Global Fund financing.</p> <p>vi. Throughout the process, the Secretariat will encourage CCMs and PRs to actively engage with technical partners to identify mechanisms to ensure continuity of services. </p> <p>vii. In a resource-constrained environment, the Global Fund shall prioritize Extraordinary Requests for Continued Funding for Treatment for anticipated expiration and Extraordinary Requests for Continued Funding for Treatment for unanticipated termination at the same level as Phase 2 renewals.</p> <p>The following additional conditions shall apply in cases of anticipated expiration:</p> <p>viii. CCMs that submit an Extraordinary Request must provide evidence of compliance with Global Fund counterpart financing requirements during the period for which they make the request.</p> <p>ix. In addition to the merit of the request, the primary factor affecting the Secretariat's recommendation to the Board with respect to the amount and duration of funding for the continuity of treatment shall be the income level of the country of the applicant (as defined by the World Bank income classification of the applicant in the year of application of an Extraordinary Request); the Secretariat may also take into account other relevant considerations such as the size of the treatment program (in terms of cost or number of patients).</p>

<p>The Board acknowledges the lessons learned by the Technical Review Panel (TRP) and Secretariat during the Round 6 proposals process as presented in the Report of TRP and the Secretariat on Round 6 Proposals (GF/B14/10), and delegates authority to the Portfolio Committee to:</p><p>a. approve appropriate revisions to the Proposal Form and Guidelines for future Rounds by 1 March 2007; and</p><p>b. approve appropriate revisions to the process for screening and clarification of proposals prior to submission to the TRP.</p>

#

<p>The Board requests the Finance and Audit Committee (FAC) to develop a framework to guide future reviews by the FAC of the Secretariat's annual budget proposals. </p><p>As part of the framework development process, (i) the Board requests the Executive Director, in consultation with the FAC and other Board committees to initiate an external evaluation of the Global Fund's staffing, including its structure and size; and (ii) the FAC will identify appropriate budgetary parameters to assist future budget reviews. </p><p>The Board requests the FAC to take into account the operational implications of the Resource Mobilization Task Team and the Four-Year Strategic Plan.</p><p>The Board requests that the FAC report to the Board on its progress at the April 2007 Board meeting.</p>

The Report of the Thirteenth Board Meeting (GF/B14/2) is approved, as amended at the Fourteenth Board Meeting.

<p>The Board acknowledges UNITAID's offer to finance the purchase by the Green Light Committee of the Stop TB Partnership ("GLC") as procurement agent of MDR-TB medicines (the "MDR-TB Contributions"), to eligible programs financed by the Global Fund (the "GF Programs") for scale-up of their existing MDR-TB targets. The Board acknowledges, further, UNITAID's initial approval of USD 7.9 million (the "Initial MDR-TB Funding") to finance MDR-TB Contributions and acknowledges UNITAID's intention to approve additional funding for MDR-TB Contributions (the "Additional Funding") once the Global Fund Secretariat has determined the estimated maximum amount needed for the scale-up of potentially eligible GF Programs through their Phase 2 (the "Maximum MDR-TB Amount"). The Additional Funding shall be equal to the difference between the Maximum MDR-TB Amount and the Initial MDR-TB Funding.</p><p>The Board accepts, in principle, UNITAID's request that the Global Fund assume sole responsibility for (a) the determination of which GF Programs shall receive MDR-TB Contributions; (b) the adjustment of the relevant grant agreements to reflect MDR-TB scale-up; (c) the monitoring of GF Program results linked to MDR-TB scale-up; (d) the authorization of the delivery of shipments of MDR-TB Contributions to GF Programs procured by the GLC based on performance; and (e) the determination at the end of Phase 1 of funding (where applicable) of whether GF Programs receiving MDR-TB Contributions shall continue to receive MDR-TB Contributions during their Phase 2. </p><p>The Board acknowledges that UNITAID's funding is limited to medicines and diagnostics only, and does not include operational costs that enable scale-up in MDR-TB treatment. The Board acknowledges UNITAID's intention, where a GF Program is covered by MDR-TB Contributions and a material increase in expenditure on operational costs is caused by the scale-up in MDR-TB targets, to finance up to the entire purchase price of MDR-TB medicines that the Global Fund is already committed to purchasing, so as to allow the Global Fund to shift expenditure to required operational costs that UNITAID could not finance.</p><p>The Board requests the Secretariat to contact Country Coordinating Mechanisms and Principal Recipients which, based on past performance, appear to have demonstrated the capacity to scale up existing MDR-TB targets, and invite them to apply for MDR-TB contributions, stating in their applications the value of such requested MDR-TB contributions. Based on these applications, the Secretariat shall calculate the Maximum MDR-TB Amount so that the UNITAID Board can approve the Additional Funding.</p><p>Once UNITAID has approved the Additional Funding, the Global Fund Board shall, if appropriate, delegate to the Secretariat the authority to do the following:</p><ol><li>enter into contracts with UNITAID and the GLC to document how MDR-TB Contributions by UNITAID will be financed and made available;</li><li>determine which GF Programs shall receive MDR-TB Contributions ("Approvals"), subject to the following: <ol type="a"><li>the Local Fund Agent shall make recommendations with respect to the capacity of Principal Recipients to implement the proposed scale-up, and the Secretariat shall consider such recommendations prior to any Approvals; </li><li>the Technical Review Panel ("TRP") shall make funding recommendations with respect to applications where the scale-up in MDR-TB targets causes material variations in other objectives of the relevant GF Program; and</li><li>the total value of the MDR-TB Contributions authorized by the Secretariat shall not exceed the Maximum MDR-TB Amount;</li></ol></li><li>negotiate and execute amendments of grant agreements to reflect the approved scale-up and MDR-TB Contributions; and</li><li>monitor the GF Program results linked to MDR-TB scale-up, and authorize the delivery of MDR-TB Contributions procured by the GLC to GF Programs based on performance.</li></ol><p>The Board requests the Secretariat to report back to it on implementation of this decision at the Fifteenth Board meeting.</p>

<p>The Board decides to re-advertise the position of Executive Director, and constitute a Nomination Committee. </p><p>The Nomination Committee shall refine the process for selecting the shortlist of candidates for the new Executive Director and present them to the Board no later than its Fifteenth Board Meeting (April 2007).</p><p>The Board requests the Nomination Committee to recommend to the Board possible changes in the Selection Process and Voting Procedures for deciding amongst the short-listed candidates for Executive Director, based on the experience of the Fourteenth Board Meeting (November 2006) and advise the Board (in consultation with the Chair of the Finance and Audit Committee) of the budgetary implications of this decision.</p>

<p>The Board refers to the strategic issue of "Global Fund size" which the Policy and Strategy Committee (PSC) is currently considering. The Board recognizes that significantly increased resources are needed in the fight against the three diseases, including additional contributions to the Global Fund.</p><p>The Board requests the proposed Resource Mobilization Task Team to develop a resource mobilization strategy for how to achieve the following annual target funding levels, and to highlight in each case the associated implications:</p><p>• US$ 4-6 billion per year by 2010; and</p><p>• US$ 8-10 billion per year by 2010.</p><p>The Board further requests the proposed Resource Mobilization Task Team to deliver its findings by 15 February 2007 to inform the PSC's further deliberations on the strategic issue of "Global Fund size".</p>

<p>The Board endorses the recommendation of the Policy and Strategy Committee, as part of the strategic issue of "Market Dynamics," that the Global Fund assume a deliberate and strategic role in improving impact of grants through influencing market dynamics.</p><p>The Board notes the draft objective and guiding principles for developing the Global Fund's market dynamics strategy set out in the Report of the Policy and Strategy Committee (GF/B14/7).</p><p>The Board requests that the Policy and Strategy Committee further explore the issue and present any additional matters, including any potential modifications to the objective and guiding principles for the Global Fund's market dynamics strategy, for Board consideration at the Fifteenth Board meeting.</p>

<p>1. The Board approves for funding for an initial two years, subject to paragraphs 3 and 4 below, the Round 6 proposals recommended for funding by the Technical Review Panel (TRP) and</p> <p>a. listed in Annex 2, Rev. 2 to the Report of the TRP and Secretariat on Round 6 Proposals (GF/B14/10, Rev.1) as 'Category 1' and 'Category 2', and</p> <p>b. listed in Annex 6<a id="_ftnref1" name="_ftnref1"></a>[1] to GF/B14/10 as 'Category 2B' with Composite indices 8 and 6,</p> <p>with the clear understanding that the grant amounts requested in such Annex for "2 Years" are upper ceilings subject to TRP clarifications and grant negotiations rather than final approved grant amounts.</p> <p>2. The remaining Round 6 proposals recommended for funding by the TRP as 'Category 2B' and listed in Annex 6, to GF/B14/10, will be approved, subject to paragraph 4 below, through Board confirmation by email (or, if appropriate, at a Board meeting), as funds become available under the terms of the Comprehensive Funding Policy (GF/B7/2, p. 6), as amended at the Thirteenth Board meeting (GF/B14/2, p. 25-6) based on the composite ranking of such proposals in compliance with Board's decision entitled 'Prioritization in Resource Constrained Environments' (GF/B8/2, p. 13), but not later than 31 July 2007. In the interim, the Board requests the Secretariat to proceed with the TRP clarifications with respect to those proposals.</p> <p>3. The applicants whose proposals are recommended for funding as 'Category 1' shall conclude the TRP clarifications process, as indicated by the written approval of the Chair and/or Vice Chair of the TRP, not later than four weeks after notification in writing by the Secretariat to the applicant of the Board's decision.</p> <p>4. The applicants whose proposals are recommended for funding as 'Category 2' and 'Category 2B' shall:</p> <p>a. provide an initial detailed written response to the requested TRP clarifications and adjustments by not later than six weeks after notification in writing by the Secretariat to the applicant of the Board's decision; and</p> <p>b. conclude the TRP clarifications process, as indicated by the written approval of the Chair and Vice Chair of the TRP, not later than four months from the Secretariat's receipt of the applicant's initial detailed response to the issues raised for clarification and/or adjustment.</p> <p>5. The Board declines to approve for funding those proposals categorized by the TRP as 'Category 3' as indicated in Annex 2 to GF/B14/10, although such applicants are encouraged to resubmit a proposal in a future funding round after major revision of such proposal.</p> <p>6. The Board declines to approve for funding those proposals categorized by the TRP as 'Category 4' as indicated in Annex 2 to GF/B14/10.</p>

<ol start="1" type="1"> <li>The Board approves the document entitled "Phase 2 Decision-Making Policies and Procedures" included as Annex 3b, version 2 to the Report of the Portfolio Committee (GF/B14/8) and revokes the previous version of this document approved at the Twelfth Board Meeting.</li> </ol> <ol start="2" type="1"> <li>The Board revokes Point 1 of the decision approved at the Tenth Board Meeting entitled "Phase 2 Decisions Process" (GF/B11/2, p. 21).</li> </ol> <ol start="3" type="1"> <li>The Board replaces Point 2 of the decision approved at the Twelfth Board Meeting entitled "Extension of Proposal Completion Dates" (GF/B13/2, p. 27) with the following decision:</li> </ol> <p>The Board decides that in circumstances where the term of a Phase 1 Grant Agreement has been extended in accordance with paragraph 7 of the Phase 2 Decision-Making Policies and Procedures attached as Annex 3b, version 2 to the Report of the Portfolio Committee (GF/B14/8) (a "Phase 1 Extension"), the Secretariat may extend the Phase 2 term of Grant Agreements by up to an equal length of time as the Phase 1 Extension without committing any additional funding.</p>

<p>The Board approves the establishment of a funding channel ("rolling continuation channel") that provides an opportunity for Country Coordinating Mechanisms ("CCMs") to apply for continued funding for grants that are reaching the end of their funding terms ("expiring grants") under conditions different from those available for proposals submitted as part of new rounds of financing ("rounds-based channel").</p> <p>The rolling continuation channel shall operate according to the following principles:</p> <ol> <li>The Secretariat shall conduct a review of all grants before the end of their Phase 2 (the "determination of qualification") to determine whether they qualify to apply for continuation of funding through the rolling continuation channel. The Secretariat's determination of qualification shall be final and not subject to appeal.</li> <li>The Secretariat shall establish a standing cross-functional panel (the "qualification panel") to conduct the determination of qualification of grants. This panel will conduct its work several times each year, scheduling determinations of qualification so that grants that do not qualify for the rolling continuation channel have sufficient time to apply through the rounds-based channel.</li> <li>The qualification panel shall base its determination of qualification on the following factors: <ol type="a"> <li>The primary factors shall be the following: <ol type="i"> <li>Strong performance, as determined by the Secretariat having assigned to the grant a performance rating of 'A' in more than half of its reviews of the grant's progress updates over the 18 months immediately preceding the determination of qualification; and</li> <li>Evidence of potential for impact by, for example, demonstration of the grant contributing to a national effort that has had, or has the potential to have in the near future, a measurable impact on the burden of the relevant disease.</li> </ol> </li> <li>In addition, in making a final determination, the qualification panel shall consider the following factors:</li> <ol type="i"> <li>Sustainability, as determined by the extent to which the grant contributes to a national plan which is inclusive of civil society and the private sector and transparently shows the financial contributions made to the plan by major funding sources, including domestic sources; and</li> <li>Whether, in exceptional cases, severe and unexpected changes in circumstances have had a material negative impact on program implementation.</li> </ol> </ol> </li> <li>On the basis of the above factors, the Board expects (based on information provided by the Secretariat) that between a quarter and a third of the grants that expire in a given year would qualify to apply through the rolling continuation channel. The Secretariat will monitor the share of grants that qualify for the rolling continuation channel and report this information to the Board as part of its annual reporting process.</li> <li>Upon completion of each determination of qualification, the qualification panel shall provide feedback to the CCM on the grant's overall performance in a standardized format, and highlight any implementation challenges or sustainability issues that the CCM might address in a subsequent grant proposal. It shall also provide this standardized feedback to the Chair and the Vice Chair of the Technical Review Panel under revised terms of reference and membership(henceforth referred to as "the TRP") to inform consideration by the TRP of a subsequent proposal by that CCM.</li> <li>The determination of qualification shall rely, as much as possible, on existing processes and information, so as to minimize additional work and transaction costs.</li> <li>CCMs that qualify to submit a proposal for continuation of funding through the rolling continuation channel may apply either through the rolling continuation channel or the rounds based channel, but the CCM may not submit proposals covering the same activities through both channels.</li> <li>The process for grant proposals submitted through the rolling continuation channel shall include proposal submission, independent technical review, funding recommendation and if relevant, Board approval, all of which shall occur on a rolling basis.³ The proposal submission and review process shall be as light as possible, without sacrificing technical rigor.</li> <li>The Secretariat shall modify the proposal requirements and review criteria for the rolling continuation channel as appropriate compared to those for the rounds-based channel. As is the case for proposals for the rounds-based channel, they shall reflect considerations of sustainability and alignment with national strategies and plans.</li> <li>CCMs may submit rolling continuation proposals that allow for the continuation of the broader package of interventions to which the expiring grant was contributing. The TRP shall determine whether a proposal's scope demonstrates a material difference, as defined by the Secretariat, compared to the scope of the grant it seeks to continue. A proposal that the TRP deems materially different from the original one shall not be allowable under the rolling continuation channel.</li> <li>The Secretariat shall propose principles-based guidance in the proposal form or guidelines on the extent to which CCMs may increase the scale of the activities financed by expiring grants in rolling continuation proposals.⁵</li> <li>All rolling continuation proposals shall undergo a level of independent technical review as rigorous as that for the rounds-based channel. This review shall be performed by the TRP.</li> <li>The Secretariat shall present to the Board the TRP's funding recommendations not more often than once every three months, unless it is necessary, because of exceptional circumstances, to present a recommendation to the Board more frequently.</li> <li>The TRP shall have the authority to recommend that the Board make its approval of a rolling continuation proposal conditional upon the CCM removing a limited set of specific elements from the proposal.</li> <li>There shall be an appeals process for unsuccessful rolling continuation proposals. The primary grounds for appeal shall be a significant and obvious error made by the TRP regarding information contained in the proposal.⁶</li> <li>CCMs may submit proposals under the rolling continuation channel covering a maximum term of six years, in two phases of three years each, with funding for the second phase subject to the approval of the Board based on a mid-point performance review. The Board shall approve rolling continuation of funding proposals for the entire term of the proposal, with a financial commitment for the initial three years. Grants funded under the rolling continuation channel shall undergo assessments at each disbursement similar to those done for grants funded through the rounds-based channel.</li> <li>The Global Fund shall prioritize funding for proposals submitted through the rolling continuation channel below the funding of Phase 2 renewals of proposals submitted through the rounds based channel and funding of Extraordinary Requests for Continued Funding of Treatment under the Continuity of Services Policy, but above the funding of proposals submitted through the rounds-based channel. The Secretariat, in consultation with the Finance and Audit Committee, shall communicate to the Board at the end of a given financial year a projection of the financial resources potentially available for these funding channels for the subsequent year, specifically noting confirmed pledges.</li> </ol> <p>The Board delegates authority to the Portfolio Committee to apply the principles set out in this decision point and (i) approve the proposal form and guidelines for the rolling continuation channel, and (ii) approve the appropriate policy guidance in relation to the appropriate appeals process for unsuccessful rolling continuation proposals, and requests it to do so by end of March 2007.</p> <p>The Board requests the Policy and Strategy Committee to present for approval at the Fifteenth Board meeting the appropriate procedure for the Board to make funding decisions on proposals for rolling continuation funding recommended by the TRP in accordance with the principles set out in this decision point.</p> <p>The Board requests the Finance and Audit Committee to present for approval at the Fifteenth Board meeting appropriate amendments that arise from this decision to each of the following: (i) the Comprehensive Funding Policy approved at the Sixth Board Meeting (and amended at the Thirteenth Board Meeting); and (ii) the decision on prioritization of Phase 2 funding approved at the Eighth Board Meeting (GF/B9/2, p. 9).</p>

<p>The Board refers to its approval of the establishment of a funding channel ("rolling continuation channel") that provides an opportunity for Country Coordinating Mechanisms (CCMs) to apply for continued funding for grants reaching the end of their funding terms under conditions different from those available for proposals submitted as part of new rounds of financing ("rounds-based channel").¹</p> <p>The Board considers that, in order to conduct technical reviews of proposals submitted under the rolling continuation channel, it will be necessary to build additional flexibility into the staffing and procedures of the Technical Review Panel ("TRP"). For that purpose:</p> <p>1. The Board requests the Portfolio Committee to propose amendments of the Terms of Reference of the TRP for approval at the Fifteenth Board Meeting. Such amendments shall reflect the following principles:</p> <p>a. No change shall be made to the current procedures and membership principles of the TRP for the purpose of review of proposals received through the rounds-based channel.</p> <p>b. The Chair and Vice Chair of the TRP shall, acting together, have the authority to convene ad hoc groups for the purpose of reviewing and making recommendations on proposals received through the rolling continuation channel.</p> <p>c. Such ad hoc groups may include TRP members, alternate members, members of the TRP support group, and former members of the TRP. The Chair and Vice Chair of the TRP, acting together, shall determine the appropriate number and composition of reviewers in each group, based on their fields of expertise and the content of the proposals.     </p> <p>2. The Board requests the TRP Chair and Vice Chair to review rolling continuation channel proposals based on the principles set forth in this decision point and decision point "Establishment of a Rolling Continuation Channel" (GF/B14/DP9) if any such proposals are received before the Board has amended the terms of reference of the TRP.</p>

<p>The Board approves for funding for an initial two years, subject to paragraph 4 of the decision GF/B14/DP5, all remaining Round 6 proposals recommended for funding by the Technical Review Panel and listed in Annex 2, Rev. 2 to GF/B14/10 Rev. 1 as 'Category 2B' that the Board did not previously approve for funding due to resource constraints. </p> <p>All conditions placed on Round 6 approvals listed in decision GF/B14/DP5 apply to the approvals made under this decision.</p>

<p>The Board approves the terms of reference of the Resource Mobilization Task Team ("RMTT"), as set forth in GF/B14/9, Revision 2 (the "Terms of Reference"), and appoints Mr Mike Madnick as its Chair. </p><p>The Board requests the Chair of the RMTT in consultation with the Chair and Vice Chair of the Finance and Audit Committee, and the Chair and Vice Chair of the Policy and Strategy Committee, to establish the membership of the Committee, based on the parameters listed in the Terms of Reference. </p><p>The Board requests the RMTT to present a report at the Fifteenth Board Meeting.</p>

<p>The Board adopts the recommendations for a Second Voluntary Replenishment of the Global Fund as outlined in Annex 5 to GF/B14/9, Report of the Finance and Audit Committee. </p><p>The Board decides that the Second Voluntary Replenishment will cover a three year period, 2008-2010.</p><p>The Board decides that the Finance and Audit Committee shall approve the agenda for the two voluntary replenishment meetings.</p><p>The Board decides that the next voluntary replenishment structure shall be grounded in the policies of the Four-Year Strategic Plan.</p><p>The Board confirms the nomination of Mr. Kofi Annan, current Secretary-General of the United Nations, as Chair and Mr. Sven Sandström as Vice Chair of the Second Voluntary Replenishment of the Global Fund. The Board expresses its appreciation to both Mr. Annan and Mr. Sandström for their excellent leadership during the First Replenishment and willingness to continue this important service.</p>

<p>The Board notes that the Policy and Strategy Committee discussed (a) establishing fixed dates for the launch and approval of rounds to make progress towards greater alignment of Global Fund processes with country cycles and greater harmonization with partners' actions; and (b) ideas to develop a more flexible system whereby funding by the Global Fund of some grants or proposals might move away from rounds-based timing.</p><p>For those proposals that remain on a rounds-based system, the Board endorses the recommendation of the Policy and Strategy Committee that the Board establish and announce to the public, with significant advance notice, a fixed set of dates for future rounds of funding.</p><p>The Board decides the following:</p><ol start="1" type="1"><li>The Secretariat shall issue a minimum of one Call for Proposals in each calendar year, which it shall issue at approximately the same date(s) each year;</li></ol><ol start="2" type="1"><li>The Global Fund Board shall, with significant advance notice, announce the dates for the next two Calls forProposalsand the dates when the Board foresees it will approve proposals;</li></ol><ol start="3" type="1"><li>The Secretariat shall issue Calls forProposalsat least four months earlier than the due date for such proposals;</li></ol><ol start="4" type="1"><li>The Global Fund Board shall continue to make all decisions regarding the funding of proposals through a round at Board meetings; and</li></ol><ol start="5" type="1"><li>In accordance with the Comprehensive Funding Policy, the Secretariat will announce a forecast of the resources available for the round at the time it issues each Call forProposals.</li></ol><p>The Board requests that at the appropriate times the Secretariat propose the appropriate dates for the next Call for Proposals and for Board approval of such proposals. These dates should take into account the schedules of recipients, partners, donors and the Secretariat.</p>

<p>The Board refers to its earlier decision on grant consolidation, taken at its Thirteenth Meeting. To obtain useful experience that could inform the development of policies for grant consolidation, the Board authorizes the Secretariat to modify the application of existing policies to the extent necessary to consolidate grants on a pilot basis (the "Pilot Grants") in multiple countries, which the Secretariat shall select with the consent of the relevant Principal Recipients (PRs) and Country Coordinating Mechanisms (CCMs) and in consultation with other country stakeholders.</p> <p>The purpose of grant consolidation includes streamlining grant management for PRs and the Secretariat, as well as enabling increased alignment with national plans, strategies and systems. The specific objectives of the grant consolidation pilot project are as follows:</p> <ol type="a"> <li>to assess the added value and feasibility of grant consolidation for the Global Fund and for PRs;</li> <li>to identify specific policy and architectural changes that will be required to enable grant consolidation across the Global Fund portfolio (as appropriate) and to inform the development, for the Board's consideration, of strategy and policy recommendations to this end; and</li> <li>to draw operational, policy and architectural lessons from the pilot exercises that could facilitate a broader roll-out of grant consolidation across the Global Fund portfolio and in particular, to identify the criteria for and situations that favor grant consolidation.</li> </ol> <p>Specifically, the Board authorizes the Secretariat, solely in respect to the Pilot Grants, to modify the application of existing policies and procedures so as to achieve objectives that include, but are not limited to the following:</p> <ol type="a"> <li>The consolidation of grants to the same PR into a single grant agreement for the consolidated grant, with aggregated performance targets; </li> <li>The rescheduling of Phase 2 decision dates with respect to the individual grants that are merged into the consolidated grant so as to achieve a single Phase 2 decision date for the entire consolidated grant; and </li> <li>The rescheduling of Phase 1 and Phase 2 end dates with respect to the individual grants that are merged into the consolidated grant so as to achieve single Phase 1 and Phase 2 end dates that apply to the entire consolidated grant.</li> </ol> <p>Any modifications of the application of existing policies and procedures made in connection with Pilot Grants shall be consistent with the Framework Document of the Global Fund.</p> <p>The Board requests the Portfolio Committee to oversee the Pilot Grants and report on the lessons learned that can inform the development of policies for grant consolidation, and update the Board on progress as appropriate.</p> <p>This decision point will expire upon the completion of the terms of the grant agreements of the Pilot Grants.</p>

<p>The Board approves the Five-Year Evaluation plan, and its overall timeframe, budget and implementation arrangements, as presented by the Technical Evaluation Reference Group. The Board requests the Secretariat to seek cost efficiencies through tendering and contract negotiation processes and by building on existing investments by countries and partners.</p><p>The Board requests the Technical Evaluation Reference Group to report on progress of the evaluation at each Board meeting until a final report is delivered and thereafter on the implementation of the recommendations.</p>

The Board requests the Portfolio Committee to consider modifications to the Global Fund policy on eligibility, particularly with regard to the criteria for Upper-Middle Income Countries, and to make a recommendation to the Board by early February 2007, so that the Board may take a vote by e-mail following a Board conference call that is informed by prior submissions from Board delegations on any such recommendations prior to the launch of the Call for Proposals for Round 7.

<p>Decision 1:</p> <p>The Board adopts the proposed methodology for measuring the Executive Director's performance:</p> <ul> <li>Assessment of Executive Director against two dimensions (Key Performance Indicators and competencies);</li> <li>Adoption of best practice "balanced scorecard" approach to define Executive Director Key Performance Indicators;</li> <li>Use of a system that can be used consistently at all levels of the Secretariat to measure performance, and integrated into other key processes such as talent development, strategic planning and budgeting.</li> </ul> <p>Decision 2:</p> <p>The Board approves the proposed 14 Key Performance Indicators for the Executive Director and associated 2005 targets (see page 10 of Annex 1 to GF/B9/15).</p> <p>Decision 3:</p> <p>The Board approves the competency model and associated behaviors that will be used to assess how the Executive Director has achieved targets (see page 12 of Annex 1 to GF/B9/15).</p> <p>Decision 4:</p> <p>The Board agrees to the timing and process for annual evaluation of Executive Director performance:</p> <ul> <li>KPIs and targets proposed by Executive Director and approved by Board before start of year;</li> <li>Assessment of competencies led by external evaluator (professional assessment firm);</li> <li>Final report on Executive Director performance prepared by a small Performance Assessment Committee (consisting of Board members) in January-February of each year.</li> </ul> <p>Decision 5:</p> <p>The Board agrees to the adoption of 5 key Board objectives, metrics and targets for which it has responsibility (related to results and impact, mobilizing resources, supporting country-level implementation, deciding on long-term strategy and providing best practice governance ), and agrees to an annual self-evaluation against these targets (see page 19 of Annex 1 to GF/B9/15, for details).</p>

The Board agrees to launch a Call for Proposals for Round 5 with the intention of reviewing and approving recommended proposals at the Eleventh Board Meeting in July 2005.

<p>The Board amends the Committee Rules and Procedures, para. 1.2.3, to read as follows:</p><p>The Ethics Committee may conduct business only when three or more members and the Chair are present.</p><p>There are no material budgetary implications of this decision.</p>

<p><b>Decision Point 1</b> </p><p>The Board adopts the following system for addressing continuity of services in the context of the Phase 2 renewal decision:</p><ol type="a"><li>A recipient (typically a CCM) whose Request for Continued Funding is not approved may submit an Extra-ordinary Request for Continued Funding for Treatment.</li><li>The Extra-ordinary Request will be limited to expenses directly related to the continuation of treatment (including medicines [which, in the case of discontinuation of antiretroviral therapy, includes drugs for HIV-related opportunistic infections], diagnostics, and, as appropriate, costs for medical staff and other personnel directly involved in care of the patients on treatment) for those people already placed on life-long treatment under the existing proposal at the time of the Extra-ordinary Request.</li><li>The Extra-ordinary Request will be limited to the amount required to provide services directly related to the continuation of treatment for one year from the date of submission of the Extra-ordinary Request, less the amount granted under the Phase 1 proposal not disbursed at the time of the Extra-ordinary Request.</li><li>In addition to a budget, the Extra-ordinary Request shall contain a description of the steps that are being taken to find sustainable sources of financing for the people on treatment, and to ensure that treatment is being delivered effectively.</li><li>The Secretariat will review these plans for sustainable financing and the budget, and provide a recommendation to the Board on their appropriateness. The Extra-ordinary Request will not be subject to a performance-based review unless the Secretariat has pre-existing information to suggest that the approach to care and/or quality of care was inadequate. The frequency and modality for the provision of the Secretariat's recommendations, and the mechanism by which funds are committed to the Extra-ordinary Requests will be in line with the decision that the Board adopts for the broader Phase 2 decision-making process.</li><li>Throughout the process, the Secretariat will actively engage with technical partners to identify mechanisms to ensure continuity of services.</li></ol><p>There are no material budgetary implications for this decision point.</p><p><b>Decision Point 2</b> </p><p>The Board asks the Secretariat to explore with key partners (including WHO, UNAIDS, the World Bank, bilateral agencies, recipients, non-governmental organizations, and people living with the three diseases) a process that will result in long-term solutions to the issues of continuity of treatment, care and support, and prevention services for HIV/AIDS, tuberculosis, and malaria. The Secretariat should report back to the PMPC on the process before the Tenth Board Meeting. The Secretariat should report back to the Board through the PMPC on potential solutions in time for the Eleventh Board Meeting.</p><p>Budgetary implications: The additional cost of implementing this recommendation is estimated at $90,000.</p>

<p><b>Decision Point 1:</b> </p><p>The Board requests the Secretariat to commission a background study of the options and choices available to the Global Fund in its fiscal management structure and processes. </p><p>There are no material budgetary implications for this decision point as it is anticipated that this study can be done on a pro-bono basis.</p><p><b>Decision Point 2:</b> </p><p>The Board requests the MEFA Committee to pursue a review of the Comprehensive Funding Policy and report back at the Tenth Board meeting in April 2005. </p><p>There are no material budgetary implications for this decision point.</p>

<ul> <li>The agenda for the Ninth Board Meeting is approved.</li> </ul>

<p>Decision Point 1</p> <p>The Board mandates the Secretariat to develop an early warning system to identify technical support needs and engage, in a timely and coordinated manner, partners in technical collaboration.</p> <p>Decision Point 2</p> <p>The Board requests the Secretariat to work closely with partners (multi- and bilateral partners, international and national NGOs, horizontal collaboration initiatives, private sector, academia) to facilitate the provision of technical support throughout the life cycle of the grant (proposal development, grant negotiation, implementation, monitoring and evaluation).</p> <p>Decision Point 3</p> <p>The Board mandates the appropriate committee(s) to provide guidance on the allocation of a specified proportion of grant money to be used for technical support to CCMs.</p> <p>Decision Point 4</p> <p>The Board recognizes the increased need for funding to respond to the rising demand placed on partners for technical support. The Board further mandates the appropriate committee(s) to provide guidance on the development of:</p> <p>a. specific funding mechanisms for technical partners to effectively respond to the growing technical support needs.</p> <p>b. appropriate funding strategies to facilitate the meaningful participation of affected communities and civil society organizations in CCMs and all phases of grant implementation.</p>

<p>Decision Point 1:</p> <p>The Board takes note of the lessons learned presented in the report and instructs future Steering Committees and the Secretariat to take these into account for future events.</p> <p>There are no material budgetary implications for this recommendation.</p> <p>Decision Point 2</p> <p>The Board will consider the reconstitution of the Partnership Forum Steering Committee (PFSC) at its Eleventh meeting in July 2005. </p> <p>There are no material budgetary implications for this recommendation.</p>

<p>The Board adopts the following recommendations on Committee structure, role and process:</p> <ul> <li>Streamline the number of core Board Committees from 6 to 4 to reflect the changing needs of the Fund<br /><br /> <ul> <li>Strategy &amp; Policy Committee</li> <li>Portfolio Management Committee</li> <li>Finance &amp; Audit Committee</li> <li>Ethics Committee</li> </ul> </li> </ul> <ul> <li>Maintain the Ethics Committee as a small standing committee. The Committee is to meet as ethical issues arise and are referred by the Board. The Committee will maintain its current size and continue to be comprised of Board members or their alternates only</li> </ul> <ul> <li>Require financial literacy to serve as the Chair or Member of the Finance &amp; Audit Committee</li> </ul> <ul> <li>Require Committee Chair selection to explicitly consider the Chair's Committee leadership and management skills, specifically an ability to enforce adherence to the Committee's role and an ability to drive meetings efficiently</li> </ul> <ul> <li>Confirm that only one delegate is permitted per Committee and that that delegate is expected to be available for all Committee meetings. In the event that membership must permanently change from one delegate to another, permit an overlap period of one committee meeting</li> </ul> <ul> <li>Confirm the role of Committees to frame issues and bring options and recommendations on major strategies and policies, with supporting rationale, to the full Board for decision - to provide operational oversight but otherwise leave implementation activities to the Secretariat</li> </ul> <ul> <li>Request Committee Chairs and Secretariat liaisons hold quarterly telephone calls. Parties should confirm that each is adhering to respective roles and discuss points of issue. This confirmation should be sent to the Board Chair and Vice Chair. Lack of agreement on roles should be reported to the Board Chair and Vice Chair for assistance in resolution if required.</li> </ul> <ul> <li>Eliminate duplicate assignment of issues to Committees and resolve issues of consistency and duplication at the end of each Board meeting among decisions taken by the Board</li> </ul> <ul> <li>Create a standard initiation manual for new Committee members and staff that communicates the roles and functions of the Committees and staff and expectations of Committee members to be approved by the Strategy and Policy Committee</li> </ul> <ul> <li>Committees should monitor their own performance and conduct an annual "health check" - formal role and scope should be assessed every 2-3 years</li> </ul>

The agenda for the Fourteenth Board Meeting (GF/B14/1, Revision 2) is approved, as amended at the Fourteenth Board Meeting.

The Board endorses the "Draft Paper on a Process to Develop a Policy on Donations of Products and Services" (GF/B14/9, Annex 7) and requests the Chair of the Finance and Audit Committee (FAC), in consultation with the Policy and Strategy Committee (PSC), to constitute the Joint Steering Group on Product and Service Donations as per the parameters outlined in Annex 7 of GF/B14/9. The Board requests the FAC to report back on progress at the Fifteenth Board meeting.

The Board approves the amendments to the document entitled "Global Fund Policy on Secretariat Procurement of Goods and Services" (approved at the Fifth Board Meeting and presented as Annex 4 to GF/B5/8) as presented in Annex 6 to the Report of the Finance and Audit Committee (GF/B14/9).

The Board requests the Policy and Strategy Committee to work with the Secretariat and the Finance and Audit Committee to develop a roadmap for future collaboration with UNITAID and present it for approval by the Board at the Fifteenth Board Meeting. 

The Board approves the Action Plan for the Selection of the Executive Director of the Global Fund, as presented by the Nomination Committee on 1 December 2006.

The Board approves additional funding of not more than US$2,412,466 for the Madagascar Round 4 malaria grant to Population Services Inc. (Grant Number MDG-405-G07-M).

The Board requests the Finance and Audit Committee, in consultation with the Policy and Strategy Committee, to develop a comprehensive policy on targeted financial contributions for consideration at the Fifteenth Board meeting.

<ol><li>The Board requests the Secretariat to make the necessary preparations and announce to the public as soon as possible that: <ol type="a"><li> The Secretariat will issue a Call for Proposals for Round 7 by 1 March 2007, and provide for review of those proposals in time for approval at the Sixteenth Board meeting; and</li><li> The Secretariat will issue a Call for Proposals for Round 8 by 1 March 2008, and provide for review of those proposals in time for approval at the last Board Meeting of 2008.</li></ol></li><li>The Board requests the Secretariat to propose at the Sixteenth Board Meeting the appropriate dates for Round 9.</li></ol>

<p>The Board acknowledges UNITAID's offer to finance the purchase by UNICEF as procurement agent of artemisinin-based combination therapy (ACT) medicines (the "ACT Contributions"), for eligible programs financed by the Global Fund (the "GF Programs") for the scale-up of their existing ACT targets. The Board acknowledges, further, UNITAID's initial approval of US$9,050,000 (the "Initial ACT Funding") to finance ACT Contributions, and acknowledges UNITAID's intention to approve additional funding for ACT Contributions (the "Additional Funding") once the Fund Secretariat has determined the estimated maximum amount needed for the scale-up of potentially eligible Global Fund Programs through their Phase 2 (the "Maximum ACT Amount"). The Additional Funding shall be equal to the difference between the Maximum ACT Amount and the Initial ACT Funding.</p><p>The Board accepts, in principle, UNITAID's request that the Global Fund assume sole responsibility for (a) the determination of which GF Programs shall receive ACT Contributions; (b) the adjustment of the relevant grant agreements to reflect ACT scale-up; (c) the monitoring of GF Program results linked to ACT scale-up; (d) the authorization of shipments of ACT Contributions to GF Programs procured by UNICEF based on performance; and (e) the determination at the end of Phase 1 of funding (where applicable) of whether GF Programs that are receiving ACT Contributions shall continue to receive ACT Contributions during their Phase 2. However, the Global Fund discourages non-competitive use of procurement agents so this is not intended to set a precedent.</p><p>The Board requests the Secretariat to contact Country Coordinating Mechanisms and Principal Recipients which, based on past performance, appear to have demonstrated the capacity to scale up existing ACT targets, and invite them to apply for ACT contributions, by stating in their applications the value of such requested ACT contributions. Based on these applications, the Secretariat shall calculate the Maximum ACT Amount so that the UNITAID Board can approve the Additional Funding.</p><p>Once UNITAID has approved the Additional Funding, the Global Fund Board shall, if appropriate, delegate to the Secretariat the authority to do the following: </p><ol><li> enter into contracts with UNITAID and UNICEF to document how ACT Contributions by UNITAID will be financed and made available;</li><li> determine which GF programs shall receive ACT Contributions ("Approvals"), subject to the following: <ol type="a"><li> The Local Fund Agent shall make recommendations with respect to the capacity of Principal Recipients to implement the proposed scale-up, and the Secretariat shall consider such recommendations prior to any Approvals; </li><li> The Technical Review Panel ("TRP") shall make funding recommendations with respect to applications where the scale-up in ACT targets causes material variations in other objectives of the relevant GF Program; and</li><li> The total value of the ACT Contributions authorized by the Secretariat shall not exceed the Maximum ACT Amount; </li></ol></li><li>negotiate and execute amendments of grant agreements reflecting the approved scale-up and ACT Contributions; and</li><li>monitor the GF Program results linked to ACT scale-up and authorize the delivery of ACT Contributions procured by UNICEF to GF Programs based on performance. </li></ol><p>The Board requests the Secretariat to report back to it on implementation of this decision at the Fifteenth Board meeting.</p>

The Board decides to approve the request of Michel Sidibe for a waiver of the one-year "cooling off" period set forth in Section 7 of the Policy on Ethics and Conflict of Interest for Global Fund Institutions.

<p>The Global Fund Board directs the Secretariat to draft a policy for the Global Fund Board and Secretariat concerning the maintenance of confidentiality of any recordings of Executive Sessions of the Global Fund Board, and the circumstances, policies and procedures under which any individual may receive access to these recordings. </p><p>The Board requests the Secretariat to present such draft policy in time for consideration of the next meeting of the Policy and Strategy Committee (PSC), and requests the PSC to present its recommendation for a policy on the "Confidentiality of Recordings of the Executive Sessions of the Board" for approval by the Board at the April 2007 Board Meeting.</p>

<ol start="1" type="1"><li>The Board takes note of the "Partnership Forum 2006 Report" (GF/B14/14) and agrees to use the recommendations contained therein to inform ongoing strategic planning and management of the Global Fund.</li></ol><ol start="2" type="1"><li>The Board agrees to hold the Third Partnership Forum in 2008 and mandates the Policy and Strategy Committee to convene a Partnership Forum Steering Committee to start planning for this event early in 2007.</li></ol><ol start="3" type="1"><li>The format and duration of the Third Partnership Forum should build on the lessons learned from previous Partnership Fora.</li></ol><ol start="4" type="1"><li>The Board approves a budget of US$1,200,000 as an upper limit for the Third Partnership Forum and requests the Finance and Audit Committee to ensure that provision is made for appropriate secretariat staffing levels in the 2007 and 2008 budgets.</li></ol>

<p>The Board endorses Part 1 of the Report of the Finance and Audit Committee (GF/B14/9), and, accordingly, decides to engage in the necessary preparations to discontinue its present Administrative Services Agreement (ASA) with the World Health Organization after appropriate preparations for administrative independence have been made. </p><p>The Board accordingly requests the FAC to work with the Secretariat to present for approval a detailed plan covering such preparations at the April 2007 Board Meeting. The plan shall include proposed measures to be taken prior to termination of the ASA, their costs, and the timeline over which they are intended to occur, and steps to be taken that would safeguard the interests of staff as outlined in paragraph 11 of GF/B14/9. The plan shall be consistent with the principles set forth in GF/B14/9. The Board will make its final decision at the April 2007 Board meeting.</p>

<p>The Board decides to establish a new Nomination Committee to assist with the selection of the next Executive Director of the Global Fund. The members of the Nomination Committee shall be Sheila Dinotshe Tlou, Ren Minghui, Abdalla Abdillahi Miguil, Carole Presern, Melinda Kimble, Masaru Tsuji, Stefano Vella, chaired by Peter van Rooijen, supported by Bobby John. </p><p>The Board decides that the Executive Director shall be selected based on a list of candidates which might include the nominees considered at the Fourteenth Board Meeting in a special Board Meeting to be held in Geneva, before mid-February 2007, and that the Nomination Committee shall propose voting procedures that would allow the Board to make a selection at that session.</p><p>The Board re-affirms the "Selection Criteria for Executive Director" and the "Terms of Reference of the Executive Director of The Global Fund to Fight AIDS, Tuberculosis and Malaria" (GF/14/5, Annex 1).</p><p>The Board decides that the Nomination Committee shall submit to the Board a shortlist of five nominees. The Nomination Committee shall provide an indicative ranking, which shall not be binding on the Board, of the nominees based on the extent to which they meet the Selection Criteria. </p><p>The Nomination Committee shall, not later than 1 December 2006, present an Action Plan to the Board for approval by email. The Action Plan shall set forth the powers of the Nomination Committee and include the following:</p><p>-    The actions that the Nomination Committee will carry out and their timing;</p><p>-    A description of the additional search process that is required;</p><p>-    A description of the limited involvement of an executive search firm in the nomination process;</p><p>-    The timeline for submission of a decision making process for the selection of a new Executive Director to the Board for approval.</p><p>- A weighting/ranking of the selection criteria</p>

<p>The Board approves the appointment of Magda Robalo Correia e Silva as Vice-Chair of the Ethics and Governance Committee, to commence her term on 23 May 2022 and serve for three years or until appointment of her successor (whichever is earlier).</p>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituentgrants, as listed in Table 1 of GF/B47/ER01 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by theproposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemedappropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and(b)shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding availablefor each country disease component among its constituent grants, provided that the TechnicalReview Panel (the “TRP”) validates any redistribution that constitutes a material change fromthe program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 2 of GF/B47/ER02(“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceilingamount that may be available for the relevant implementation period of each country diseasecomponent’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding availablefor each country disease component among its constituent grants, provided that the TechnicalReview Panel (the “TRP”) validates any redistribution that constitutes a material change fromthe program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>Based on the recommendation of the Ethics and Governance Committee (the “EGC”), as presented in GF/B47/06 – Revision 1, the Board:</p> <ol> <li>Acknowledges the changes to the Charter of the Strategy Committee already approved through GF/B46/DP06 and which will be effective as of 31 December 2022;</li> <li>Amends the Charters of the Standing Committees of the Board (“the Charters”), as set forth respectively in Annexes 5, 6 and 7 of GF/B47/06 – Revision 1, which shall each become effective upon the conclusion of the forty-seventh Board meeting; and</li> <li>Acknowledging the specific scope and intent of the changes to the Charters, requests the EGC leadership to determine, after consultation with the Board leadership, Coordinating Group, Standing Committees and Secretariat, as relevant, whether a more complete review of the Charters may be required during the next EGC term.</li> </ol>

<ol> <li>The Board notes:<br /> <ol type="a"> <li>Its decision in May 2019 (GF/B41/DP03) that (i) established the allocation methodology for the 2020 - 2022 allocation period; and (ii) acknowledged the technical parameters for the 2020 - 2022 allocation period; and</li> <li>The decision by the Strategy Committee (the “SC”) in March 2022 GF/SC18/DP05, under authority delegated by the Board, to establish technical parameters for the 2023 – 2025 allocation period (the “Technical Parameters”).</li> </ol> </li> <li>Accordingly, based on the recommendations of the SC, as presented in GF/B47/03, the Board:<br /> <ol type="a"> <li>Approves the allocation methodology presented in Annex 1 to GF/B47/03 (the “Allocation Methodology”);</li> <li>Acknowledges the Technical Parameters for the 2023 – 2025 allocation period, as presented in Annex 2 to GF/B47/03 and</li> <li>Approves that no more than 7.5% of the total sources of funds available for country allocations be used to ensure scale-up, impact and paced reductions, as described in paragraph 4.c of the Allocation Methodology; and</li> </ol> </li> <li>Accordingly, the Board:<br /> <ol type="a"> <li>Requests the SC to review and approve, at its July 2022 meeting, the method by which the Secretariat will apply and report on the qualitative adjustment process; and</li> <li>Acknowledges that the Allocation Methodology and Technical Parameters shall apply for the 2023– 2025 allocation period and supersede the 2020 – 2022 allocation methodology and technical parameters presented in GF/B41/02.</li> </ol> </li> </ol>

<p>Mišo Pejković from the Eastern Europe and Central Asia Constituency is designated as Rapporteur for the 47th Board Meeting.</p>

<ol> <li>Based on the recommendation of the Strategy Committee, the Board approves the revised Eligibility Policy, as set forth in Annex 1 to GF/B47/02 (the “Revised Eligibility Policy”).</li> <li>Accordingly, the Board: <ol type="i"> <li>Acknowledges that this decision point and the Revised Eligibility Policy supersede the decision point GF/B39/DP03 and the previous Eligibility Policy as set forth in Annex 1 to GF/B39/02 (the “Previous Eligibility Policy”); and</li> <li>Notes that, notwithstanding paragraph 2.i of this decision point, the Previous Eligibility Policy remains applicable to grant programs originating from the 2020-2022 allocation period.</li> </ol> </li> </ol>

<p>Based on the recommendation of the Strategy Committee, as presented in GF/B4704 – Revision 1, the Board:</p> <ol> <li>Acknowledges that the total amount of sources of funds for allocation for the 2023-2025 allocation period will be decided by the Board in November 2022, based on the recommendation of the Audit and Finance Committee following announced replenishment results from the 7th Replenishment;</li> <li>Approves that the total amount of funding for catalytic investments in the 2023-2025 allocation period (“Catalytic Investments”) will be determined by the total amount of sources of funds for allocation for the 2023-2025 allocation period;</li> <li>Approves Catalytic Investments for the 2023 –2025 allocation period, based on the total amount of sources of funds for allocation, as set forth in Table 1 of GF/B47/DP06;</li> <li>Agrees that in the event that sources of funds for allocation for the 2023-2025 allocation period are above the midpoint of the funding range specified for any scenario in Table 1 of GF/B47/DP06, the Secretariat may recommend to the Board to approve additional amounts for Catalytic Investments (up to 50% of the difference in total catalytic funding for the applicable scenario and the next higher funding scenario) to be invested in the priority areas for the next higher funding scenario in Table 1 of GF/B47/DP06;</li> <li>Acknowledging that additional refinements may be required to the catalytic investment amounts for the priorities under the “RSSH/Cross-Cutting” section of Table 1 to GF/B47/DP06, delegates authority to the Strategy Committee to approve, within such RSSH/Cross-Cutting section (with the exclusion of the Emergency Fund priority): (i) a decrease in the amount of any priority by up to 15% and (ii) the inclusion of such decreased amounts within another priority in this group. Any changes made under this paragraph will be approved by the Strategy Committee at its July 2022 meeting, and will be informed by input to be provided by the Secretariat as described in paragraph 6.ii below</li> <li>Approves that the Secretariat will:<br /> <ol type="i"> <li>operationalize Catalytic Investments, considering TRP and TERG recommendations as well as available program and financial performance data from ongoing catalytic investments, and work with partners to ensure that Catalytic Investments have clear objectives, expected outcomes and impact and transparency in the investment decisions on geographic prioritization and country selection;</li> <li>update the Strategy Committee, at its July 2022 meeting, on the status of such operationalization and planned next steps, and report, bi-annually, to the Strategy Committee and Board thereafter on further operationalization;</li> <li>have flexibility, within the total amount of funding for Catalytic Investments, to increase or decrease the amount for any approved priority up to 15% and report to the Strategy Committee on any such changes; and</li> <li>present any increase or decrease of an amount for any approved priority above 15% to the Strategy Committee for approval; and</li> </ol> </li> <li>Agrees that the Secretariat will have delegated authority to increase the amount of funding available for the Emergency Fund, by up to 50% of the amount approved for this priority, using funding approved as available by the Audit and Finance Committee for portfolio optimization, and that paragraph 6.iv above will not apply to increases to the Emergency Fund. Any increase above 50% will be presented to the Board for its urgent, no-objection approval.</li> </ol>

<p>The Board approves the amendments to the (i) Terms of Reference Chair and Vice-Chair of<br />the Board of the Global Fund, (ii) Bylaws of the Global Fund; and (iii) the Operating Procedures of the Board and Committees of the Global Fund, set out respectively in annexes 1, 2 and 3 to GF/B47/05.</p>

<p>The Agenda for the 47th Board Meeting (GF/B47/01) is approved.</p>

<p>Based on the recommendation of the Strategy Committee, the Board approves the eligibility of the six (6) Transition Funding components from the 2020-2022 allocation period for an additional allocation of Transition Funding for the 2023-2025 allocation period.</p>

<p>The Board:</p> <p>1. Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B44/ER19 (“Table 1”);</p> <p>2. Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</p> <p>3. Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</p> <p>4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </p>

<ol> <li>The Board approves the appointment of Mr Mauro Ghirotti, representing the European Commission, Belgium, Italy, Portugal, Spain Constituency, as a voting member of the Audit and Finance Committee for a term that will expire in May 2022, or until the appointment of his successor.</li> <li>The Board approves the appointment of Mr Josephat Kakoma from the Eastern and Southern Africa Constituency, to serve in his personal capacity as a voting member of the Ethics and Governance Committee for a term that will expire in May 2022, or until the appointment of his successor. </li> </ol>

<p>The Board:</p> <ol> <li>Recalls GF/B43/EDP07 where it decided to extend the scope of the wambo.org pilot to allow for eligible buyers, as defined in GF/B42/DP05, to purchase all COVID-19products available in wambo.org for procurement by Global Fund Principal Recipients and specified that such non-Global Fund financed transactions forCOVID-19 products will be issued as purchase orders by wambo.org within the period ending 31 December 2020, unless extended by the Board following recommendation by the Strategy Committee;</li> <li>Recalls GF/B43/EDP17 where the Board approved the change in the end date of such period to 31 May 2021; and</li> <li>Based on the recommendation of the Strategy Committee, approves the change in the end date of such period through which non-Global Fund financed transactions for COVID-19 products may be issued as purchase orders by wambo.org until November 2022 or until the Board approves a future strategy for wambo.org if earlier and confirms that all other conditions and flexibilities set forth in GF/B43/EDP07 shall continue to apply.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B44/ER15 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board acknowledges its previous decision establishing the Global Fund COVID-19 Response Mechanism (C19RM) and agrees that the COVID-19 pandemic continues to have a devastating impact on global health systems, jeopardizing the fight against HIV, tuberculosis, and malaria and progress towards 2030 goals for the three diseases. Recognizing the acute needs at country-level, and the threat of diversion of resources towards COVID-19, the Board agrees that additional funding to support country responses to COVID-19 is necessary to safeguard the USD 14 billion raised through the 6th replenishment for HIV, tuberculosis, and malaria (HTM) programs. The Board further acknowledges that certain public donors wish to make significant additional pledges to the Global Fund to provide further support for country responses to COVID-19 and that this decision does not preclude further discussion and Board decisions within the Strategy development process on the future role and scope of Global Fund support for pandemic preparedness and response.</p> <p>The Board agrees that C19RM should leverage existing Global Fund processes, controls, and frameworks, while acknowledging that modifications may be necessary to ensure the level of speed and agility necessary for an emergency response. The Board further agrees on the need for greater transparency on the operationalization and implementation of C19RM, to facilitate and ensure an appropriate degree of oversight from, and accountability to, the Board.</p> <p>The Board therefore approves the following:</p> <p>1. Timelines:</p> <ol type="a"> <li>C19RM is a temporary, timebound mechanism established to address the current global emergency related to the COVID-19 pandemic;</li> <li>The Secretariat will, through 31 December 2021, continue to mobilize additional funds from public donors and, pursuant to existing policies, private donors, which will be used to support C19RM;</li> <li>C19RM funds may be awarded through 31 March 2022;</li> <li>C19RM will continue to finance interventions across the 5th and 6th replenishment periods; and</li> <li>While C19RM funding is expected to be used rapidly for emergency needs, the final deadline for use of C19RM funds will be 31 December 2023, to reduce the additional cost and burden associated with establishing and monitoring an independent deadline within core grants.</li> </ol> <p>2. Use of funding:</p> <ol type="a"> <li>C19RM funding will finance interventions consistent with applicable World Health Organization (WHO) guidance, including on COVID-19;</li> <li>C19RM funding must be aligned with national Strategic Preparedness and Response Plans;</li> <li>C19RM funding may be used for the following types of interventions: <ol type="a"> <li>COVID-19 control and containment interventions, including personal protective equipment, diagnostics, treatment, communications and other public measures as specified in WHO guidance;</li> <li>COVID-19-related risk mitigation measures for programs to fight HTM (including, but not limited to, support for COVID-19 interventions needed to safely implement campaigns, community and health facility level HTM programs, and additional delivery and procurement costs for HTM programs where related to addressing COVID-19 disruptions); and</li> <li>iii. Expanded reinforcement of key aspects of health systems, such as laboratory networks, supply chains, and community-led response systems, to address advocacy, services, accountability, and human rights based approaches;</li> </ol> </li> <li>C19RM funds may be used to procure COVID-19 products approved under the WHO Emergency Use and Listing procedures or under other emergency procedures set up by any Stringent Regulatory Authorities as defined under the Quality Assurance Policy for Pharmaceutical Products and Quality Assurance Policy for Diagnostic Products; and</li> <li>The Secretariat will develop detailed technical guidance on eligible C19RM interventions for countries, in consultation with relevant partners, as described in paragraphs 27.a and 44 of GF/B44/ER12 – Revision 2.</li> </ol> <p>3. Allocations:</p> <ol type="a"> <li>C19RM funding awards will use countries’ 2020-2022 allocations as a starting basis; and</li> <li>C19RM funding awards will be qualitatively adjusted to better reflect countries’ COVID-19 needs using the following factors: (i) COVID-19 burden; (ii) level of disruption to systems of health, including HTM services; (iii) availability of other sources of funding; and (iv) utilization of funds already awarded.</li> </ol> <p>4. Funding requests:</p> <ol type="a"> <li>C19RM funding requests must be endorsed by Country Coordinating Mechanisms;</li> <li>C19RM funding requests must be developed through appropriate, multisectoral consultation, and fully-inclusive decision-making, which must engage communities and civil society, and ensure coordination with the national COVID-19 response coordinator;</li> <li>C19RM funding request development must include consideration of appropriate community, rights, and gender-related interventions, in alignment with the Global Fund’s underlying principles of gender equity and human rights, and funding requests must articulate national HTM program adaptation needs and how these needs will be covered (e.g. through C19RM funding, grant funding, or other sources); and</li> <li>The Board calls on partners to support countries at the country, regional and global levels to develop robust, technically-sound C19RM funding requests.</li> </ol> <p>5. C19RM Funding Request Review and Approval:</p> <ol type="a"> <li>GAC: <ol type="i"> <li>C19RM funding requests will be shared with partners on the Grant Approvals Committee (GAC) for review and input;</li> <li>C19RM funding requests will also be shared with a technical advisory group composed of relevant ACT-Accelerator partners with technical COVID-19 expertise (CTAG) for review and input;</li> <li>iii. The Secretariat will consider input from GAC partners and CTAG in determining C19RM funding awards or recommendations; and</li> <li>The Secretariat will convene regular GAC review of C19RM to discuss awards made, emerging thematic issues relating to C19RM and Global Fund programs, and concerns and observations from partners. CTAG partners will be invited to participate in these reviews.</li> </ol> </li> <li>TRP: <ol type="i"> <li>The TRP will be requested to input into upfront technical guidance relating to HTM adaptations/risk mitigation as referenced in paragraph 2.e above; and</li> <li>The TRP will also be requested to conduct an expedited review of HTM program adaptation/risk mitigation elements of C19RM funding requests that entail material changes to existing Global Fund programs.</li> </ol> </li> <li>Fast-track investments: The Secretariat may award countries up to USD 900 million of C19RM funding on an accelerated basis to support urgent needs for COVID-19 commodities (including personal protective equipment, diagnostics, and therapeutics) and costs relating to the effective deployment of such commodities.</li> <li>Board approval: <ol type="i"> <li>The Board must approve any C19RM awards exceeding USD 35 million, as measured in aggregate by country and not including any funding awarded pursuant to paragraph 5.c above or previously awarded C19RM funding;</li> <li>Commodity orders relating to paragraph 5.d.i above may be placed pending Board approval; and</li> <li>iii. For C19RM awards approved by the Board, the Secretariat will have delegated authority to increase such awards by up to USD 10 million, in order to avoid the need for repeated Board approvals for increases to the same grants. This authority will be limited to increases that scale up interventions previously approved by the Board.</li> </ol> </li> </ol> <p>6. Reporting, Monitoring and Evaluation:</p> <ol type="a"> <li>The Board emphasizes the need for comprehensive reporting, monitoring and evaluation of C19RM investments, while acknowledging the challenges of measuring results within an emergency response to a rapidly evolving pandemic. The Secretariat and TERG will further develop an evaluation approach for C19RM, as described in paragraphs 50 - 56 of GF/B44/ER12 – Revision 2. This approach will be presented to the Strategy Committee at its 16th meeting (July 2021) for review and input;</li> <li>The Board emphasizes the need for enhanced transparency on C19RM. The Secretariat will provide monthly detailed reporting to the Board on C19RM operationalization, as described in paragraph 21 of GF/B44/ER12 - Revision 2. This reporting will also be available on the Global Fund’s external website to increase transparency of investments and support coordination of external support for COVID-19; and</li> <li>The Secretariat will continue to provide updates through regular Board and Committee engagements.</li> </ol> <p>7. Centrally Managed Investments</p> <ol type="a"> <li>Up to 2.5% of C19RM funding may be used for centrally managed investments to address needs that are not well addressed through awards to individual countries, as described in paragraph 57 of GF/B44/ER12 – Revision 2; and</li> <li>The Secretariat will develop any centrally managed investments under this provision in coordination with GAC and CTAG, and will report all such investments to the Board and its relevant Committees.</li> </ol> <p>8. Management and Operating costs</p> <ol type="a"> <li>Up to 3% of C19RM funds may be used by the Secretariat to cover additional management and operating costs relating to C19RM. These costs may include (i) additional Secretariat resources and expertise, (ii) additional assurance costs, (iii) additional costs relating to enhanced reporting and monitoring and evaluation of C19RM investments, and (iv) additional costs to support CCMs;</li> <li>Management and operating costs under this provision are timebound, reflecting the temporary nature of C19RM, and will not form part of the Secretariat’s annual budget for operating expenditures;</li> <li>The Audit and Finance Committee will review the Secretariat’s plan for costs under this provision; and</li> <li>The Secretariat will provide regular reporting on any costs under this provision to the Audit and Finance Committee and the Board.</li> </ol> <p>9. Additional changes:</p> <ol type="a"> <li>The Board will monitor C19RM on an ongoing basis to determine whether any changes are required as the pandemic continues to evolve; and</li> <li>The Secretariat will return to the Board, through its Committees, as relevant, for additional consideration and approval of any further modifications to C19RM.</li> </ol> <p>10. Limited exceptions to Quality Assurance Policies:</p> <ol type="a"> <li>The Secretariat may continue to grant limited exceptions to the Quality Assurance Policies to waive the requirement for pre-shipment sampling and testing (as originally approved under paragraph 3 of GF/B42/EDP10) through 31 March 2022.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B44/ER13 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2020 Statutory Financial Statements, which have been audited by KPMG SA, as set forth in Annex 2 to GF/B44/ER15.</p>

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2020 Annual Financial Report, including the 2020 Annual Financial Statements which have been audited by KPMG SA, as set forth in Annex 1 to GF/B44/ER15.</p>

<p>The Board approves a modification to the mandate and functions of the Office of the Inspector General through a change to the Charter of the Office of the Inspector General (the “OIG Charter”), as revised and set forth in Annex 1 to GF/B47/EDP04.</p>

<ol> <li>Based on the recommendation of the Ethics and Governance Committee, the Board approves the revisions to the Amended and Restated Code of Conduct for Governance Officials, as set forth in Annex 1 to GF/B44/ER10.</li> <li>Accordingly, the Board acknowledges that this decision point and the revisions to the Amended and Restated Code of Conduct for Governance Officials shall supersede the approval of the previous Amended and Restated Code of Conduct for Governance Officials, pursuant to decision point GF/B43/EDP05.</li> </ol>

<p>Based on the recommendation of the EGC, the Board approves the amendments tothe Operating Procedures of the Board and Committees of the Global Fund, as set out in Annex 2 to GF/B47/ER04. The amendments to the BCOP shall enter into force upon the adoption of this decision point.</p>

<p>The Board approves the appointment of Susanne Kuehn to serve as the next Global Fund Ethics Officer for a three-year term which can be renewed no more than once.</p>

The Board approves the 2007 Operating Expense budget in the amount of US$ 104,728,000 as set out in Annex 8 to GF/B14/9 and as recommended by the Finance and Audit Committee and proposed by the Secretariat.

Françoise Ndayishimiye from the Communities (NGOs representative of the Communities Living with the Diseases) Constituency is designated as Rapporteur for the Fourteenth Board Meeting.

<p>The Board requests the Secretariat to report on the core set of Performance Indicators for the Global Fund (formerly the Soft Performance Measures) to the Board during its first meeting of each calendar year. </p><p>The Secretariat shall link the report of these indicators to the report on the Corporate Key Performance Indicators (formerly the Key Performance Indicators for the Executive Director). </p><p>The Board requests the Secretariat to include impact measures as part of the core set of performance indicators as soon as feasible under the guidance of the Technical Evaluation Reference Group. </p><p>The Board also requests the Secretariat to work on including gender in performance and impact measures where feasible and available in recipient country systems under the guidance of the Technical Evaluation Reference Group.</p>

<p>The Board recognizes the importance of encouraging countries to actively seek innovative sustainability strategies.</p><p>In this context, the Board notes:</p><ol start="1" type="a"><li>the commitment of the Government of South Africa to achieve sustainability of the HIV/AIDS program entitled "Strengthening and Expanding the Western Cape HIV/AIDS prevention, treatment and care programs" (the "Program") by the end of the Phase 2 term, therefore not requiring further Global Fund support for these activities beyond the next four years;</li></ol><ol start="2" type="a"><li>the Program is performing well and is A-rated;</li></ol><ol start="3" type="a"><li>the CCM of South Africa and the Principal Recipient of the grant have committed to achieving or exceeding the targets in the proposal within the originally contemplated five-year term and to appropriate increased targets for the sixth year; and</li></ol><ol start="4" type="a"><li>the CCM of South Africa has not requested additional funding for Phase 2 of the grant beyond that requested in the proposal.</li></ol><p>Therefore, the Board authorizes the Secretariat, on an exceptional basis and without setting a precedent, to consider the Request for Continued Funding submitted by the CCM of South Africa for the Round 3 South Africa grant for the Program (Grant Number SAF-304-G04-H) which anticipates a 4-year Phase 2 term. The Board requests the Secretariat to provide by 1 December 2006 a recommendation for continued funding for this grant. Such recommendation shall include a condition for continued funding that the Government of South Africa makes significant counterpart financing contributions to the Program over the next four years.</p>

<p>The Board welcomes the decision of the UNITAID Board to provide finance for Round 6 to increase the number of patients on treatment. The Board decides to accept a contribution from UNITAID in the amount of US $52,500,000 for Round 6 grants, subject to the execution of appropriate contractual documentation by both parties.</p><p>In addition, the Board:</p><ol><li>acknowledges, without setting any precedent, that the contribution shall be used exclusively for the financing of the purchase of medicines in the treatment areas listed in the UNITAID Board resolution on Round 6 in the amounts specified therein; </li><li>decides that the Secretariat shall employ the contribution in conformity with UNITAID's eligibility requirements and in compliance with existing Global Fund procurement and other policies;</li><li>notes that UNITAID's commitment to improving the price and availability of medicines and diagnostics is consistent with the Global Fund's own endorsement in principle, expressed at its Thirteenth Meeting, of the facilitation of voluntary pooled procurement, subject to the approval of a suitable business plan, and informs the Policy and Strategy Committee's ongoing work on the issue of market dynamics; and</li><li>delegates authority to the Secretariat to negotiate, under the oversight of the PSC, a contribution agreement with UNITAID that reflects the above.</li></ol>

<p>The Board recognizes that its decision points require clear directions with respect to interpretation, policy and staffing implications, and directs the Secretariat to incorporate additional staffing needs, in addition to budgetary implications in all its decision points. </p><p>The Board furthermore acknowledges that it has a responsibility for the impact on the workload of the Secretariat and Board Committees of decisions that have not been brought to the Board through a Committee process. Therefore, the Board delegates authority to the Chair of the Board Committee with jurisdiction over the matter addressed in that decision point, who shall consult with the Executive Director, to clarify any necessary follow up in relation to interpretation and its policy implications and to make recommendations on its staffing implications.</p><p>The Board requests the Finance and Audit Committee to incorporate in the process of developing a framework that guides review of Secretariat's annual budget and the evaluation of Global Fund's staffing as requested by the Board at its Fourteenth Board Meeting, a process for handling the recommendations on staffing implications in the event that the approved decision point results in a need for additional resources.</p>

<p>1. The Board commends the Technical Review Panel for its report and presentation on the Round 6 proposal evaluation process, and its dedicated efforts to ensure that the Global Fund finances only technically sound proposals.</p><p>2. The Board gives special recognition to the outgoing chair of the Technical Review Panel, Dr Jonathan Broomberg, for his leadership, dedication and commitment to the principles of the Global Fund and the work of the Technical Review Panel.</p>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituentgrants, as listed in Table 1 of GF/B47/ER15 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by theproposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemedappropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and(b)shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding availablefor each country disease component among its constituent grants, provided that the TechnicalReview Panel (the “TRP”) validates any redistribution that constitutes a material change fromthe program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 2 of GF/B47/ER15 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding availablefor each country disease component among its constituent grants, provided that the TechnicalReview Panel (the “TRP”) validates any redistribution that constitutes a material change fromthe program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 1 of GF/B47/ER13 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceilingamount that may be available for the relevant implementation period of each country diseasecomponent’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding availablefor each country disease component among its constituent grants, provided that the TechnicalReview Panel (the “TRP”) validates any redistribution that constitutes a material change fromthe program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board reaffirms the importance of responding efficiently and rapidly to emergency situations to ensure the continuity of life-saving health services delivered through Global Fund-supported programs. The Board recognizes the devastating impact that recent natural disasters, climate-related events, and ongoing and protracted conflicts such as those in Pakistan, Ukraine, and Somalia have had on the health and well-being of people supported by Global Fund programs and reaffirms the importance of the Emergency Fund in rapidly responding to such contexts.</p> <p>Therefore, the Board approves the reallocation of USD $ 40 million from Audit and Finance Committee (AFC)-approved portfolio optimization funds to the Emergency Fund.</p>

<p>The Board approves the appointment of:</p> <ol> <li>Harriet Ludwig, representing the Germany Constituency, as a voting member of the Strategy Committee for a term that will expire on May 2025, or until the appointment of her successor;</li> <li>Rouksana Simjee, to serve in her personal capacity as a voting member of the Ethics and Governance Committee for a term that will expire on May 2025, or until the appointment of her successor.</li> </ol>

<p>Based on the recommendation of the Strategy Committee, the Board approves the revision to Key Performance Indicator 4 as presented in GF/B47/ER11.</p>

<ol> <li>The Board notes the recommendation of the Ethics and Governance Committee, as set forth in GF/B47/ER10, relating to the membership of the Board Leadership Nomination Committee (“Nomination Committee”).</li> <li>Accordingly, the Board appoints the following individuals to serve as members of the Nomination Committee in accordance with the terms of reference of the Nomination Committee approved under electronic decision point GF/B39/EDP08 and set out in Annex 4 to GF/B39/ER07: <ol type="a"> <li>Grace Rwakarema, Chair of the Nomination Committee;</li> <li>Sherwin Charles, Vice-Chair of the Nomination Committee;</li> <li>Cecilia Senoo, Member;</li> <li>Heiko Warnken, Member;</li> <li>Fiu Williame-Igara, Member;</li> <li>Mamadi Yilla, Member; and,</li> <li>Ren Minghui, Member.</li> </ol> </li> </ol>

<p>Based on the recommendation of the Strategy Committee described in [GF/B47/ER08], the Board:</p> <ol> <li>Acknowledges that the Eligibility Policy (GF/B47/03) allows certain non-eligible countries to be recommended to be exceptionally eligible for malaria in line with paragraph 11 of the Policy;</li> <li>Acknowledges that the Eligibility Policy’s treatment of Venezuela’s exceptional tuberculosis (“TB”) eligibility must consider the fact that Venezuela is the only country in the World Bank’s classification system that is temporarily unclassified;</li> <li>Based on the Secretariat and technical partners’ recommendation described in [GF/B47/ER08], approves that Venezuela’s malaria and TB components be made exceptionally eligible for the 2023-2025 Allocation period; and</li> <li>Notes that any components made exceptionally eligible will be governed by the Allocation Methodology 2023-2025 and existing Global Fund policies and processes.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituentgrants, as listed in Table 1 of GF/B47/ER09 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by theproposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemedappropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and(b)shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding availablefor each country disease component among its constituent grants, provided that the TechnicalReview Panel (the “TRP”) validates any redistribution that constitutes a material change fromthe program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 2 of GF/B47/ER09(“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceilingamount that may be available for the relevant implementation period of each country diseasecomponent’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding availablefor each country disease component among its constituent grants, provided that the TechnicalReview Panel (the “TRP”) validates any redistribution that constitutes a material change fromthe program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board approves the Report of the Global Fund 47th Board Meeting, as set forth in GF/B47/22.</p>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B47/ER06 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B47/ER05 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

The Board approves the Annual Report as presented in GF/B13/15 and as amended at the Thirteenth Board Meeting. 

<ol start="1" type="1"><li>The Board approves the appointment of Ambassador Michèle Boccoz as a voting member of the Strategy Committee for a term that will expire on 26 May 2018, or until the appointment of her successor.</li></ol><p></p>

1. The Board acknowledges the 2017 - 2022 Strategic Key Performance Indicator Framework (the "Strategic KPI Framework"), as presented in Annex 1 to GF/B35/ER05, and the additional methodological work required to set performance targets.<br/>2. Accordingly, the Board approves the Strategic KPI Framework and directs the Secretariat to present the Board with the Strategic KPI Framework's performance targets for approval at the final Board meeting in 2016.

<p>The Board approves for funding for an initial two years those Round 8 proposals recommended for funding by the Technical Review Panel (TRP) and identified as ‘Category 2B’ proposals with composite index 6 and as listed in the following table, subject to Decision Point GF/B18/DP13 and paragraph 5 of Decision Point GF/B18/DP14. </p>

The Board requests the Portfolio Committee (PC) to oversee the Secretariat's study of the quality assurance status of pharmaceutical products other than anti-retroviral, anti-malaria and anti-tuberculosis medicines. The Secretariat shall present the findings of the first phase of the study to the PC at its 12^th Meeting in September 2009. Based on these findings, the PC may permit the Secretariat to undertake the later stages of the study to explore the possibility of establishing a quality assurance policy for these products. The Board requests the PC to update the Board on the progress of the study at the Board's first meeting in 2010.

H.E. Dr Leslie Ramsammy from the Latin America and Caribbean constituency is designated as Rapporteur for the Nineteenth Board Meeting.

The agenda for the Nineteenth Board Meeting (GF/B19/1, Revision 3) is approved.

<p>Recognizing the continued role of the Technical Evaluation Reference Group (TERG) in the follow-up to the Five Year Evaluation (5YE), as part of the TERG mandate to provide independent advice, assessment and oversight for the Global Fund's work on monitoring and evaluation (M&amp;E), the Board:</p> <p>1. welcomes the findings and recommendations included in the Study Area (SA) 3 Report and in the Synthesis Report of the 5YE, as summarized in the TERG Report (GF/B19/10);</p> <p>2. endorses the TERG's call for action for the Global Fund to work with partners to strengthen country monitoring and evaluation, and information systems for performance and impact, to build analytical capacity in countries and to support development of country-owned impact evaluation platforms;</p> <p>3. requests the Secretariat to articulate a process and timeline for responding to and implementing the recommendations set out in SA3 and the Synthesis Report by 15 June 2009, and to report to the Board at its Twentieth Meeting, through the Policy and Strategy Committee (PSC), on the Secretariat's progress in responding to recommendations contained in the SA1, SA2, SA3 and Synthesis Reports, as well as the TERG recommendations in relation to these reports;</p> <p>4. requests the Chair of the Board, in consultation with Committee Chairs, to set up a small ad-hoc committee by 30 June 2009 with the specific task of assisting the Board, through the PSC, to (i) follow-up on, and formulate the Board's responses to the 5YE recommendations, and (ii) further define the role of the TERG in relation to independent evaluations, the resources required and Board oversight of the process.</p> <p>This decision supersedes the Board Decision (GF/B18/DP21).</p>

<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard.</p><p>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p><p>SCHEDULE A </p><ol><li>Belarus, TB – Round 6<br/>Grant Number: BLR-607-G02-T <br/>CCM Requested Amount (Total Phase 2 in US$): 7,488,285 <br/>Approved Funding Amount (Incremental in US$): 7,468,729 <br/>Recommendation Category: Go<br/><br/></li><li>Bosnia and Herzegovina, TB Round 6 <br/>Grant Number: BIH-607-G02-T <br/>CCM Requested Amount (Total Phase 2 in US$): 3,088,672 <br/>Approved Funding Amount (Incremental in US$): 3,088,672 <br/>Recommendation Category: Go<br/><br/></li><li>Burkina Faso, HIV Round 6 <br/>Grant Number: BUR-607-G06-H Euro <br/>CCM Requested Amount (Total Phase 2 in US$): 23,770,535(1) <br/>Approved Funding Amount (Incremental in US$): Euro 19,780,000 = US$ 28,210,236(1) <br/>Recommendation Category: Go<br/><br/></li><li>Iraq, TB Round 6 <br/>Grant Number: IRQ-607-G01-T <br/>CCM Requested Amount (Total Phase 2 in US$): 8,110,000 <br/>Approved Funding Amount (Incremental in US$): 8,056,257 <br/>Recommendation Category: Go<br/><br/></li><li>Moldova, TB Round 6 <br/>Grant Number: MOL-607-G02-T <br/>CCM Requested Amount (Total Phase 2 in US$): 5,871,489 <br/>Approved Funding Amount (Incremental in US$): 5,500,000 <br/>Recommendation Category: Go<br/><br/></li><li>Papua New Guinea, TB Round 6 <br/>Grant Number: PNG-607-G03-T <br/>CCM Requested Amount (Total Phase 2 in US$): 16,267,739(2) <br/>Approved Funding Amount (Incremental in US$): 14,185,291 <br/>Recommendation Category: Go<br/><br/></li><li>Peru, HIV Round 6<br/>Grant Number: PER-607-G05-H <br/>CCM Requested Amount (Total Phase 2 in US$): 10,847,949 <br/>Approved Funding Amount (Incremental in US$): 9,256,222 <br/>Recommendation Category: Go<br/><br/></li><li>Romania, TB Round 6 <br/>Grant Number: ROM-607-G04-T Euro <br/>CCM Requested Amount (Total Phase 2 in US$): 4,050,099 (1) <br/>Approved Funding Amount (Incremental in US$): Euro 3,555,623 = US$5,071,030(1) <br/>Recommendation Category: Go<br/><br/></li><li>Thailand, TB Round 6 <br/>Grant Number: THA-607-G07-T <br/>CCM Requested Amount (Total Phase 2 in US$): 5,319,698 <br/>Approved Funding Amount (Incremental in US$): 4,334,035 <br/>Recommendation Category: Go<br/><br/></li><li>Thailand, TB Round 6 <br/>Grant Number: THA-607-G08-T <br/>CCM Requested Amount (Total Phase 2 in US$): 5,342,916 <br/>Approved Funding Amount (Incremental in US$): 4,514,102 <br/>Recommendation Category: Go<br/><br/></li><li>Tunisia, HIV Round 6 <br/>Grant Number: TUN-607-G01-H <br/>CCM Requested Amount (Total Phase 2 in US$): 7,013,846 <br/>Approved Funding Amount (Incremental in US$): 6,614,846 <br/>Recommendation Category: Conditional Go <br/><br/>Total US$96,299,420</li></ol>

<p>The Board decides to correct an error in the definition of high disease burden for Global Fund financing of tuberculosis in Upper-Middle Income Countries by amending paragraph 2 of Part 3 of the document entitled "Income Level and Cost Sharing Eligibility Criteria for Proposals for Funding from the Global Fund" (GF/B16/7 Attachment 1, Revision 1) as follows:</p><p>"The country in which the proposal activities are targeted is included on the WHO list of high-burden countries or on the WHO list of countries that account for 97 percent of all new cases attributable to HIV/AIDS." </p>

<p>We, the Board, express our sincere and deep gratitude to Helen Evans for her service to the Global Fund. Her dedication, fortitude, and ability to handle the many demands made on her with equity, patience and grace, especially during challenging times, is universally admired. Her ability to lead in so many critical areas of the Global Fund speaks volumes to her strength and skills. </p><p>We appreciate her passion, commitment and loyalty to the Global Fund and its mission and her principled leadership and tireless efforts to ensure its success. She will be much missed by the Board and by the Secretariat staff.  </p><p>We wish Helen all the best in her endeavors, and look forward to continuing to work with her in her continuing role as a global health leader dedicated to improving global health.</p>

<ol> <li>The Board notes the broad and inclusive consultations undertaken to inform the development of the next Global Fund Strategy, including the partnership-wide 2020 Open Consultation, 6th Partnership Forums, and extensive Strategy Committee (“SC”) and Board guidance.</li> <li>The Board also notes that the Strategy Narrative will be developed based on the approved Strategy Framework and presented to the Board for approval, based on a recommendation from the SC, at its 46th meeting in November 2021.</li> <li>Accordingly, based on the recommendation of the SC, as presented in GF/EB01-2021/02 – Revision 1, the Board: <ol type="a"> <li>Approves the Strategy Framework presented in Annex 1 to GF/EB01- 2021/02 – Revision 1 for the Global Fund Strategy covering the period 2023-2028; and</li> <li>Requests that the Secretariat develop, for the SC’s recommendation to the Board, the Strategy Narrative to further articulate areas of focus described in the Strategy Framework, based on input received to date through the Strategy development process.</li> </ol> </li> </ol>

<p>The Board decides to change the timing of the determination of the income level eligibility for funding from the Global Fund by amending paragraph 4 of Part 3 of the document entitled "Income Level and Cost Sharing Eligibility Criteria for Proposals for Funding from the Global Fund" (GF/B16/7 Attachment 1, Revision 1) as follows:</p><p>4. The Secretariat will make income level eligibility determinations on an annual basis following the release of the World Bank Country Income Classifications in July of each year (or following the month of publication if different from July), to be reviewed by the Portfolio Committee at its next meeting. These income level eligibility determinations will be effective for all calls for applications to the Global Fund under all funding channels from 1 January to 31 December for the following calendar year.</p>

<p>On the recommendation of the Board Chair and Vice Chair, the Board makes the following decisions with respect to the AMFm Ad Hoc Committee leadership and membership.</p><p>The Board decides that, in order to enable the new Board leadership to ensure appropriate balance, the leadership and membership of the AMFm Committee shall be renewed at the same time as all the other committees of the Board. The Board clarifies that the membership of the AMFm Committee is 10 voting members, plus representation by WHO, RBM and UNITAID.</p><p>The Board notes that the AMFm Committee Chair is resigning and approves the appointment of Professor Eyitayo Lambo as acting Chair of the AMFm Committee pending renewal of committee leadership and membership. </p><p>The Board notes that UNITAID has requested a role in the governance of AMFm. Recognizing UNITAID as a key partner in support of AMFm, the Board decides, as a one-time exception to the Committee Rules and Procedures and without setting a precedent, to request the Board Chair to invite the UNITAID Board to nominate a suitable representative to serve as Vice-Chair of the AMFm Committee. The appointment of the UNITAID Board representative shall be subject to the approval of the Board Chair and Vice Chair and the AMFm Committee Chair. </p>

<p>The Board approves the appointment of the following:</p><p>1. to strengthen the TRP's cross-cutting expertise with a focus on gender and sexual minorities, Drs Ondina Leal, Tim Brown, Sarah Hawkes, Mabel Bianco and Katya Burns as members of the TRP Support Group;</p><p>2. Mr Tim Brown (HIV), Ms Daphne Toupozis (HIV), Mr Nomathemba Mazelani (HIV), Ms Hanem Zaher (Tuberculosis), Ms Ondina Leal (Cross-Cutting), Ms Mabel Bianco (Cross-Cutting), Mr George Gotsadze (Cross-Cutting) and Mr Tore Rose (Cross-Cutting) as Permanent Members of the TRP to serve up to four Rounds commencing from Round 9; and</p><p>3. in respect of calls for proposals made in 2009, the twelve (12) persons identified as Alternate Members in the Report of the Portfolio Committee (GF/B19/5 - Revision 1). </p><p>each of whom have been recommended by the Portfolio Committee and the Executive Director upon consideration of required technical expertise, as well as geographical distribution and gender balance.</p>

<ol><li>The Board decides to create one additional non-voting seat on the Board to represent the constituency of key partners (Partners Constituency) whose mission is directly related to the Global Fund and who are not currently represented on the Board. <br/><br/></li><li>The Board decides to invite the Stop TB Partnership, Roll Back Malaria and UNITAID to be the founding members of the Partners Constituency. Any key partner that wishes to be represented on the Global Fund Board through the Partners Constituency should make a formal request to the Board who will determine the appropriateness of their inclusion in the Partners constituency. <br/><br/></li><li>Accordingly, the Board approves the following amendments to the By-laws: <br/><br/>Article 7. Foundation Board <br/><br/>7.1. Composition <br/><br/>The Foundation Board shall consist of twenty voting members and five six nonvoting members. Each voting member shall have one vote. <br/><br/>[…] <br/><br/>The <strike>five</strike><u>six</u> ex-officio nonvoting members of the Foundation Board shall consist of: <br/><br/><ul><li>One representative from the WHO;</li><li>One representative from the Joint United Nations Programme on HIV/AIDS ("UNAIDS"); </li><li><u> One representative from the Partners constituency; </u></li><li> One representative from the trustee; <strike>and</strike></li><li> One Swiss citizen with his or her domicile in Switzerland authorized to act on behalf of the Foundation to the extent required by Swiss law.; <u>and</u></li><li>The Executive Director of the Foundation. <br/><br/></li></ul></li></ol><li type="1" value="4">The Board requests the PSC to review the purpose, allocation and composition of all non-voting Board seats and report to the Board at its Twenty-Third Meeting. </li>

<p>The Board recalls its decision GF/B14/DP/28 in which it authorized the Secretariat, on an exceptional basis, to consider the Request for Continued Funding submitted by the CCM of South Africa for the Round 3 South Africa Grant number SAF-304-G04-H, which anticipated a 4-year Phase 2 term.</p> <p>This decision was based on the commitment of the Government of South Africa at the time to achieve sustainability of the HIV/AIDS program in the Western Cape province and not requiring further Global Fund support for those activities beyond September 2010. The Board decides that due to the change in circumstances surrounding the implementation of the Western Cape HIV/AIDS program, it is willing to consider a further request from the CCM of South Africa for continued support of the program by the Global Fund, and authorizes the Secretariat to consider the grant for qualification under the Rolling Continuation Channel.</p>

<p>The Global Fund does not tolerate corruption, fraud, misappropriation or abuse of any kind in relation to its grants. As part of the comprehensive risk management framework, the Board requests the Executive Director to take strong, immediate action in all circumstances where the Inspector General has determined that there is credible and substantive evidence of fraud, abuse, misappropriation or corruption involving Global Fund grants. </p><p>Such action will include the Executive Director restricting the signature of new grants with the nominated principal recipient(s), if the evidence concerns the nominated principal recipient(s), or of all new grants in the country, if the evidence points to country risks.</p><p>Restrictions may also include the suspension of disbursements under existing grants in the affected country or countries, the temporary or permanent debarment of any entity under investigation from receiving grant funding or any other measure deemed appropriate and justified under the circumstances by the Executive Director. </p><p>In such situations, the Executive Director shall ensure that measures imposed balance the impact on the country's health systems, other reliant projects and the continuation of the provision of essential services, against the risks to the Global Fund and adherence to the Global Fund's core ethical values and principles. This balance to be struck should not allow any acceptance of fraud.</p><p>The Secretariat and the OIG will - each based on their respective role and responsibilities - report on restrictions imposed in relation to any grant(s) in such situations, the specific actions required to lift such restrictions, and the status of the situation. This will be done as soon as possible to the Board via an appropriate mechanism as well as on a regular basis through the FAC and at the Board meeting.</p><p>If signature of a new grant with a nominated principal recipient has been restricted, the deadline for signature of a grant agreement shall automatically be extended by a period equal to the period of the restriction in the following limited situations: (i) an OIG investigation or audit by the OIG finds no wrongdoing, or (ii) in the opinion of the Secretariat and OIG, the wrongdoing is not material or the risks to Global Fund grant funds under the new grant are manageable, or (iii) a new principal recipient is identified for the grant under implementation arrangements that address the risks. </p>

<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard.</p><p> The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p><p>SCHEDULE A </p><ol><li>Egypt, TB – Round 6 <br/>Grant Number: EGY-607-G02-T <br/>CCM Requested Amount (Total Phase 2 in US$): 3,541,080 <br/>Approved Funding Amount (Incremental in US$): 4,124,080 <br/>Recommendation Category: Conditional Go<br/><br/></li><li>Guatemala, TB – Round 6 <br/>Grant Number: GUA-607-G03-T <br/>CCM Requested Amount (Total Phase 2 in US$): 4,098,790 <br/>Approved Funding Amount (Incremental in US$): 3,699,920 <br/>Recommendation Category: Go<br/><br/></li><li>Kazakhstan, TB – Round 6 <br/>Grant Number: KAZ-607-G02-T <br/>CCM Requested Amount (Total Phase 2 in US$): 4,400,023<br/> Approved Funding Amount (Incremental in US$): 3,672,383 <br/>Recommendation Category: Go<br/><br/></li><li>Lao PDR, Malaria – Round 6 <br/>Grant Number: LAO-607-G07-M <br/>CCM Requested Amount (Total Phase 2 in US$): 2,109,804 <br/>Approved Funding Amount (Incremental in US$): 1,941,538 <br/>Recommendation Category: Conditional Go<br/><br/></li><li>Liberia, HIV – Round 6 <br/>Grant Number: LBR-607-G04-H CCM <br/>Requested Amount (Total Phase 2 in US$): 20,515,516 <br/>Approved Funding Amount (Incremental in US$): 19,142,000 <br/>Recommendation Category: Go<br/><br/></li><li>Maldives, HIV – Round 6 <br/>Grant Number: MDV-607-G01-H <br/>CCM Requested Amount (Total Phase 2 in US$): 1,905,124 <br/>Approved Funding Amount (Incremental in US$): 1,486,772 <br/>Recommendation Category: Conditional Go<br/><br/></li><li> Mali, Malaria – Round 6 <br/>Grant Number: MAL-607-G05-M <br/>CCM Requested Amount (Total Phase 2 in US$): 11,010,553 <br/>Approved Funding Amount (Incremental in US$): 8,965,242 <br/>Recommendation Category: Go</li></ol><p>Total US$43,031,935</p><p>Next Steps:The Secretariat will begin negotiations immediately for the extension of the grants listed in Schedule A.</p>

<p>The Board:</p><ol><li>Amends the composition of the Ad Hoc Market Dynamic and Commodities Committee (as set out in GF/B19/4, Attachment 4) as follows:… <br/><br/>Composition: <br/><br/>The proposed membership to include (8) <u>10 </u>representatives of voting Board constituencies + WHO + World Bank <u>UNAIDS </u>+ 2-4 external experts … <br/><br/></li><li>Approves the appointment of the following members to the Ad Hoc Market Dynamic and Commodities Committee.</li></ol> <table class="table"><tbody><tr><td style="cursor: default;"> </td><td style="cursor: default;"><b>Constituency</b> </td><td style="cursor: default;"><b>Name </b> </td><td style="cursor: default;"><b>Role </b> </td></tr><tr><td style="cursor: default;" rowspan="1" colspan="4"><b> Leadership </b> </td></tr><tr><td style="cursor: default;"> 1</td><td style="cursor: default;">Private Foundations</td><td style="cursor: default;">Dai Ellis Executive Vice President, Access Programs, Clinton HIV/AIDS Initiative </td><td style="cursor: default;">Chair</td></tr><tr><td style="cursor: default;"> 2</td><td style="cursor: default;">UNAIDS</td><td style="cursor: default;">Shanelle Hall Director, Supply Division, UNICEF  </td><td style="cursor: default;">Vice-Chair </td></tr><tr><td style="cursor: default;" rowspan="1" colspan="4"> <b>Donor </b></td></tr><tr><td style="cursor: default;"> 3</td><td style="cursor: default;">Private Sector</td><td style="cursor: default;">Ian Boulton Managing Director, TropMed Pharma Consulting </td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;"> 4</td><td style="cursor: default;">Point 7</td><td style="cursor: default;">Turid Kongsvik Counselor, Norwegian Permanent Mission to the Council of Europe </td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;"> 5</td><td style="cursor: default;">United Kingdom</td><td style="cursor: default;">Saul Walker Senior Policy Adviser (Access to Medicines), DFID, (AIDS expert) </td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;"> 6</td><td style="cursor: default;">United States</td><td style="cursor: default;">Mike Hope Senior Pharmacist, Office of HIV/AIDS, USAID</td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;" rowspan="1" colspan="4"><b> Implementer </b> </td></tr><tr><td style="cursor: default;"> 7</td><td style="cursor: default;">Western and Central Africa</td><td style="cursor: default;">Lazare Bansse General Manager, Central Purchasing of Essential and Generic Drugs, Burkina Faso and Permanent Secretary, Association of Central Purchasing of Essential Drugs, Africa</td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;"> 8</td><td style="cursor: default;">Latin America and the Caribbean</td><td style="cursor: default;">Carl Browne Director, Pan Caribbean Partnership Against HIV/AIDS </td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;"> 9</td><td style="cursor: default;">Developed Country NGOs</td><td style="cursor: default;">Mohga Kamal-Yanni Senior Health and HIV Policy Advisor, Oxfam </td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;"> 10</td><td style="cursor: default;">Eastern Europe</td><td style="cursor: default;">Tonka Varleva, Secretary, National Committee for Prevention of AIDS and STIs, Bulgaria </td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;"> 11</td><td style="cursor: default;">Western Pacific </td><td style="cursor: default;">Lin-hua Tang Director, National Institute of Parasitic Disease, China, (malaria expert) </td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;" rowspan="1" colspan="4"><b> Non-voting member </b> </td></tr><tr><td style="cursor: default;"> 12</td><td style="cursor: default;">WHO </td><td style="cursor: default;">Rob Matiru Chief of Operations, Global Drug Facility, (TB expert) </td><td style="cursor: default;">Member</td></tr></tbody></table>

The report of the Eighteenth Board Meeting (GF/B19/2, Revision 2) is approved.

The Board approves the terms of reference for the Chair and Vice-Chair of the Board, as laid out in Attachment 6 of GF/B19/4. The terms of reference shall be used by the Board in its consideration of the candidature of any proposed applicant for the positions as well as the candidates themselves to ensure they are fully aware of what the role(s) involve.

<p>The agenda for the Extraordinary Board Meeting (GF/EB01-2021) is approved.</p>

<p>Dasho Kunzang Wangdi from the South East Asia Constituency is designated as Rapporteur for the Extraordinary Board Meeting.</p>

<p><b>Decision Point 1: </b> </p><p>The Board authorizes the Secretariat to extend the Phase 2 term of Grant Agreements by up to six months, without committing any additional funding, in circumstances where the Principal Recipient is prevented, due to exceptional circumstances, from using the full amount of Grant funds during the Phase 2 term. </p><p><b>Decision Point 2: </b> </p><p>The Board decides that in circumstances where the term of a Phase 1 Grant Agreement has been extended in accordance with paragraph 4 of the Phase 2 Decision-Making Policies and Procedures attached as Annex 1 of the Report of the Portfolio Committee (GF/B12/6) (a "Phase 1 Extension"), the Secretariat may extend the Phase 2 term of Grant Agreements by up to an equal length of time as the Phase 1 Extension without committing any additional funding. </p><p>The Secretariat shall inform the Board immediately upon taking action under Decision Point 1 and 2. </p>

The Board approves the document entitled "Phase 2 Decision-Making Policies and Procedures" included as Annex 1 to the Report of the Portfolio Committee (GF/B12/6) and as amended at the 12th Board Meeting and revokes all previously approved versions of such document. 

The agenda for the Twelfth Board Meeting (GF/B12/1, Rev. 3) is approved.

<p>1. The Board may commit funds for Phase 2 renewals (up to the full duration of a proposal) up to the cumulative uncommitted amount pledged through the calendar year of the Board decision.</p><p>2. The Board makes funding decisions for Phase 2 renewals based on its review of Secretariat or Technical Review Panel (TRP) recommendations, according to procedures agreed by the Board.</p><p>3. The Secretariat or TRP will present the Board with its recommendations on the first of every month (notice to Board constituencies of a recommendation shall be effective upon the posting of the recommendation on the Global Fund website; the Secretariat will inform Board constituencies via e-mail when recommendations have been posted). The Board will vote by email on each recommendation on a no-objection basis. Votes must be received by the Secretariat no later than the tenth of the same month.</p><p>4. In exceptional circumstances, the Secretariat may need to take more than 20 months to provide a Phase 2 recommendation to the Board. In such situations, the Secretariat may extend, at no cost, the term of Phase 1 grant agreements by up to six months. The Secretariat shall inform the Board immediately upon taking action under this decision.</p><p>5. If the Secretariat decides to issue a "No Go" recommendation, it shall give notice of that intention and the reasons for it to the relevant CCM and allow that CCM four weeks to comment on the information submitted to it by the Secretariat. </p><p>6. The Secretariat shall review and consider the information provided by the CCM, and then make its recommendation to the Board. The information provided by the CCM shall be made available to the Board.  </p><p>7. A Board decision in favor of a Secretariat or TRP recommendation either:</p><ul><li>commits additional resources in the amount proposed in the recommendation (in the case of recommendations of "Go," "Conditional Go," and "Revised Go"); or</li><li>does not commit any additional resources (in the case of recommendations of "No Go"), thereby discontinuing the proposal after Phase 1.</li></ul><p>8. If the Board does not decide in favor of a Secretariat or TRP recommendation, this would serve to request further clarification on the recommendation and ask the Secretariat or TRP to reassess its recommendation. To facilitate the clarifications process, those Board constituencies that are not ready to decide in favor of a Secretariat or TRP recommendation would provide a written explanation that is made publicly available. The Secretariat or TRP will review its recommendation in light of the questions and comments of those Board constituencies and will then present a second recommendation on the first day of the subsequent month (unless time-constraints make it necessary to wait to the month thereafter). The Board then votes again, on the second Secretariat or TRP recommendation, using the procedures described above.</p><p>9. A Board decision in favor of the second Secretariat or TRP recommendation either:</p><ul><li>Commits additional resources in the amount proposed in the recommendation (in the case of recommendations of "Go," "Conditional Go," and "Revised Go"); or</li><li>Does not commit any additional resources (in the case of recommendations of "No Go"), thereby discontinuing the proposal after Phase 1.</li></ul><p>10. In the event that (i) the Board rejects a first "No Go" recommendation, (ii) the Secretariat issues a second "No Go" recommendation to the Board and (iii) the Board rejects the Secretariat's second "No Go" recommendation, the matter shall be referred to an independent panel, which shall assess the specific areas where the Board and the Secretariat differ on their assessment of the grant and report its conclusions to the Board. </p><p>11. The composition of the Independent Panel will be based on the following principles:</p><ul><li>Size: Two senior members supported by 1-2 contracted analysts, as appropriate;</li><li>Independence: Potential conflict of interest should be taken into consideration in selecting these members;</li><li>Profile of Senior Members: The team of senior members should have a solid understanding of country processes;</li><li>Profile of Analysts: Analysts should have the capability to fully understand GF principles and procedures;</li><li>Identification of Candidates: Pool of pre-qualified candidates for Senior Members and Analysts is identified through partners, including WHO, UNAIDS and the World Bank. A list of these candidates is compiled by the Secretariat and each candidate submits a CV to the file for review. A proposed "reserve list" will be compiled based on this selection process;</li><li>Selection of Panel: The list of tentative candidates will be submitted to the Chair and Vice-Chair of the Board and the Chair and Vice-Chair of the PC. The selection of the Senior Members and Analysts of the independent panel shall be carried out by the Chair and Vice-Chair of the Board in consultation with the Chair and Vice-Chair of the PC;</li><li>Panel members (Senior members and contracted analysts) will be remunerated; and</li><li>The Secretariat will facilitate the process.</li></ul><p>12. The Independent Panel's scope of work will be based on the following principles:</p><ul><li>The objective of the external assessment will be to submit conclusions to the Board based on all information put forth by the CCM, PR, Secretariat and Board constituencies;</li><li>The analysis shall include a chronology of information provided, a typology of the content and an analysis of the source and flow of information;</li><li>The assessment shall take into consideration the different arguments analyzing how they refer to each other, highlighting areas of agreement and disagreement, and defining the areas which have not been previously addressed by the parties involved; and</li><li>The Independent Panel shall report to the Board no later than six weeks after receipt of the relevant information from the Secretariat.</li></ul><p>13. The final decision on making a funding commitment will be made at the next Board meeting. </p><p>14. In circumstances in which insufficient resources remain in Phase 1 to cover financing needs until any Board decision in the Phase 2 procedure can be operationalized, the Board authorizes the Secretariat to extend the terms of the grants by up to six months, and to provide bridge funding for such grants as appropriate. The Board authorizes the Secretariat to commit up to a maximum of one-half of the first year budget contained in the Request for Continued Funding in question for these purposes, which would be financed by utilizing the Phase 2 renewal funding of the proposal. The actual amount committed by the Secretariat would be based primarily on the performance and disbursement patterns in Phase 1.</p><p>15. For proposals for which the Board commits Phase 2 funds, a sufficient amount of assets to cover the full costs of the extension of the Grant Agreement must be deposited with the Trustee or readily available on demand prior to the Secretariat extending a Grant Agreement.</p><p>16. The Technical Reference Group (TERG) will regularly review and report on the soundness of the Phase 2 review and decision process to the Board through the Portfolio Committee. </p><p>17. The Phase 2 decisions will typically be taken based on recommendations that are made 20 months after the Program Starting Date (exceptions could include for situations of force majeure). The decision may be taken earlier in cases of (i) accelerated implementation; or (ii) severe exchange rate fluctuations.</p><p>18. These procedures for the Board commitment of funds for Phase 2 are subject to a time-limited trial period. The Board asks the Portfolio Committee to review these procedures or should adopt an alternative set of procedures. Based on these recommendations the Board will reconsider the procedures at the Thirteenth Board Meeting.</p>

The Board commits additional funds up to USD 4,125,000 to the Round 1 Honduras HIV/AIDS grant (HND-102-G01-H-00) to cover the program’s funding requirements for the period to 31 July 2006.

<p><b>Decision Point 1:</b> </p><p>Mindful of the current distribution of the geographic diversity of the Technical Review Panel pool, the Board requests the Portfolio Committee to recommend for approval at the 13th Board meeting one additional Alternate Member of the Technical Review Panel for each area of expertise (HIV/AIDS, tuberculosis, malaria and cross-cutting). </p><p><b>Decision Point 2:</b> </p><p>The Board authorizes the Chair and Vice Chair of the Technical Review Panel to add temporarily up to four members, which shall be selected from existing Alternate Members, to the membership of the TRP for a given round of proposals, where appropriate in light of the number of proposals and their distribution among categories.</p>

Peter van Rooijen from the Developed Country NGO Constituency is designated as Rapporteur for the Twelfth Board Meeting.

<p><b>Decision Point 1:</b> </p><p> The Board requests the Chair to launch a process to produce a performance assessment of the Executive Director in time for the Thirteen Board Meeting.</p><p><b>Decision Point 2: </b> </p><p> The Board decides to establish a Committee, composed of the Chairs and Vice Chairs of the Policy and Strategy Committee, Finance and Audit Committee, Portfolio Committee and Ethics Committee, to prepare recommendations for the Thirteenth Board Meeting, which will include updated Terms of Reference for the position of Executive Director. </p><p><b>Decision Point 3: </b> </p><p> The Board decides to amend its By-laws and Board Operating Procedures for the appointment of the Executive Director to be in line with the text appearing below. The Board requests the Chair to work with WHO and the Global Fund's Legal Counsel and outside Swiss counsel to produce draft amendments for adoption at the Thirteen Board Meeting.</p><p>APPOINTMENT OF THE EXECUTIVE DIRECTOR</p><p><b>I. Term and Term Limits: </b> </p><p> The Board decides to amend Article 8.1 of its By-Laws. The Board selects the Executive Director for a period of four (4) years, renewable for a period of three (3) years. The Board will make this selection on a merit-based, non-political and open basis.</p><p><b>I I. Options for Board Decision</b> </p><p>At least six months before the end of the incumbent Executive Director's first term, the Board makes one of three decisions: </p><ol><li> Launch a recruitment procedure, and encourage the Executive Director to let his/her name stand for the post; </li><li> Reappoint the Executive Director, subject to performance appraisal; or</li><li> Launch a recruitment procedure, and do not encourage the Executive Director to let her/his name stand for the post.</li></ol><p>The norm is Option One. In that case, the Board will make public that it has invited the incumbent Executive Director to re-apply for the post.</p><p><b>III. Recruitment/reappointment procedure </b> </p><p>The Board decides to modify its Board Operating Procedures to include a recruitment procedure and a reappointment procedure, as decided in Paragraph 2 above. </p><p>3.1. Recruitment procedure ;</p><ol type="a"><li> At least six months before the end of the term of an incumbent Executive Director, or any other time decided by the Board, the recruitment process will be followed as below. The Board at that time approves updated Terms of Reference, including selection criteria, for the position of Executive Director. </li><li> The Board Chair nominates, and the Board approves, a selection committee.</li><li> The Board launches the recruitment process. </li><li> The selection committee interviews candidates, and presents the best-ranking candidates to the Board for decision. </li></ol><p>3.2. Reappointment procedure </p><p>On the basis of the performance assessments, the Board could decide to reappoint an Executive Director for one additional term of three (3) years, under the conditions in Paragraph One above.</p><p>Under this system, the annual performance assessment of the Executive Director would, of course, continue, in line with normal best practice. All material for the evaluation will be provided to the Board in the first quarter of the calendar year. </p>

<p>The Board approves the 2006 operating expense budget in the amount of US$83,200,000 as set out in Annex 1 to the Report of the Finance and Audit Committee (GF/B12/7) and as recommended by the Finance and Audit Committee (FAC) and proposed by the Secretariat. </p><p>The Board notes that the budget includes envisaged cost savings and requests FAC to review actual expenditure and budgetary needs after the first half of 2006 and, if necessary, make further recommendations to the Board at that time.</p>

#

<p>1. Election Procedures for Vice Chair</p><p><span></span></p><p>1.1 The Board takes note of the resignation of Ambassador Michel Kazatchkine as the Vice Chair of the Board and recognizes that, pursuant to Articles 7.3 and 12 of the By-laws, his successor as Vice Chair (who completes his term) must be from the donor group described in Article 7.6 of the By-laws. </p><p>1.2 The Board further notes that, in accordance with Article 18 of the Board Operating Procedures, the election of the Vice Chair of the Board should normally take place at the 13^th Board meeting.</p><p>1.3 The Board decides that, in this case, an exception to the Board Operating Procedures is appropriate and that the vote to elect the Vice Chair of the Board shall take place by email vote in accordance with Article 7.6 of the Bylaws.</p><p>1.4 The Board notes that the deadline set for the submission of nominations for the position of Vice Chair of the Board is currently 7 April 2006. The Board further notes that the donor group has unanimously supported the nomination of a single candidate for the position of Vice Chair and that such candidate has confirmed her willingness to act as Vice Chair. The Board therefore decides to close the nomination process as of 9 March 2006. </p><p><span></span></p><p>2. Election of Vice Chair</p><p><span></span></p><p>Dr. Lieve Fransen of the European Commission constituency is elected with immediate effect to serve as Vice Chair of the Board for the unexpired term of Ambassador Michel Kazatchkine. </p>

<p>The Board recognizes that in exceptional circumstances there may be a need to provide funding for the continuation of treatment in grants where funding ends (whether due to termination, a decision not to provide Phase 2 funding, or a grant reaching the end of its term). The Board recognizes that discussions on whether and how to provide continued funding for treatment will be part of the strategy process. To address exceptional cases that may arise before a comprehensive approach to the issue has been decided, however, the Board replaces the decision at the Ninth Board Meeting on continuity of services (GF/B10/2, Decision Points: Continuity of Services, Decision Point 1) with the following:</p> <p>The Board adopts the following system for addressing continuity of services:</p> <ol type="i"> <li>A recipient (typically a CCM, or, if appropriate, in the case of a non-CCM proposal, the grant applicant) whose funding has ended, has been terminated or is less than four months from the end of its term may submit an Extraordinary Request for Continued Funding for Treatment.</li> <li>The Extraordinary Request will be limited to expenses directly related to the continuation of treatment (including medicines [which, in the case of discontinuation of antiretroviral therapy, includes drugs for HIV-related opportunistic infections], diagnostics, and, as appropriate, costs for medical staff and other personnel directly involved in care of the patients on treatment) for those people already placed on life-long treatment under the existing proposal at the time of the Extraordinary Request.</li> <li>The Extraordinary Request will be limited to the amount required to provide services directly related to the continuation of treatment for up to two years (taking into account any amount which remains available under the existing grant).</li> <li>The Extraordinary Request shall contain a description of the steps that are being taken to find sustainable sources of financing for the people on treatment, and to ensure that treatment is being delivered effectively. To be eligible for funding under this provision the CCM (or, in the case of non-CCM proposals, the grant applicant) shall demonstrate that it has used its best efforts to identify other sources of funding to provide continuity of services but has been unsuccessful.</li> <li>The Secretariat will review the Extraordinary Request, and provide a funding recommendation to the Board for its approval. The Secretariat will address performance issues as appropriate, and shall make any adjustments to existing implementation arrangements necessary to ensure the effective use of grant funds.</li> <li>Throughout the process, the Secretariat will actively engage with technical partners to identify mechanisms to ensure continuity of services.</li> <li>In a resource-constrained environment, Extraordinary Requests for Continued Funding for Treatment shall be treated the same as Phase 2 renewals for the purpose of the decision on prioritization set out in GF/B9/2 page 9, Decision Point 2.</li> </ol> <p>This decision shall expire at the first Board meeting of 2007 unless renewed.</p>

<p>1. The following proposals will be approved by the Board as Category 2 proposals, based upon the Appeal Panel recommendation, subject to paragraph 2 below and through Board confirmation by e-mail, as funds become available to cover all four proposals under the terms of the Comprehensive Funding Policy: </p><p>i. Equatorial Guinea (Malaria)</p><p>ii. Philippines (Tuberculosis)</p><p>iii. Sudan (HIV/AIDS)</p><p>iv. Sudan (Tuberculosis)</p><p>The Board's approval will be for the amount indicated as "Total 2 years" in Annex 2 to the Report of the Internal Appeal Panel (GF/B12/8) and will be made with the clear understanding that such amounts are upper ceilings rather than the final Phase 1 Grant amounts.</p><p>2. The proposal applicants shall provide an initial reply to the clarifications requested by the Appeal Panel no later than six weeks after notification in writing by the Secretariat to the applicant of the Board's decision. Any further adjustments and clarifications shall be completed within four months from the receipt of the initial reply from the applicant.</p>

The Board decides to extend the Terms of Reference of the Ethics Committee to cover conflicts of interest in relation to former staff members of the Secretariat and requests the Ethics Committee to develop a policy regarding this matter at the Thirteenth Board Meeting.

<span>Mr Jerry O’Dwyer of the Point Seven constituency is appointed with immediate effect to serve as Chair of the Finance and Audit Committee.</span>

The Board acknowledges the progress made on developing the situation assessments and affirms the prioritization of issues and the principles to guide option development outlined in the Report of the Policy and Strategy Committee (GF/B12/5). It requests that the work proceed to the stage of option development and that the Policy and Strategy Committee report on progress at the Thirteenth Board Meeting.

<p>1. The Board approves for funding, subject to paragraph 2 below, all remaining Round 5 proposals recommended as eligible for funding by the Technical Review Panel ("TRP") listed in Annex VI to the Report of the TRP and the Secretariat on Round 5 Proposals (GF/B11/6) that could not be approved for funding at the Eleventh Board meeting due to resource constraints. </p> <p>The Board's approval is for the amount indicated as 'Total 2 Years' in such Annex, and is made with the clear understanding that such amounts are upper ceilings rather than final Phase 1 Grant amounts. The aggregate amount of funding for the proposals approved by this decision shall not exceed US$343,539,127.</p> <p>2. The Board notes that the Secretariat has previously notified the applicants of the clarifications and adjustments requested by the TRP. These adjustments and clarifications shall be completed within four months from the receipt of the initial reply from the applicant. The Board's approval is conditional on the final approval of the TRP Chair and/or Vice Chair based on consultations with the TRP primary and secondary reviewers.</p>

#

<p>The Board requests that the Secretariat make the necessary preparations for a Board decision, including a forecast of resources available, so that a Call for Proposals for Round 6 can be launched and proposals reviewed and approved in 2006. The Secretariat should furthermore work in close collaboration with relevant committees taking into account the established process to develop a strategy for the Global Fund.</p><p>These preparations should ensure the minimum of disruption to countries' ongoing work. </p><p>The Board notes that the mid-term review of the Replenishment process in June 2006 and other resource mobilization efforts are essential for securing adequate funding for Round 6.</p>

<p>The Board recognizes the commitment of the Fund management to implement the recommendations and the findings of the WHO Office of Internal Oversight Services report.</p><p>The Board acknowledges its own responsibility to oversee appropriate follow-on measures and ensure that systems and processes for personal and institutional accountability are enforced. </p><p>Therefore, the Board decides to establish an <i>ad hoc</i> Oversight Committee to oversee the following:</p><p>1. On contracts, payments, and recruitment</p><ul type="disc"><li>The Board finds the proposed actions in the Response of the Management appropriate</li><li>The Board requests that the management present an action plan to the Oversight Committee of the Board for review and approval</li><li>The Board requests that the Oversight Committee report to the 13^thBoard meeting</li><li>The Board requests that the Oversight Committee involve the Fund's Inspector General in this process</li></ul><p>2. On involvement of family members of Fund staff</p><ul type="disc"><li>The Board finds the proposed action in the Response of the Management appropriate</li><li>The Board requests that the management present an action plan to the Board's Ethics Committee</li><li>The Board requests that the Ethics Committee review the action plan and report to the 13^thBoard meeting</li></ul><p>3. Furthermore, the Board requests that the Ethics Committee review and make recommendations to strengthen the Fund's conflict of interest policy in light of the deliberations of the 12^th Board meeting.</p><p>4. The Board requests the Fund's Deputy Executive Director, together with the Fund's Legal Counsel, to prepare appropriate excerpts from the IOS report to be presented to relevant employees with respect to whom there have been adverse findings in the report. Taking into account their responses, Fund management should take measures to determine who is responsible for any improprieties in order to document accountability. In this process, protection of whistleblowers is also essential. </p><p>5. The Board requests the Chair and Vice Chair of the Board to ensure that the IOS report as a whole and the Response of the Management are taken into account in the annual performance evaluation of the Fund's Executive Director. </p><p>6. The Board directs the Executive Director to provide a full report at the 13th Board meeting on steps taken to improve oversight of compliance with existing Global Fund and WHO policies and procedures, including those already developed in response to the Report.</p><p>7. The Board decides that the mandate of the Fund's Inspector General includes oversight of the implementation of this decision point. The Board further requests that, in advance of the 13^th Board meeting, the Inspector General and the Oversight Committee report to the Board about progress in preparations and implementation called for in this decision point.</p><p>The Board approves the Statement of the Board for public release regarding the report of the IOS of the WHO on allegations of improprieties in the operations of the Global Fund: </p><p><b>Statement</b> </p><p>The Global Fund to Fight AIDS, Tuberculosis, and Malaria has in its first three years of operations achieved significant results that are saving lives. It strives to operate with the highest level of integrity and transparency to ensure that resources provided are properly utilized and focused on providing life-saving services in the fight against AIDS, tuberculosis, and malaria. </p><p>The Board received allegations in July 2005 involving contracting and payments, recruitment of staff, and the involvement of a family member. These allegations concerned activities within the Secretariat in Geneva. </p><p>Acting immediately, the Board Chair and Vice Chair and the Executive Director referred the allegations to the WHO's Office of Internal Oversight Services (IOS)<a id="_ftnref1" name="_ftnref1" target="_self"></a>, which after a substantial review provided a Report to the Board. </p><p>Based on the IOS Report and a review by its Ethics Committee, the Board finds that:</p><ul type="disc"><li>There was no evidence of fraud and misuse of funds.</li><li>There was no evidence of violations of the Policy on Ethics and Conflict of Interest for Global Fund Institutions, though there were actions that created concerns about lack of transparency.</li><li>There were instances of violation of established Global Fund and WHO rules and procedures.</li></ul><p>In response, the Board takes the following actions:</p><ul><li>A new Ad Hoc Committee is established to facilitate Board oversight of corrective measures being taken by Secretariat management.</li><li>The Office of Inspector General will advise the Board on progress made by the Secretariat in implementing recommendations made in the Report and related directives of the Board, as well as to propose additional improvements that might be needed.</li><li>The Executive Director is directed to provide a full report at the next Board meeting (April 2006) on steps taken to improve oversight of compliance with existing Global Fund and WHO policies and procedures, including those already developed in response to the Report.</li></ul><p>In addition to these allegations, the Board also received concerns about Secretariat culture and morale, which it takes seriously. The Global Fund's success depends on the hard work and commitment of its staff. Therefore, the Deputy Executive Director has already been tasked by the Board with responding to these concerns and is now directed to provide a comprehensive progress report at the next Board meeting.</p>

<p>The Board notes with concern increasing reports of threats to HIV/AIDS, tuberculosis (TB), and malaria treatment continuity. For example, recent estimates by the World Bank indicate that antiretroviral treatment to 1.7 million people is under threat, with 15 countries "highly exposed" to the risk of treatment interruption. </p><p>Therefore, the Board requests the Chair and Vice Chair to delegate to the appropriate committee(s) the task of reporting back to the Board at its Twentieth Meeting with an update on this issue, including an analysis - undertaken by the Secretariat in cooperation with partners as a matter of urgency - that indicates which countries receiving Global Fund support for HIV/AIDS, TB and malaria treatment are at risk of treatment disruption in 2009-10. The Board requests that the Secretariat, while continuing its ongoing work to minimize the risk of stock-outs and treatment disruption, report to the appropriate committee(s) on whether or not existing procedures are adequate and propose solutions to minimize the risk of stock-outs and treatment disruption on an ongoing basis. </p><p>The Board also requests the Secretariat to designate a focal point to liaise with specified focal points among relevant partners and affected communities to facilitate communication and respond effectively and collectively to threats to treatment continuity. </p>

The Board recognizes the significant improvements in collaboration between UNDP and the Global Fund on audits and investigations relating to grant funds. However, the Board notes that there are still areas where the collaboration could be improved and therefore requests the Chair of the Board, in support of the OIG and Secretariat, to secure greater assurance from the UNDP Board regarding audits and investigations of Global Fund grants where UNDP acts as Principal Recipient, including access to the full text of audit and investigation reports.

<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard.The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p><p>The Board approves additional funding for the Phase 2 period of the Round 5 Nigeria TB grant (NGA-506-G06-T) as a Conditional Go in the amount of up to US$ 39,617,817, subject to TRP clarifications and conditions within a limited timeframe, and also subject to possible additional conditions to be cleared by the Secretariat.The Board reaffirms that the maximum funding amount for Phase 2 of this grant shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p><p>SCHEDULE A </p><p>Brazil, TB – Round 5 <br/>Grant Number: BRA-506-G01-T <br/>CCM Requested Amount (Total Phase 2 in US$): 2,183,419 <br/>Approved Funding Amount (Incremental in US$): 1,754,028 <br/>Recommendation Category: Go <br/><br/>Brazil, TB – Round 5 <br/>Grant Number: BRA-506-G02-T <br/>CCM Requested Amount (Total Phase 2 in US$): 11,960,082 <br/>Approved Funding Amount (Incremental in US$): 9,664,550 <br/>Recommendation Category: Conditional Go <br/><br/>China, Malaria – Round 6 <br/>Grant Number: CHN-607-G09-M <br/>CCM Requested Amount (Total Phase 2 in US$): 10,121,428 <br/>Approved Funding Amount (Incremental in US$): 8,471,314 <br/>Recommendation Category: Go <br/><br/>Djibouti, Malaria – Round 6 <br/>Grant Number: DJB-607-G02-M <br/>CCM Requested Amount (Total Phase 2 in US$): 1,190,000 <br/>Approved Funding Amount (Incremental in US$): 958,138 <br/>Recommendation Category: Conditional Go <br/><br/>India, HIV – Round 6 <br/>Grant Number: IDA-607-G10-H <br/>CCM Requested Amount (Total Phase 2 in US$): 22,729,077 <br/>Approved Funding Amount (Incremental in US$): 20,390,449 <br/>Recommendation Category: Go <br/><br/>India, HIV – Round 6 <br/>Grant Number: IDA-607-G11-H <br/>CCM Requested Amount (Total Phase 2 in US$): 145,546,072 <br/>Approved Funding Amount (Incremental in US$): 97,852,982 <br/>Recommendation Category: Conditional Go <br/><br/>Namibia, Malaria – Round 6 <br/>Grant Number: NMB-607-G06-M <br/>CCM Requested Amount (Total Phase 2 in US$): 7,152,683 <br/>Approved Funding Amount (Incremental in US$): 5,015,506 <br/>Recommendation Category: Conditional Go <br/><br/>Paraguay, HIV – Round 6 <br/>Grant Number: PRY-607-G02-H <br/>CCM Requested Amount (Total Phase 2 in US$): 5,749,894 <br/>Approved Funding Amount (Incremental in US$): 5,395,205 <br/>Recommendation Category: o <br/><br/>Tajikistan, TB – Round 6 <br/>Grant Number: TAJ-607-GO6-T <br/>CCM Requested Amount (Total Phase 2 in US$): 7,251,791 <br/>Approved Funding Amount (Incremental in US$): 6,865,442 <br/>Recommendation Category: Go <br/><br/>Ukraine, HIV – Round 6 <br/>Grant Number: UKR-607-G05-H <br/>CCM Requested Amount (Total Phase 2 in US$): 66,026,690 <br/>Approved Funding Amount (Incremental in US$): 63,557,000 <br/>Recommendation Category: Conditional Go <br/><br/>Ukraine, HIV – Round 6 <br/>Grant Number: UKR-607-G06-H <br/>CCM Requested Amount (Total Phase 2 in US$): 42,717,774 <br/>Approved Funding Amount (Incremental in US$): 38,366,000 <br/>Recommendation Category: Conditional Go <br/><br/>Total US$258,290,614</p><p>The Secretariat received comments from Board members on some of the grants. The comments will be taken into account during grant negotiations.</p><p>Next Steps:The Secretariat will begin negotiations immediately for the extension of the grants listed in Schedule A and the Nigeria Round 5 TB grant (NGA-506-G06-T)</p>

<p>The Board recognizes that, as a result of the termination of the Administrative Services Agreement with the World Health Organization, all operating expenses are now required to be paid through the Global Fund's Credit Suisse bank account. The Board decides to rescind its previous decision on the policy for the Credit Suisse bank account (GF/SB1/DP6). The Credit Suisse bank account shall be maintained and used by the Global Fund in accordance with the Global Fund's Financial Rules and Regulations for the following:</p> <p>1. to hold the foundation's capital, of CHF 50,000, as required by Swiss law;</p> <p>2. to pay for all Secretariat operating expenses in accordance with the Board-approved annual budget; and </p> <p>3. to receive private-sector contributions that the Trustee is not able to receive directly and other miscellaneous receipts.</p> <p>The Board requests the Finance and Audit Committee to continue its oversight of the Credit Suisse bank account.</p>

<p>The Board adopts the model for restructuring the Board committees set out in the Report of the Policy and Strategy Committee (GF/B19/4) - the "PSC Report".</p><p>Accordingly, the Board decides:</p><p>1. to create an ad hoc committee of the Board for market dynamics, procurement, and commodities matters (the "Market Dynamics and Commodities Committee" or "MDC") with the terms of reference set out in document GF/B19/4 - Attachment 4 for the period up to the first Board meeting in 2011, when the Board will consider whether to continue the MDC's mandate. Membership in the MDC shall not count towards the two-committee limit set forth in Section 23 of the Board Operating Procedures. This committee will temporarily remove the Portfolio Committee's responsibilities in this area;</p><p>2. to continue the mandate of the AMFm Ad Hoc Committee for the AMFm Phase 1 Period;</p><p>3. to rename the Portfolio Committee the "Portfolio and Implementation Committee" (PIC); and</p><p>4. to approve the amendments to the Committee Rules and Procedures set out in document GF/B19/4 - Attachment 5.</p><p>The Board requests the Board Chair and Vice Chair to review prior Board decisions with a view to clarifying and, if necessary, re-assigning responsibilities among the Committees in line with this decision.</p>

<p>The Board decides that the Executive Director shall be an ex-officio non voting member of the Board, with immediate effect, and approves the following Amendments to Articles 7.1 and 7.2 of the Bylaws and Part A, Section 1 of the Board Operating Procedures:</p><p>Bylaws: Articles 7.1 and 7.2</p><p>7.1 Composition</p><p>The Foundation Board shall consist of twenty voting members and five nonvoting members. Each voting member shall have one vote. […] The five ex-officio nonvoting members of the Foundation Board shall consist of:</p><ul><li>One representative from WHO;</li><li>One representative from the Joint United Nations Programme on HIV/AIDS ("UNAIDS");</li><li>One representative from the trustee; </li><li>One Swiss Citizen with his or her domicile in Switzerland authorized to act of behalf of the Foundation to the extent required by Swiss law.; and</li><li><u>The Executive Director of the Foundation.</u></li></ul><p>7.2 Appointment of Foundation Board Members</p><p>[…] Board Members shall be deemed to act in their capacity as representatives of their respective Governments, organizations, constituencies or other entities. T<u>he Executive Director shall act in his or her capacity as chief executive officer of the Foundation and will serve on the Foundation Board for the duration of his or her term. </u> […]</p><p>Board Operating Procedures: Part A, Section 1</p><p>Board Members</p><p>[…] Board Members serve as the representative of the particular county, organization or other entity, or other constituency holding the Board seat. <u>The Executive Director shall hold an ex-officio seat on the Board as Chief Executive Officer of the Foundation for the duration of his or her term. </u>Except as provided for in Sections A.4 and A.5 below, only properly accredited Board Members have the right to vote and to participate in Board deliberations.</p>

<p>Additions to Technical Review Panel (TRP) Leadership and Membership</p><p>The Board decides to amend the Terms of Reference of the Technical Review Panel (TRP) to add a second Vice-Chair and to increase the overall maximum number of Permanent TRP members from 35 to 40 persons. The revised Terms of Reference are set forth in Attachment 1 of the Report of the Portfolio Committee (GF/B19/5 - Revision 1).</p>

<p>The Board reiterates its endorsement of the Global Fund's initiative to obtain a decision of the UN General Assembly granting Observer Status to the Global Fund at the UN General Assembly (Decision Point GF/B18/DP15).</p> <p>The Board notes that the Global Fund would be represented by the Executive Director at the UN General Assembly.</p>

<p>The Board decides to amend the upper ceiling amounts for the three Round 10 consolidated proposals listed below:</p><table class="table" dropzone="copy"><tbody><tr><td style="cursor: default;">Country/ Disease Component</td><td style="cursor: default;">Amended Phase 1 Upper ceiling (2 years)(US$)</td><td style="cursor: default;">Amended Lifetime Upper ceiling (Up to 5 Years) (US$)</td></tr><tr><td style="cursor: default;">Bangladesh/TB</td><td style="cursor: default;">16,363,126</td><td style="cursor: default;">105,724,068</td></tr><tr><td style="cursor: default;">Mongolia/TB, including cross-cutting HSS</td><td style="cursor: default;">5,763,691</td><td style="cursor: default;"> 9,124,194</td></tr><tr><td style="cursor: default;">Swaziland/TB</td><td style="cursor: default;">12,864,643</td><td style="cursor: default;">39,709,609</td></tr></tbody></table><p>The Board approves the amended upper ceiling amounts specified above for the initial two years.</p><p>This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.</p>

<p>The Board sets the Phase 1 Start Date for the Côte d‟Ivoire HIV Grant CIV-910-G13-H at 1 October 2011 and decides that the program implementation period runs for five years from that time, subject to the Board‟s approval of Phase 2 funding and the terms and conditions of the grant agreement. The End Date for the program is 30 September 2016.</p><p>This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.</p>

His Excellency Ambassador Patrice Debré from France’s constituency is designated as rapporteur for the Twenty-Fourth Board Meeting.

<ol> <li>The Board recognizes uncertainties in relation to the expected funding envelope for Round 11, the Second Wave of NSAs and HSFP applications and notes that it has been revised downward to a current estimate of not more than US$0.8 billion, which may not be available until the fourth quarter of 2013.<br /><br /></li> <li>The Board and the Secretariat will examine options for modification of the application, renewal and approval processes for new and existing investments in light of these resource constraints, the recommendations of the High Level Panel and the Global Fund's strategy and reform processes. The Board will communicate the results of those deliberations no later than 1 December 2011. These deliberations will also consider options for reallocation of existing commitments to prioritize high-impact interventions, which could increase resources available for new investments.<br /><br /></li> <li>As a result of the expected delay in availability of resources, the Board extends the application deadline for Round 11, the Second Wave of NSAs and HSFP applications until at least 1 March 2012.</li> </ol>

<p>The Board recognizes that Decision Point GF/B19/DP19 entitled “Flexibilities to Set Grant Start Dates” delegates to the Secretariat the authority to set the Start Date for grant agreements up to 18 months after Board approval of a proposal to allow for alignment and harmonization.</p> <p>The Board extends that delegated authority by further authorising the Secretariat to delay a Start Date to allow for exceptional circumstances. The following events are indicative of the standard required to justify „exceptional circumstances‟: natural disasters, sudden outbreaks of disease, sudden or unforeseen outbreaks of civil or political unrest that would severely hinder programmatic start up activities.</p> <p>This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.</p>

<ol> <li>The Board thanks the High-Level Independent Review Panel (HLP) and its support team for their hard work in delivering to the Board the report titled "Turning the Page from Emergency to Sustainability" dated 19 September 2011 (the "HLP Report").<br /><br /></li> <li>The Board adopts the HLP Report and accepts the underlying analysis, noting that it presents a compelling case for a rapid and urgent transformation of the Global Fund. The HLP acknowledges the achievements of the Global Fund over the past decade, and the importance of ensuring its success.<br /><br /></li> <li>The Board acknowledges that the Global Fund has significant weaknesses of fiduciary control and financial oversight, as identified in the HLP Report, and the Board is determined to take the necessary corrective actions to address these weaknesses. The Board takes note that the Executive Director and the Inspector General also agree with the HLP Report findings.<br /><br /></li> <li>The Board recognizes that implementation of the HLP's recommendations will require a detailed implementation plan, and that this should be informed by best-practice and draw on available experience.<br /><br /></li> <li>To take forward the recommendations of the HLP, the Board decides to execute the following action plan immediately:<br /><br />5.1 - Consistent with Recommendation 6.3 of the HLP Report ("Consolidate the Reform Agenda") the Board Chair and Vice-Chair, with the Secretariat and the Office of the Inspector General (OIG), will develop a single, time-bound and costed Consolidated Transformation Plan which integrates other reform work streams currently underway with recommendations by the HLP into one single plan, which will include prioritized action items, deliverables, timelines, and parties responsible for the delivery of each item in a logical, coherent, manageable, efficient and timely manner;<br /><br />5.2 - A draft of the Consolidated Transformation Plan will be circulated to the full Board for comment by 31 October 2011, and a final draft will be transmitted to the Board by 10 November 2011 for formal adoption at the Twenty-Fifth Board Meeting; and<br /><br />5.3 - The Coordinating Group (see Paragraph 6.3.1.2 below) will be responsible for monitoring, tracking and reporting to the Board on progress of this Consolidated Transformation Plan until all action items are completed.<br /><br /></li> <li> Acknowledging that they will be important components of the Consolidated Transformation Plan that will be approved in November 2011, the Board decides that the following key actions shall commence immediately, with status reports or decision points, as appropriate, being presented at the Twenty-Fifth Board Meeting:<br /><br />6.1 - The Secretariat and OIG will commence implementation of Recommendation 1 of the HLP Report ("Turn the Page from Emergency to Sustainable Response"), in close consultation with the Board Chair, Vice-Chair and Finance and Audit Committee (FAC);<br /><br />6.2 - The Board, Secretariat and OIG will commence implementation of Recommendation 2 of the HLP Report ("Define a Doctrine of Risk and Manage to It"), except Recommendations 2.3.iii.a-b of the HLP Report. The Board will give further consideration to Recommendations 2.3.iii.a-b of the HLP Report, taking into account the clarification provided by the HLP during the Twenty-Fourth Board Meeting;<br /><br />6.3 - The Board Chair and Vice-Chair, as part of their leadership of the Governance Reform process, will integrate Recommendation 3 of the HLP Report ("Strengthen Internal Governance") into the Board Governance Plan they will finalize. To accelerate implementation of the Governance Reform process the Board:<br /><br /> <ul> <li>6.3.1 - Adopts Recommendation 3 of the HLP Report ("Strengthen Internal Governance") with the following modifications to commence from 1 December 2011:<br /><br /> <ul> <li>6.3.1.1 - The existing four standing committees will be replaced by three standing committees titled and composed as follows:<br /><br /> <ul> <li>i. Strategy, Investment and Impact: ten voting members, five from the donor bloc and five from the implementer bloc, with a chair from the donor bloc;<br /><br /></li> <li>ii. Finance and Operational Performance: ten voting members, five from the implementer bloc and five from the donor bloc with a chair from the implementer bloc; and<br /><br /></li> <li>iii. Audit and Ethics - seven members, with four independent members, one of whom will be the Chair;<br /><br /></li> </ul> </li> <li>6.3.1.2 - There will be a Coordinating Group comprised of Board and committee chairs and vice-chairs;<br /><br /></li> <li>6.3.1.3 - The Board leadership will have a casting vote on two of the committees, as follows:<br /><br /> <ul> <li>i. For the Strategy, Investment and Impact Committee, the Chair of the Board will have a casting vote; and<br /><br /></li> <li>ii. For the Finance and Operational Performance Committee, the Vice Chair of the Board will have a casting vote;<br /><br /></li> </ul> </li> <li>6.3.1.4 - The terms of reference of the three committees will include the duties as recommended by the HLP Report and will be further developed under the leadership of the Board Chair and Vice-Chair. Ethics-related matters will be included in the terms of reference of the Audit and Ethics Committee; and<br /><br /></li> <li>6.3.1.5 - To optimize their performance, the committees can include ex-officio members of the Board and will have the ability to delegate operational matters to the Secretariat.<br /><br /></li> </ul> </li> <li>6.3.2 - Requests the Chair and Vice-Chair to seek nominations from Board constituencies for the three Board Member seats of the Audit and Ethics Committee, and to identify three appropriately qualified persons as member-designates. The Board further requests the three member-designates to commence an open and transparent process to identify the four independent members of that committee, for recommendation to the Board for approval at the Twenty-Fifth Board meeting.<br /><br /></li> </ul> 6.4 - The Policy and Strategy Committee (PSC) and its Strategy Development Working Group will include Recommendation 4 of the HLP Report ("Institute a New Grant-Approval Process") into the five-year Strategy that will be finalized and submitted to the Board for approval at the Twenty-Fifth Board Meeting; and<br /><br />6.5 - The Secretariat, in close and regular consultation with the Chair and Vice-Chair of the Board, FAC, PSC and OIG, will implement Recommendation 5 of the HLP Report ("Empower Middle-Management's Decision-Making") and Recommendations 6.1 and 6.2 of the HLP Report ("Measure Outcomes, Not Inputs" and "Focus on Quality and Value, Rather Than Quantity" respectively), and provide a progress report to the Board at the Twenty-Fifth Board Meeting.<br /><br /></li> <li>In implementing these actions and recommendations, the Board expects the Global Fund Secretariat to pursue the overall objectives of aid-effectiveness,1 to stabilize staff levels and to avoid any increase in general administrative overheads without the prior approval of the Board.</li> </ol>

<p>The Board expresses its appreciation to Simon Bland for his leadership as interim Chair of the Board after the resignation of Martin Dinham as Chair due to ill health.</p> <p>Following recommendation of a candidate by the donor constituency as requested by the Board, the Board appoints Simon Bland as Chair of the Board for the period commencing from the date of this decision until the adjournment of the first Board Meeting in 2013.</p> <p>The Board expresses its gratitude for the continued leadership of Dr. Mphu Ramatlapeng as Vice-Chair of the Board, whose term will also end at the adjournment of the first Board Meeting in 2013.</p> <p>This decision has no material budgetary implications for the 2011 operating budget.</p>

<p>The Board decides that for all Rolling Continuation Channel grants which are not consolidated into Single Streams of Funding (“RCC Grants”),</p> <ol> <li>the Phase 2 Decision Making Policies and Procedures (GF/B16/DP16, Document GF/B16/7 Revision 1, Attachment 1, Section 3)(“PDMPP”) shall be applied to RCC Grants, subject to the following: <ol> <li>Paragraph 5 of the PDMPP shall be amended to read as follows: “The Phase 2 decisions will typically be taken on the basis of the reported results of a program as of the end of the 18th month of implementation, or the 24th month in the case of Rolling Continuation Channel (“RCC”) programs, and the Secretariat‟s recommendations that are made up to 23 months, or 30 months in the case of RCCs programs, after the Program Starting Date/Phase 1 Starting Date/ RCC I Starting Date (exceptions could include for situations of force majeure). The decision may be taken earlier in cases of (i) accelerated implementation; or (ii) severe exchange rate fluctuations.”; and</li> <li>The provisions of the PDMPP relating to extensions shall not apply to RCC Grants.</li> </ol> </li> <li>the “Exceptional Extensions” section under paragraph 17 of the Periodic Reviews and Commitments Policy (Annex 2a, version 2, to GF/B20/4 “Report of the Policy and Strategy Committee” and approved under GF/B20/DP31) shall be applied to RCC Grants.</li> <li>the Secretariat may extend the term of Phase 1 of an RCC Grant by up to six months to allow for flexibility in aligning the grant with in-country cycles and/or to facilitate the transition of the grant to a single stream of funding agreement. Any such extension will not alter the overall end date of the Board-approved proposal.</li> </ol> <p>This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.</p>

The agenda for the Twenty-Fourth Board Meeting (GF/B24/1 Revision 1), as amended to discuss the current funding position, is approved.

<p>The Board refers to the following Decision establishing a „Policy on Timeframes for Grant Agreements‟ approved at its Eighth Board meeting:</p> <p>"If a grant agreement has not been signed 12 months after Board approval, the proposal should no longer be considered approved unless the Board decides to allow a further exceptional time extension based on information received from the Secretariat and CCMs. This time extension will be limited to a maximum of 3 months.</p> <p>The Board decides that this policy should apply for Round 3 and subsequent Rounds.”</p> <p>The Board delegates to the Secretariat the authority to allow extensions of up to three months to the signing timeframe for Round 10 proposals on an exceptional basis and only in situations in which there is a strong justification for granting an extension.</p> <p>By 30 April 2012, the Secretariat will provide a report to the Board or its relevant Committee identifying those Round 10 proposals that were granted extensions to the signing deadline, together with the justification for these extensions.</p> <p>This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.</p>

<p>The Board:</p> <ol> <li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to paragraph 3.c. of the Comprehensive Funding Policy (GF/B20/DP9)^[1].</li> <li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 146,486,654 for the following grants: AFG-809-G07-T ; MDG-405-G07-M ; SRL-809-G10-M ; SRL-809-G11-M ; SRL-809-G12-M ; UGD-708-G07-H</p>

<ol> <li>The Board decides to amend the Charters of the Audit and Ethics Committee (the "AEC") and the Finance and Operational Performance Committee (the "FOPC") to reallocate the advisory and oversight responsibilities related to the external audit of the Global Fund's annual financial statements between the AEC and FOPC, as set forth in Annexes 3 and 4 to GF/B27/07.</li> <li>The AEC and FOPC Charters, as amended and set forth in Annexes 3 and 4 of GF/B27/07, shall be effective as of the date of this decision.</li> </ol>

The report of the Twenty-Sixth Board Meeting (GF/B27/12 Revision 1) is approved.

<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of USD 636,344,148 for the following grants: BEN-304-G04-M ; BEN-T-PNTUB ; BIH-T-UNDP ; BOL-910-G09-H ; BOL-910- G10-T ; MOL-H-PCIMU ; MOL-809-G06-H ; NIC-910-G07-M ; SLE-H-NAS ; TKM-910-G01-T ; TNZ-809-G13-H ; AZE-910-G05-H ; AZE-910-G06-T ; BAN-T-BRAC ; BAN-T-NTP ; GMB-S10-G07-M (GMB-M-MOH) ; GMB-M-CRS ; GYA-810-G06-T ; IDA-910-G23-M ; IDA-910-G22-M ; SSD-910-G13-S</p>

<p>The Board refers to its earlier decision regarding the duration of Phase 1 of the Affordable Medicines Facility - malaria ("AMFm") (GF/B22/DP13) and notes that Phase 1 will end on 31 December 2012.</p> <p>The Board recognizes the importance of an orderly transition for those countries that are part of the Phase 1 pilot following its decision expected in November 2012 on whether to expand, accelerate, modify, terminate or suspend the AMFm business line. In order to support an orderly transition towards implementing the outcome of the November decision, the Global Fund will continue to host AMFm during a twelve-month transition period, and the Board will approve the details of the transition in November.</p> <p>In order to support the transition period, the capacity of the Global Fund Secretariat to manage the activities of the AMFm shall be extended by twelve months (until 31 December 2013). The Board requests that the Secretariat include the appropriate budgetary implications of the extended mandate of the AMFm in the 2013 Operating Expenses Budget.</p>

<p>The Board agrees to delay the election of the Board Chair and Vice Chair until no later than 15 July, 2009.</p><p>The Board requests a group representing the entire Implementing Voting Group, with assistance from the Secretariat, to recommend candidate(s) from the Implementing Voting Group before the election vote. Each constituency within the Implementing Voting Group shall appoint a participant for this group.</p><p>The Implementing Voting Group will ensure that its constituency members are fully informed and receive clear explanations in relevant languages of the nomination and election process and will facilitate discussion and agreement on the candidate(s). </p><p>The Board requests the Secretariat, supported by the Implementing Voting Group, to use other opportunities to explain the nomination and election process to delegations, such as at side meetings at the World Health Assembly, as well as efforts to directly inform individual delegations.</p><p>If there is only one recommended candidate for the Chair, the Board shall vote on the election of the Chair and Vice-Chair by electronic vote. If there is more than one recommended candidate, the Board shall vote on the election at a Special Board Meeting in person, combined with other business and with attendance limited to Board Members and Alternates. </p><p>As an interim measure, the Board decides to extend the terms of</p><p>(a) the current Board Chair and Vice-Chair, until the new Board leadership is appointed; and</p><p>(b) the current leadership and membership of the existing committees until the Twentieth Board Meeting after which the new leadership and membership of the committees will be established.</p><p>The Board requests the current Chair and Vice-Chair to constitute the new Market Dynamics Committee with full consultation with all Board members.</p><p>The Board requests the Policy and Strategy Committee (PSC) to review the procedures for nomination and election of the Board Chair and Vice-Chair taking into account lessons learned and report to the Board at its Twenty-First Meeting.</p>

#

The Board notes the Secretariat's continued focus on strengthening the Global Fund's relationship with its key partners in the fight against the three diseases. In this context, the Board expresses its satisfaction with and endorsement for the principles of the memorandum of understanding with the Organization of Islamic Conference (the "OIC MoU") set out in Attachment 2 of the Policy and Strategy Committee's Report to the Board (GF/B19/4), and requests the Executive Director to finalize and sign the OIC MoU.

<p>The Board affirms the importance of rapid grant signature and disbursement of approved funds as reflected in the target of 8 months for the 2009 Key Performance Indicator for the average time from Board approval to first disbursement. At the same time, the Board also recognizes the value of aligning disbursements with national cycles.</p><p>The Board delegates to the Secretariat the authority to set the starting date for Grant Agreements up to 18 months after Board approval of a proposal to align with national fiscal and programmatic cycles and support harmonization with existing Global Fund grants and other donor-funded programs. The starting date shall continue to be based on the timing of receipt by the Principal Recipient of the first disbursement of grant funds under a Grant Agreement. </p>

<p>The Board approves for funding for an initial two years those Round 8 proposals recommended for funding by the Technical Review Panel (TRP) and identified as ‘Category 2B’ proposals with composite index 6 and as listed in the following table, subject to Decision Point GF/B18/DP13 and paragraph 5 of Decision Point GF/B18/DP14.</p>

<p>Dr. Tedros Adhanom Ghebreyesus of the Eastern and Southern Africa constituency is elected as Chair of the Board for the period commencing on 6 July 2009 until the adjournment of the first Board meeting of 2011.</p><p>Mr. Ernest Loevinsohn of the Canada-Germany-Switzerland constituency is elected as Vice-Chair of the Board for the period commencing on 6 July 2009 until the adjournment of the first Board meeting of 2011.</p>

<p>The Board recalls its decision regarding the Affordable Medicine Facility - malaria ("AMFM") (GF/B18/DP7).</p> <p>The Board notes that it will vote on the AMFm proposals at its Twentieth meeting. The Board understands that the independent evaluation of AMFm Phase 1 is now estimated to be completed in the second half of 2011. </p> <p>The Board decides to maintain the AMFm Ad Hoc Committee as a separate committee of the Board for the duration of the AMFm of the AMFm Phase 1 period with the terms of reference set out in Annex 1 to the Report of the AMFm Committee (GF/B19/7).</p> <p>The Board confirms that the Technical Evaluation Reference Group (TERG) will provide guidance with regard to the technical parameters of the design of the independent evaluation of the AMFm, under the oversight of the AMFm Ad Hoc Committee. Consistent with its previous decisions, the Board confirms that the Secretariat will continue to have responsibility for commissioning of the independent evaluation, under the oversight of the AMFm Ad Hoc Committee.</p> <p>The Board notes pending WHO guidance that fixed-dosed co-formulations (FDCs) are strongly preferable to co-blistered ACTs and may help to delay resistance to artemisinin. The Board also notes that multiple technical issues need to be taken into account to ensure a smooth transition to an exclusive use of FDC ACTs. The Board urges that WHO expedite finalization of this guidance on FDCs and co-blistered ACTs.</p> <p>The Board requests its Chair to delegate to the relevant committee(s) the task of identifying and considering options for the Global Fund, within its mandate as a financing institution, to support countries in expediting the transition to FDCs, taking into consideration the implications for quality, supply, pricing and appropriate use of ACTs, and to report back to the Board at its Twentieth meeting.</p>

<p>The Board decides that the one year "grace period" applicable for income level eligibility determinations for Global Fund funding where a country moves up from one income category to the next does not apply in the case that a country moves from "upper-middle income" to "high income". Therefore, the Board decides to amend paragraph 4 of Part 3 of the document entitled "Income Level and Cost Sharing Eligibility Criteria for Proposals for Funding from the Global Fund" (GF/B16/7 Attachment 1, Revision 1) by adding the following paragraph: </p><p>"In line with the general principle that high income countries are not eligible for Global Fund funding, the one-year grace period only applies to countries moving from the "low-income" category to the "lower-middle income" category and for countries moving from the "lower-middle income" category to the "upper-middle income" category. Those countries moving from "upper-middle income" to "high-income" are not eligible for funding."</p>

<p>Based on the updated Demand Scenarios and Resource Forecasts, the Board decides to establish a balanced Working Group with participation by Dr. Peter Godfrey-Faussett, the outgoing Chair of the TRP, to review the current policies that guide both resource mobilization and resource allocation and to develop a framework for managing the tension between resource demand and supply in a resource-constrained environment.</p><p>Upon the recommendation of the Board Chair and Vice-Chair, the Board approves the appointment of the following members of the Working Group:</p><table class="table" dropzone="copy"><tbody><tr><td>Name</td><td>Constituency</td><td> </td></tr><tr><td>1.</td><td>Peter van Rooijen, as Co-Chair</td><td>Developed Country NGO</td></tr><tr><td>2.</td><td>Dr. Sigrun Mögedal, as Co-Chair</td><td>Point 7</td></tr><tr><td>3.</td><td>Javier Hourcade Bellocq</td><td>Communities</td></tr><tr><td>4.</td><td>Dr. Agnes Binagwaho</td><td>Eastern and Southern Africa</td></tr><tr><td>5.</td><td>Simon Bland</td><td>UK/Australia</td></tr><tr><td>6.</td><td>Amb. Patrice Debré</td><td>France/Spain</td></tr><tr><td>7.</td><td>Michelle Moloney-Kitts</td><td>USA</td></tr><tr><td>8.</td><td>Bill Parr</td><td>Western Pacific Region</td></tr><tr><td>9.</td><td>Sujatha Rao</td><td>South East Asia</td></tr><tr><td>10.</td><td>Todd Summers</td><td>Private Foundations</td></tr><tr><td>11.</td><td>Dr. Ernest Messiah</td><td>Latin America and the Caribbean</td></tr><tr><td>12.</td><td>Enrico Vicenti</td><td>Italy</td></tr></tbody></table><p> </p><p>The Working Group is requested to:</p><p>1. provide recommendations for amendments of existing policies regarding prioritization for funding technically sound proposals in a resource-constrained environment, subject to review at the appropriate times;</p><p>2. provide recommendations, if possible, on future resource allocation policies, to be followed-up by the appropriate Board committee(s); and</p><p>3. present options for an increased and urgent resource mobilization effort.</p><p>The Working Group is requested to seek appropriate input during its deliberations, consult with PC, PSC and FAC, and report to the Board before its Twentieth Board Meeting in November 2009. </p>

<p>The Board approves for funding for an initial two years those Round 8 proposals recommended for funding by the Technical Review Panel (TRP) and identified as ‘Category 2B’ proposals with composite indices 5 and 3 and as listed in the following table, subject to Decision Point GF/B18/DP13 and paragraph 5 of Decision Point GF/B18/DP14.</p>

The Board approves the appointment of Mr. Dai Ellis of the Private Foundations constituency as Chair of the Market Dynamics and Commodities Ad-Hoc Committee.

The Board approves "The Global Fund Strategy in Relation to Sexual Orientation and Gender Identities (SOGI)" (GF/B19/4 - Attachment 3) and requests the Secretariat to report on progress of implementation of the strategy to the Policy and Strategy Committee at its next meeting.

<p>1. As a leading multi-lateral financier of HIV/AIDS programs globally, the Board recognizes its role as a responsible steward of the Global Fund's investments on behalf of people living with and at risk of HIV and the need to ensure high impact of programs supported by the grants that it approves while achieving maximum value for money.</p><p>2. The Board recognizes that improving prevention efforts is critically important to the fight against HIV/AIDS and that the Global Fund should support countries in implementing HIV prevention strategies that are targeted, evidence-based and consistent with local epidemiology. The Board welcomes the initiative by UNAIDS to form, in an expedited manner, a working group, which may include interested Board constituencies, on assessing evidence and developing practical actions on increasing country adoption of 'combination prevention' strategies to determine relevant actions and the appropriate role for the Global Fund which will be presented to the Board at its Twentieth Meeting for relevant action. </p><p>3. The Board also recognizes that the Global Fund has a responsibility to use its influence to leverage a reduction in stigma, discrimination, criminalization of people due to their sexual orientation or gender identity and HIV+ individuals, travel restrictions and sexual and gender violence.</p><p>4. The Board recognizes that, despite important progress made, there are significant gaps in scaling up coverage of effective HIV prevention, treatment, care and support. In addition, there is an urgent need to improve the quality of care for people living with HIV, reduce the costs of treatment in the long term, and to increase the number of people served through programs supported by the Global Fund. Therefore, the Board:</p><p>i. Recognizes the urgent need to increase resource mobilization efforts, given the need to increase overall HIV treatment and care coverage to achieve the goal of universal access. In addition, acknowledges that increased uptake of innovations in HIV treatment and care may result in initial cost increases, but encourages the technical, programmatic and financial evaluation of these investments. </p><p>ii. Requests the Secretariat to work with partners to project the long-term financial costs of existing commitments and future demand on the Global Fund as a major funder of prevention, treatment, and care, including the potential impact of strategies to improve outcomes and reduce treatment costs. This study should include but not be limited to possible protocol changes. Findings should be presented to the Portfolio and Implementation Committee in order to recommend relevant Board action prior to the Twenty-First Board Meeting.</p><p>iii. Recognizing the value of new technologies to improving quality and cost-efficiency of HIV/AIDS prevention, care and treatment, requests the ad-hoc Market Dynamics Committee, in collaboration with partners, to consider how the Global Fund, its partners, Principal Recipients, and Sub-recipients can accelerate access to and uptake of cost-effective new technologies and optimized HIV treatment regimens, to improve outcomes.</p><p>iv. Requests the Secretariat to urgently work with partners to adopt measures to identify gaps and to further improve the quality of Global Fund supported prevention, treatment, care and support including operational research to identify effective scaling up strategies to improve outcomes. These measures should be reviewed by the Portfolio and Implementation Committee during its review of the Round 10 proposal form and guidelines.</p><p>5. The Board recognizes that prevention of HIV in women and preventing HIV-positive mothers from dying and babies from being infected with HIV is crucial to achieving the goals of universal access and an HIV/AIDS-free generation. Scaling-up access to, and use of effective prevention of mother-to-child transmission (PMTCT) and paediatric HIV care, support, and treatment services - which are integrated with primary, maternal and child health and comprehensive sexual and reproductive health programs - is a critical component of the Global Fund's Gender Equality Strategy. Therefore, the Board requests the Secretariat to conduct a review of the portfolio to identify paediatric HIV high burden countries with low PMTCT and paediatric HIV care, support, and treatment coverage rates and prepare options for the Portfolio and Implementation Committee to use available mechanisms to accelerate transitions to more efficacious ARV regimens for effective PMTCT strategies, which should be reported to the Board at its Twentieth Board Meeting </p><p>6. The Board urges CCMs to consider while formulating future proposals that are targeted, evidence-based and consistent with local epidemiology to (i) re-intensify efforts to prevent HIV including among vulnerable populations; and (ii) to improve the health of HIV-infected pregnant women and children through effective PMTCT and paediatric HIV care and treatment programs to ensure improved responses to high paediatric loss-to-follow-up rates; and that strengthen a family centred care approach. The Board also urges CCMs and Principal Recipients, as needed, to consider reprogramming existing grants on the basis of the above.</p>

<ol><li>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li><li>The Board approves additional funding for one year for the Continuity of Services for the proposal listed in Schedule B and described in Annex 1, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on the understanding that the Secretariat shall pursue implementation arrangements for such proposal consistent with the recommendation set forth in Annex 1.</li></ol><p>SCHEDULE A <br/>Total US$39,366,472 </p><p>Benin, TB – Round 6 <br/>Grant Number: BEN-607-G06-T <br/>CCM Requested Amount (Total Phase 2): Euro 4,020,433(1) (2) <br/>Approved Funding Amount (Incremental): Euro 3,394,175= US$4,505,767(2) <br/> Recommendation Category: Conditional Go</p><p>Djibouti, HIV – Round 6 <br/>Grant Number: DJB-607-G04-H <br/>CCM Requested Amount (Total Phase 2 in US$): 7,485,768 <br/>Approved Funding Amount (Incremental in US$): 7,485,768 <br/>Recommendation Category: Go </p><p>Djibouti, TB – Round 6 <br/>Grant Number: DJB-607-G03-T <br/>CCM Requested Amount (Total Phase 2 in US$):2,620,959(1) <br/>Approved Funding Amount (Incremental in US$): 2,415,075 <br/>Recommendation Category: Go </p><p>Senegal, HIV – Round 6 <br/>SNG-607-G05-H <br/>CCM Requested Amount (Total Phase 2): Euro 10,912,515(1) (2) <br/>Euro 9,337,573 = US$12,395,628(2) <br/> Recommendation Category: Go <br/><br/></p><p>Senegal, HIV – Round 6 <br/>Grant Number: SNG-607-G06-H <br/>CCM Requested Amount (Total Phase 2 in US$): Euro 4,166,385(1) (2) <br/>Approved Funding Amount (Incremental in US$): Euro 3,791,386 = US$5,033,065(2) <br/>Go <br/><br/></p><p>Serbia, HIV – Round 6 <br/>Grant Number: SER-607-G03-H <br/>CCM Requested Amount (Total Phase 2 in US$): Euro 4,531,534 (2) <br/>Approved Funding Amount (Incremental in US$): Euro 4,531,534 = US$6,015,611(2) <br/>Recommendation Category: Conditional Go </p><p>Suriname, HIV – Round 5 <br/>Grant Number: SUR-506-G03-H <br/>CCM Requested Amount (Total Phase 2 in US$): 1,800,000 <br/>Approved Funding Amount (Incremental in US$): 1,515,558 <br/>Recommendation Category: Conditional Go </p><p>SCHEDULE B <br/><br/>Côte D’Ivoire, HIV – Round 2 <br/>Grant Number: CIV-202-G05-H <br/>CCM Requested Amount (in US$) : 10,451,388 <br/>Approved Funding Amount (Incremental in US$): 2,950,407 <br/><br/><u><b>Next Steps:</b></u></p><p>The Secretariat will begin negotiations immediately for the extension of the grants listed in Schedules A and B. </p>

<p>a) The Board takes note of the "Partnership Forum 2008 Report" (GF/B19/14) and agrees to use the recommendations contained therein to inform ongoing strategic planning and management of the Global Fund. The Board assigns responsibility to oversee follow-up on the recommendations to its committees as laid out in Attachment 1 to GF/B19/4.</p><p>b) The Board decides to hold the fourth Partnership Forum in the first half of 2011 and approves the following amendment to Article 6.3 of the By-Laws:</p><p><i>By-Laws: Article 6.3 Frequency and notice of meetings</i></p><p><i>The Partnership Forum will meet biennially, at any time during even calendar years <b>every 24 to 30 months.</b></i></p><p><i>Meetings of the Partnership Forum shall be convened by written notice from or on behalf of the Foundation Board.</i></p><p>c) The Board mandates the Policy and Strategy Committee to establish a Partnership Forum Steering Committee to start planning for this event early in 2010.</p><p>d) The format, duration and organization of the fourth Partnership Forum should build on the lessons learned from previous Partnership Fora.</p><p>e) The Board approves a budget of US$ 1,500,000 as an upper limit for the fourth Partnership Forum and requests the Finance and Audit Committee to ensure that provision is made in the 2010 budget for adequate staff resources.</p>

The Board approves the Annual Report as presented in GF/B19/11.

<p>The Board decides to suspend the Rolling Continuation Channel (RCC) procedure for grant application until the Twentieth Board Meeting, at which time the matter will be reconsidered by the Board, other than as provided below. The Board requests the Secretariat to continue to process, using existing RCC policies:</p><ol><li type="a">all RCC proposals that have previously been submitted; and</li><li type="a">all RCC proposals submitted in response to an invitation:<br/><br/><ol><li type="i">to submit a new proposal as a result of the determination of qualification of a grant for RCC by the Secretariat prior to 1 August 2009; and</li><li type="i">to re-submit a proposal due to receipt of a recommendation from the Technical Review Panel of Category 3A.</li></ol></li></ol>

<p>The Board authorizes the Chair and Vice-Chair of the Board and the Executive Director to execute agreements on the Board's behalf. In the event the Executive Director is unavailable to exercise such authority, the Board authorizes each of the Deputy Executive Director, the Director of Country Programs and the Director of Corporate Services individually to execute agreements on the Board's behalf.</p><p>In addition, as necessary and appropriate for the fulfillment of the Executive Director's responsibilities for the day-to-day management of the operations of the Global Fund, the Board authorizes the Executive Director to issue proxies to Secretariat staff to execute agreements on behalf of the Global Fund in accordance with the Financial Rules and Regulations and requests the Executive Director to inform the FAC of his signature authority policy. </p><p>This decision replaces the Board's decision at its Thirteenth Meeting regarding delegated authority to sign agreements.</p>

The Board extends the deadline for the conclusion of the process for clarification of proposals by the TRP for the RCC Wave 5 China HIV and Benin Malaria proposals to four months from the Secretariat’s receipt of the applicant’s initial detailed response to the issues raised for clarification and/or adjustment. This decision does not have material budgetary implications. 

The Board approves the 2008 Financial Statements of the Global Fund which have been audited by Ernst &amp; Young as set out in Attachment 1 to the Report of the Finance and Audit Committee (GF/B19/6).

<p>The Board agrees that funding for Country Coordinating Mechanisms (CCMs) should be linked to their core functions as defined in the Global Fund Framework Document and further elaborated in the CCM Guidelines<a id="_ftnref1" name="_ftnref1" target="_self"></a>. The Board recognizes that the role of CCMs has expanded as Global Fund financing for programmes to fight AIDS, tuberculosis and malaria have increased. </p><p>To reduce financial constraints that hinder CCMs from fulfilling their responsibilities, the Board adopts in principle a new funding model for CCMs which allows for increased budget amounts and flexible funding modalities on the basis of the following key objectives:</p><p>i. Meaningful civil society and private sector participation (including access to funding for civil society);</p><p>ii. Enhanced CCM capacity for program oversight;</p><p>iii. Improved incentives to harmonize and align with national structures;</p><p>iv. Improved capacity to implement the Gender Equality Strategy and the Sexual Orientation and Gender Identify Strategy;</p><p>v. Introduction of performance-based funding for CCMs;</p><p>vi. Improved measurability and transparency of CCM performance;</p><p>vii. Enhanced country ownership; and</p><p>viii. Encouraging continued multi-stakeholder donor support to CCMs.</p><p>The Board delegates authority to the Portfolio Committee (PC) to approve at its 12^th Meeting (September 2009) a revised policy for funding for CCMs based upon:</p><p>i. Linking funding to function;</p><p>ii. Accountability through a robust performance framework;</p><p>iii. Strategic objectives and performance targets expressed in workplans and budgets;</p><p>iv. Different country contexts and needs;</p><p>v. Incorporating CCM best practices; and</p><p>vi. Rigorous oversight mechanisms including Local Fund Agent (LFA) verification as appropriate.</p><p>The current funding model (GF/B16/DP19) continues to apply until PC approval of the fully defined revised policy, which is expected to take effect in January 2010. </p><p>The annual budget for CCM funding will be subject to approval by the Board as part of the regular budgetary process under the oversight of the Finance and Audit Committee (FAC). The financial implications of the proposed CCM funding model are estimated to be approximately US$ 8 million in 2010 (a maximum increase of US$ 2 million over the US$ 6 million CCM budget in 2009) and US$ 12 million in 2011. </p><p>The Board also requests the Secretariat to conduct a review of the CCM Guidelines to clarify the role of CCMs and, as appropriate, to recommend amendments to the CCM Guidelines in time for the </p><p>Twentieth Board Meeting (November 2009). The review should take into consideration the recommendations of the Five Year Evaluation, lessons learned and best practice as identified in various CCM studies. </p><p>In developing the revised funding policy and reviewing the CCM Guidelines the Secretariat shall engage in a broad consultative process.</p><p><a id="_ftn1" name="_ftn1" target="_self"></a></p>

<p>The Board amends the Board Operating Procedures, Part C, Section 14, as follows:</p><p> […] 14. Restricted Session</p><p>In its discretion, the Board may conduct its business in Restricted Session (Voting Board Members and Alternates only). The Board Chair should exclude non-voting ex-officio Board members from attending a Restricted Session, unless it is deemed by the Board Chair to be appropriate to include such members based on the content of the discussion.</p>

The Board notes that the terms of six TERG members were due to expire at the conclusion of the Five-Year Evaluation, in May 2009. The Board decides to extend the terms of these six members of the TERG until the conclusion of the Twentieth Board Meeting. The Board thanks the TERG members for their contribution to the Global Fund and for their willingness to continue their work for this additional period.

<ol><li>The Board approves, subject to paragraph 2 below, the Rolling Continuation Channel proposals recommended for funding by the Technical Review Panel (TRP) as ‘Category 2’ proposals which are listed in Annex 2 to this report. The Board’s approval is for the funding up to the initial three years of each such proposal (indicated as “Total 3 Years” in Annex 1), and is made with the clear understanding that the grant amounts requested are upper ceilings subject to TRP clarifications and grant negotiations rather than final approved grant amounts.<br/><br/></li><li>The applicants whose proposals are recommended for funding as ‘Recommended Category 2 proposals’ shall:<br/><br/><ol><li type="i">provide an initial detailed written response to the requested TRP clarifications and adjustments by no later than four weeks after notification in writing by the Secretariat to the applicant of the Board’s decision; and</li><li type="i">conclude the TRP clarifications process, as indicated by the written approval of the Chair and Vice Chair of the TRP, not later than:<br/><br/><ol><li type="a">two months from the Secretariat’s receipt of the applicant’s initial detailed response to the issues raised for clarification and/or adjustment in cases where no independent budget review is requested by the TRP; and</li><li type="a">five months from the Secretariat’s receipt of the applicant’s initial detailed response to the issues raised for clarifications and/or adjustment in cases where an independent budget review is requested by the TRP during the clarification of a proposal. <br/><br/></li></ol></li></ol></li><li>The Board declines to approve for funding those proposals categorized by the TRP as ‘Recommended Category 3A’ as indicated in Annex 1, although such applicants are encouraged to resubmit a revised proposal, taking into account the issues raised by the TRP, for consideration in the next available wave of Rolling Continuation Channel proposals.<br/><br/></li><li>The Board declines to approve for funding the proposal categorized by the TRP as ‘Recommended Category 3B’ as indicated in Annex 1, although the applicant is strongly encouraged to resubmit the proposal through the Rounds-Based Channel following major revision.<br/><br/></li><li>The Board declines to approve for funding the proposal categorized by the TRP as a ‘Recommended Category 4’ as indicated in Annex 1.</li></ol>

<p>The Board approves the revised Policy on Ethics and Conflict of Interest for Global Fund Institutions attached as Annex 1 of GF/B27/07 and the revised Declaration of Interest Form attached as Annex 2 of GF/B27/07 as updated to reflect the new Board Committee structure established with the Board's adoption of the Governance Reform at its Twenty-Fifth Meeting.</p>

The Board requires that resource mobilization and the replenishment process be included as an agenda item at each Board meeting, and that the Finance and Audit Committee will develop a resource mobilization strategy to be discussed at the Thirteenth Board meeting.

#

<p>The Board approves the appointment of:</p> <ul> <li>Jamie Alison Morris, representing the Private Foundations Constituency, as voting member of the Audit and Finance Committee for a term that will expire in May 2025, or until the appointment of her successor.  <br /> </li> <li>Amelie Schmitt, to serve in her personal capacity as a voting member of the Ethics and Governance Committee for a term that will expire in May 2025, or until the appointment of her successor.</li> </ul> <p> </p>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B50/ER15 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B50/ER12 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the  “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.<br /><br /></li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grant listed in Table 2 of GF/B50/ER15 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Notes its decision in GF/B48/DP03, which approves C19RM funds to be awarded through 30 June 2023, with opportunity for subsequent C19RM Portfolio Optimization awards and implemented through 31 December 2025;</li> <li>Approves the additional funding recommended for each country listed in Table 1 of GF/B50/ER02 (“Table 1”); and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper ceiling of funding available for each country among its constituent grants, in accordance with previously approved principles under GF/B44/EDP18.</li> </ol>

<p>Based on the recommendation of the Ethics and Governance Committee (EGC), the Board:</p> <ol> <li>Approves the reactivation of the Privileges and Immunities Advisory Group (PIAG), as set out in Annex 1 to GF/B50/ER04.</li> <li>Approves the revisions to the PIAG’s terms of reference, as set out in Annex 1 to GF/B50/ER04.</li> <li>Delegates to the EGC the authority to select and appoint members to the PIAG, and to extend the term of the group or dissolve it after its initial 3-year term.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grant listed in Table 2 of GF/B50/ER08 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 2 of GF/B50/ER07 (“Table 2”); and</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 2, and (b) is subject to the availability of funding.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grant listed in Table 2 of GF/B50/ER12 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 3 of GF/B50/ER08 (“Table 3”); and</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 3, and (b) is subject to the availability of funding.</li> </ol>

<p>The Board approves the appointment of Michelle Beistle to serve as the next Global Fund Ethics Officer for a three-year term which can be renewed no more than once.</p>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B50/ER08 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B50/ER09 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country  disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates  any redistribution that constitutes a material change from the program and funding request initially reviewed and  recommended by the TRP. </li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B50/ER05 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Notes its decision in GF/B48/DP03, which approves C19RM funds to be awarded through <br />30 June 2023, with opportunity for subsequent C19RM Portfolio Optimization awards and <br />implemented through 31 December 2025;</li> <li>Approves the additional funding recommended for each country listed in Table 1 of <br />GF/B50/ER06 (“Table 1”); and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper ceiling of funding <br />available for each country among its constituent grants, in accordance with previously <br />approved principles under GF/B44/EDP18.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B50/ER07 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B50/ER03 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B50/ER01 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grant listed in Table 2 of GF/B50/ER05 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<ol> <li>The Board approves the appointment for the remainder of the 2022-2025 term of: Christel Adamou as Independent Member of the Ethics and Governance Committee.</li> <li>The individual appointed under this decision point will begin her term on 11 March 2024 and serve for the remainder of the term.</li> <li>The Board notes the independent committee member appointed under this decision point is entitled to receive honoraria in accordance with the Global Fund’s Honorarium Framework.</li> </ol>

<p>Based on the recommendation of the Audit and Finance Committee, the Board approves:</p> <ol type="i"> <li>The amended and restated Procurement Policy, which replaces in its entirety the Procurement Policy approved in 2008 through GF/B17/DP21 and the decision point contained in GF/FAC11/03, which sets out the general principles that govern the procurement of goods and services by the Global Fund, as set forth in Annex 1 to GF/B51/20- Revision 1;</li> <li>Delegation of authority from the Board to the Executive Director for operationalization of the Policy; and</li> <li>Delegation of authority to the Secretariat, in consultation with the Audit and Finance Committee Chair and Vice Chair, to make non-material adjustments to the procurement policy referenced above, in line with Annex 2 to GF/B51/20- Revision 1 and to report back to the Audit and Finance Committee and Board on all such changes.</li> </ol> <p>In addition, the Board requests annual updates from the Secretariat reporting on the operationalization of the amended and restated Procurement Policy and asks the Secretariat to work with the Audit and Finance Committee to agree on the appropriate content for these updates.</p>

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2023 Annual Financial Report, including the 2023 Annual Financial Statements which have been audited by KPMG SA, as set forth in Annex 1 to GF/B51/14A.</p>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 and Table 2 of GF/B51/ER10 (“Table 1” and “Table 2”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1 and Table 2, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Recalls its decision to delegate authority to the Secretariat to increase the amount allocated to the grant cycle 7 Emergency Fund catalytic investment priority for the 2023-2025 allocation period by up to 50% of the amount approved for this priority, pursuant to decision point GF/B47/DP06 (May 2022), using funding made available by the Audit and Finance Committee for portfolio optimization;</li> <li>Acknowledges the need for additional funding above the delegated authority of 50% of the approved priority amount of US$12 million;</li> <li>Approves the reallocation of US$30 million, from portfolio optimization funds approved by the Audit and Finance Committee, pursuant to decision point GF/AFC26/EDP01 (October 2024), to the Emergency Fund; and</li> <li>Reaffirms its commitment to ensure that the Emergency Fund has sufficient funding to respond swiftly to current and future emergency needs within the Global Fund portfolio.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grant listed in Table 2 of GF/B51/ER08 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B51/ER08 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Tables 1a and 1b of GF/B51/ER05 (“Tables 1a and 1b”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Tables 1a and 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li> </ol>

<p>The Board approves the Report of the 51st Board Meeting, as set forth in GF/B51/22.</p>

<p>Based on the recommendation of the Strategy Committee, the Board:</p> <ol> <li>Recalls its approval of the catalytic investment priorities for the 2023-2025 allocation period as set forth in Annex 1 of GF/B48/03A-Revision 1 (“2023-2025 Catalytic Investment Priorities”); and</li> <li>Approves the inclusion of a new priority for “Climate and Health” as one of the 2023-2025 Catalytic Investment Priorities to support implementation of the Global Fund’s Strategic Objectives.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B51/ER07 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>In order to ensure leadership continuity through the 8^th Replenishment and a robust selection process for the next Executive Director, the Board decides to extend the term of Peter Sands, as the Executive Director of the Global Fund, until the end of 2026 or the commencement of the term of the next Executive Director, if sooner. The next Executive Director is projected to commence his/her term before the end of 2026 and ideally by the November 2026 Board Meeting.</p> <p>The Board mandates the Chair and Vice-Chair of the Board to attend to the extension of the employment agreement of the Executive Director, with due consideration for a successful transition between the outgoing and incoming Executive Director.</p> <p>The Board extends its appreciation to Mr. Sands for his service to date as Executive Director and for his dedication to contributing to a successful leadership transition at the end of his tenure as Executive Director.</p>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grant listed in Table 2 of GF/B51/ER01 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 1 of GF/B51/ER04 (“Table 1”); and</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 1, and (b) is subject to the availability of funding. </li> </ol>

<p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 2 of GF/B51/ER02 (“Table 2”); and</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 2, and (b) is subject to the availability of funding.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B51/ER02 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program  and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B51/ER01 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board approves the appointment of:</p> <ol> <li>Sangback Lee, representing the Additional Public Donors Constituency, as a non-voting member of the Audit and Finance Committee for a term that will expire in May 2025, or until the appointment of his successor.</li> </ol>

<p>The Agenda for the 51st Board Meeting (GF/B51/01) is approved.</p>

<p>Based on the recommendation of the Strategy Committee, the Board:</p> <ol type="i"> <li>approves the Quality Assurance Policy for Vector Control Products and Related Equipment as set forth in Annex 1 to GF/B51/05;</li> <li>requests the Secretariat to work with the World Health Organization (WHO) to establish an Expert Review Panel for Vector Control Products as described in the Policy, and to conclude the necessary arrangements with WHO; and</li> <li>approves the delegation of authority to the Secretariat, in consultation with the Strategy Committee Chair and Vice Chair, to make non-material adjustments to the Policy in line with Annex 2 to GF/B51/05 and to report back to the Strategy Committee and Board on all such changes.</li> </ol> <p>Additionally, while the Board expects efforts will be made to fully implement the Policy upon its approval, the Board understands that for implementation of certain aspects of the Policy a reasonable transition period may be needed. The Board authorizes the Secretariat to allow for such a transition period when needed.</p>

<p>Susan Mochache from the Eastern and Southern Africa constituency is designated as Rapporteur for the 51st Board Meeting.</p>

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2023 Statutory Financial Statements, which have been audited by KPMG SA, as set forth in Annex 2 to GF/B51/14A.</p>

<p>The Board approves the Report of the 50th Board Meeting, as set forth in GF/B50/23.</p>

<p>Based on the recommendation of the Audit and Finance Committee, the Board approves the blended finance approach set forth in Annex 1 to GF/B50/04: Framework to Guide the Development, Review, Approval and Implementation of Blended Finance Transactions.</p>

<p>The Agenda for the 50th Board Meeting (GF/B50/01) is approved.</p>

<p>Based on the recommendation of the Audit and Finance Committee (AFC), the Board approves the following:</p> <ol type="a"> <li>the 2024 Work Plan and Budget Narrative, as set forth in GF/B50/02A; and</li> <li>the 2024 Operating Expenses Budget in the amount of US$ 342.2 million (comprising (i) PART A Secretariat Operating Expenses of US$ 277.9 million, which includes US$ 15.9 million for the Office of the Inspector General’s 2024 Operating Expenses; and (ii) PART B In-Country and Independent Bodies of US$ 64.4 million), as set forth in GF/B50/02A.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 1 of GF/B48/ER11 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<ol> <li>The Board: <ol type="a"> <li>Welcomes the invitation of the government of Viet Nam to host the Global Fund’s 49th Board Meeting on 10-11 May 2023; and</li> <li>Acknowledges the recommendation set forth in GF/B48/ER04.</li> <li>Requests the Global Fund Secretariat to engage with the Government of Viet Nam to agree on any necessary arrangements relating to hosting the Board Meeting in Viet Nam, and invites the Government of Viet Nam to consider conferring privileges and immunities to the Global Fund.</li> </ol> </li> <li>Accordingly, the Board agrees to convene the 49th Board Meeting in Hanoi, Viet Nam.</li> </ol>

<p>The Board appoints Lady Roslyn Morauta as Chair and Ms. Bience Gawanas as Vice-Chair of the Board to each serve three-year terms, or until the appointment of their respective successors, starting from the adjournment of the 49th Board Meeting on 11 May 2023.</p>

<p>The Board:</p> <ol> <li>Notes its decision in GF/B48/DP03, which approves C19RM funds to be awarded through 30 June 2023, with opportunity for subsequent C19RM Portfolio Optimization awards;</li> <li>Approves the additional funding recommended for each country listed in Table 1 of GF/B48/ER09 (“Table 1”); and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper ceiling of funding available for each country among its constituent grants, in accordance with previously approved principles under GF/B44/EDP18.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 2 of GF/B48/ER08(“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 1 of GF/B48/ER08(“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 3 of GF/B48/ER08 (“Table 3”); and</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 3, and (b) is subject to the availability of funding.</li> </ol>

<p>The Report of the 48th Board Meeting was approved by the Board of the Global Fund via electronic vote on 24th March 2023 (GF/B48/EDP06).</p>

<p>The Board approves the appointment of:</p> <ol> <li>Anne-Claire AMPROU, representing the France Constituency, as a voting member of the Strategy Committee for a term that will expire on May 2025, or until the appointment of her successor;</li> <li>Ina von Frantzius and Louis da Gama, to serve in their personal capacity as voting members of the Ethics and Governance Committee for a term that will expire on May 2025, or until the appointment of their successors.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B48/ER02 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and(b)shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 2 of GF/B48/ER02(“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>Based on the recommendation of the Ethics and Governance Committee, the Board:</p> <ol> <li>Approves the revisions to the Honorarium Framework of the Global Fund set out in Annex 4 to GF/B48/ER01; and,</li> <li>Notes that the revisions regarding the leadership of the Board’s Standing Committees (“Committee Leaderships”) shall enter into force upon the approval of this decision point, and that Committee Leaderships shall be eligible to receive, from May 2022, the honoraria provided for in the Honorarium Framework as revised pursuant to this decision; and,</li> <li>Notes that the revisions regarding the Independent Evaluation Panel shall enter into force on 1 January 2023.</li> </ol>

<p>Based on the recommendation of the Audit and Finance Committee (AFC), and the recommendation of the Secretariat to supplement the AFC’s recommendation, the Board approves the following:</p> <ol type="i"> <li>the 2023 Work Plan and Budget Narrative, as set forth in GF/B48/02A – Revision 1; and</li> <li>the 2023 Operating Expenses Budget in the amount of US$ 340 million (comprising (i) PART A Secretariat Operating Expenses of US$ 272 million, which includes US$ 16.5 million for the Office of the Inspector General’s 2023 Operating Expenses; and (ii) PART B In-Country and Independent Bodies of US$ 68 million), as set forth in GF/B48/02A – Revision 1.</li> </ol>

<ol> <li>The Board acknowledges that C19RM was established to support (i) COVID-19 control and containment interventions, (ii) COVID-19 risk-related mitigation measures for programs to fight HTM, and (iii) expanded reinforcement of key aspects of health systems, and recognizes that C19RM requests and awards through the end of 2021 largely focused on the acute response to the COVID-19 pandemic;</li> <li>The Board acknowledges that the pandemic is evolving, and that recipient priorities are correspondingly shifting towards longer-term investments in health systems’ infrastructure and capacities for pandemic preparedness and response;</li> <li>To facilitate careful planning of such investments, including alignment with potential funding requests for the Seventh Replenishment grant cycle, the Board approves that C19RM funds may be awarded through 30 June 2023, with opportunity for subsequent C19RM portfolio optimization awards;</li> <li>To enable maximization of impact from investments in resilient and sustainable systems for health, the Board approves that any C19RM funds may be implemented through 31 December 2025 and will finance interventions across the Sixth and Seventh Replenishment periods – acknowledging that the Secretariat will continue to ensure rapid deployment of funds and quality implementation notwithstanding this deadline;</li> <li>The Board approves that C19RM funding requests will continue to be developed through appropriate, multi-sectoral consultation and fully inclusive decision-making, which must engage communities and civil society, and which must ensure coordination with the national COVID-19 response coordinating body or provide other evidence of alignment with the national approach to COVID-19 response in the absence of such a coordinating body;</li> <li>The Board approves that the Secretariat may use up to 4.5% of C19RM funds, representing an increase from the prior ceiling of 3%, to cover additional management and operating costs related to extension of C19RM; and</li> <li>The Board agrees that all other parameters of C19RM under GF/B46/EDP06 remain unchanged.</li> </ol>

<ol> <li>Based on the recommendation of the Audit and Finance Committee (AFC), as presented in GF/B48/03A – Revision 1, the Board approves US$ 12.903 billion as sources of funds for allocation for the 2023-2025 allocation period. The total amount of sources of funds for allocation comprises, in accordance with the Comprehensive Funding Policy set forth in Annex 1 to GF/B36/02 – Revision 1 and approved through decision point GF/B36/DP04: <ol type="i"> <li>US$ 13.678 billion, derived from the announced replenishment results for the Seventh Replenishment, net of adjustments;</li> <li>US$ 0.250 billion of forecasted unutilized funds from the 2020-2022 allocation period; and</li> <li>a deduction of US$ 1.025 billion of forecasted aggregate operating expenses for the 2023-2025 allocation period.</li> </ol> </li> <li>Based on the recommendation of the Secretariat to supplement the recommendation of the Strategy Committee, as presented in GF/B48/03A – Revision 1, the Board approves the use of an additional US$ 0.200 billion for catalytic investments for the 2023-2025 allocation period, bringing the total amount, from sources of funds for allocation, for catalytic investments for the 2023-2025 allocation period to US$ 0.400 billion, to be made available for the priorities and associated costs set forth in Annex 1 of GF/B48/03A- Revision 1, and based on the recommendation of the Secretariat, the Board approves updating the delegated authority to the Secretariat established in paragraph 7 of GF/B47/DP06 so that the Secretariat may increase the amount of funding available for the Emergency Fund by up to an additional US$ 0.020 billion, using funding approved as available by the AFC for portfolio optimization.</li> <li>Additionally, based on the recommendation of the AFC and to help ensure the maximum amount of impact and use of funds over the 2023-2025 allocation period, the Board requests that the Secretariat include an additional US$ 0.625 billion in the amount used to determine country allocations pursuant to the allocation methodology for the 2023-2025 allocation period in accordance with decision point GF/B47/DP05 (Allocation Methodology).</li> <li>Accordingly, the Board approves that the amount of sources of funds for country allocations for the 2023-2025 allocation period is US$ 12.503 billion, to which US$ 0.625 billion will be added prior to determining the country allocation, for a total of US$ 13.128 billion, to be used in accordance with the Allocation Methodology and decision point GF/B47/DP05.</li> </ol>

<p>The Agenda for the 48th Board Meeting (GF/B48/01 - Revision 2) is approved.</p>

<p>Erika Satterwhite from the Private Sector Constituency is designated as Rapporteur for the 48th Board Meeting.</p>

<p>The Board acknowledges and appreciates the extensive work across the partnership to incorporate past lessons into development of an improved holistic approach to Monitoring and Evaluation (M&amp;E) for the new Strategy. The Board notes the recommendations of the Strategy Committee (SC) and Audit and Finance Committee (AFC), as set forth in GF/B48/04 and:</p> <ol type="i"> <li>Endorses the components of the M&amp;E Framework as described in GF/B48/04 Annex 1;</li> <li>Approves the KPI Framework (including each Key Performance Indicator), as set forth in GF/B48/04 Annex 2;</li> <li>Approves the topics for the Multi-Year Evaluation Calendar 2023-2028 as set forth in GF/B48/04 Annex 3; and</li> <li>Delegates authority to the SC to approve changes to the Multi-Year Evaluation Calendar in 2023, following a request by the Chief Evaluation and Learning Officer and advice from the Independent Evaluation Panel.</li> </ol>

<p>The Board:</p> <ol> <li>recalls its approval of a pilot for procurement of health and non-health products via wambo.org for eligible buyers using domestic and other non-Global Fund sources of funding as detailed in GF/B37/DP09 and GF/B42/DP05; and its request that the Secretariat include the results of an evaluation of the pilot in the development of a strategy for future advancement of wambo.org to be presented for Board approval no later than November 2022;</li> <li>notes the Technical Evaluation Reference Group (“TERG”) evaluation findings and recommendations concerning the pilot discussed at the 18th meeting of the Strategy Committee; and</li> <li>understands that the Secretariat will explore appropriate solutions for the challenges raised by the TERG evaluation and continue to facilitate access to products through wambo.org, while in parallel working to strengthen the capacities of regional and national procurement channels to ensure value for money and options for access to quality-assured heath products for countries.</li> </ol> <p>Therefore, based on the Strategy Committee’s recommendation and in support of the proposed approach for non-Global Fund financed procurements, as detailed in GF/B48/05, the Board approves:</p> <ol> <li>The Secretariat’s continued operationalization of the current scope of non-Global Fund-financed orders by governments and non-government development organizations in Global Fund-eligible and transitioned countries, for products and services as they become available on wambo.org;</li> <li>Removing any cap related to non-Global Fund-financed orders; and</li> <li>Incorporating reporting on the non-Global Fund-financed procurement mechanism into annual updates to the Board on NextGen Market Shaping implementation</li> </ol>

<p>The Board:</p> <ol> <li>Notes its decision in GF/B48/DP03, which approves C19RM funds to be awarded through 30 June 2023, with opportunity for subsequent C19RM Portfolio Optimization awards;</li> <li>Approves the additional funding recommended for each country listed in Table 1 of GF/B48/ER13 (“Table 1”); and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper ceiling of funding available for each country among its constituent grants in accordance with previously approved principles under GF/B44/EDP18.</li> </ol>

The report of the Eleventh Board Meeting (GF/B12/2) is approved, as amended at the Twelfth Board Meeting.

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2022 Statutory Financial Statements, which have been audited by KPMG SA, as set forth in Annex 2 to GF/B48/ER12.</p>

<p>The Board notes the recommendations of the Audit and Finance Committee (“AFC”) as set forth in GF/AFC21/EDP02, and the Strategy Committee (“SC”) as set forth in GF/SC21A/DP01, and:</p> <ol type="i"> <li>Approves the adjustments to the 2023-2028 Key Performance Indicator (“KPI”) Framework (including each KPI) as set forth in GF/B49/03 Annex 2;</li> <li>Notes that proposed material changes to a KPI (refer to GF/B49/03 Annex 1 for the approach to assessing materiality) will continue to be recommended by the AFC or SC, within their respective allocated responsibilities (each a “Relevant Committee”) (as set forth in Annex 2 section 2.2 of GF/AFC20/09 and Annex 2 section 2.1 of GF/SC20/05 revision 2), for Board approval; and</li> <li>Delegates authority to the Secretariat, in consultation with the Relevant Committee Chair and Vice Chair, to make non-material KPI adjustments, in line with GF/B49/03 Annex 1, and report back to the Relevant Committees and Board on all such changes.</li> </ol>

<p>Based on the recommendation of the Strategy Committee, the Board approves:</p> <ol> <li>the Amended and Restated Quality Assurance Policy for Pharmaceutical Products as set forth in Annex 1 to GF/B50/05;</li> <li>the Amended and Restated Quality Assurance Policy for Medical Devices (including In-Vitro Diagnostics) and Core Personal Protective Equipment, as set forth in Annex 2 to GF/B50/05, which replaces in its entirety the former Quality Assurance Policy for Diagnostics Products; and</li> <li>the delegation of authority to the Secretariat, in consultation with the Strategy Committee Chair and Vice Chair, to make non-material adjustments to the two quality assurance policies referenced above, in line with Annex 3 to GF/B50/05 and to report back to the Strategy Committee and Board on all such changes.</li> </ol>